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Abstract 
Blood fatty acid levels have been used to determine dietary intakes of omega-3 highly 
unsaturated fatty acids, but also to examine the link between blood fatty acids, health and 
disease. However, these lipid analyses are gas chromatography-based and are dependent on 
derivatization of lipids to fatty acid methyl esters and do not provide information about the fatty 
acyl parent lipid species. The use of ultra high-performance liquid chromatography combined 
with tandem mass spectrometry (UHPLC-MS/MS) has the potential to do so. This thesis adapted 
a lipidomic approach to traditional blood fatty acid profiling to characterize lipids in their 
naturally-occurring state in human blood. Semi-quantitative methods using UHPLC-MS/MS 
were developed using a high-resolution Quadrupole-Orbitrap Hybrid Mass Spectrometer 
(Thermo Q-Exactive), and were validated for the determination of lipids in whole blood. 
Molecular species were confirmed for over 500 lipids, including phospholipids, sphingolipids, 
triacylglycerols, cholesteryl esters, free cholesterol and free fatty acids. Over 150 acyl-specific 
species were confirmed from all lipid classes. Following this, the method was used to validate 
dried blood spots for lipidomic profiling as this sampling technique offers several advantages, 
including minimally invasive sample collection, stability, and facilitated handling. Additionally, 
the UHPLC-MS/MS method was used to examine whole blood lipid remodeling that follows fish 
oil supplementation. Specifically, the blood lipidomic profiles of samples from a previous 
intervention trial comprising 20 participants that received eicosapentaenoic acid + 
docosahexaenoic acid (EPA+DHA) at 150 mg/d, 500 mg/d, and 1000 mg/d over a twelve-week 
period were determined. Notably, lipidomic profiling of whole blood suggests that three specific 
lipids (16:0/DHA phosphatidylcholine, 16:0/EPA phosphatidylcholine, and plasmenyl-
phosphatidylethanolamine P-16:0/EPA) increase in a dose-dependent manner with increasing 
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doses of EPA+DHA supplementation. Finally, lipidomic analyses of whole blood, plasma, and 
erythrocytes of individuals that consumed low, intermediate, and high amounts of EPA+DHA 
were performed. These results support previous observations on the rapid responsiveness of 
16:0/DHA phosphatidylcholine and 16:0/EPA phosphatidylcholine to varying levels of 
EPA+DHA intake. The mechanisms through which lipid remodeling occurs remain to be 
elucidated. The work presented in this thesis provides the foundation for the use of acyl-specific 
complex lipids as biomarkers for omega-3 highly unsaturated fatty acid status and the lipidomic 
profiling method developed may be extrapolated for the characterization of acyl-specific lipids in 
other biological matrices.  
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Chapter 1 
Introduction 
Lipidomics is an emerging field of study driven by advancements of analytical tools, 
particularly increased real-world usability and commercial availability of mass spectrometry 
(MS) coupled to high-performance liquid chromatography (HPLC).  Previously, changes in the 
fatty acid profile of whole tissues and lipid fractions in response to dietary intervention were 
obtained from more traditional methods, such as thin-layer chromatography and gas 
chromatography-flame ionization detection (GC-FID) (Metherel et al., 2013; Patterson et al., 
2012).  These techniques, however, provide an indirect examination of lipids due to sample 
processing as fatty acyls are removed from their parent lipid.  High-performance liquid 
chromatography coupled with tandem mass spectrometry (HPLC-MS/MS) allows the 
characterization of lipid molecules in their naturally occurring state (Sandra et al., 2010).  These 
techniques also enable the discrimination of lipid species such as glycerolipids that have isobaric 
molecular weights but different fatty acyl constituents.  These lipidomic methods enable a 
thorough understanding of molecular remodeling events that take place on cellular lipids under 
dietary manipulation but also conditions such as pregnancy and metabolic diseases (Koulman et 
al., 2014; Uhl et al., 2013; Wang et al., 2014; West et al., 2013; Zhang et al., 2013), but their use 
remains relatively limited.   
 Most of the available literature employing a lipidomic approach for human blood focuses 
on the examination of either plasma or erythrocyte fractions.  The use of whole blood for fatty 
acid determinations has increased recently as it is inclusive of cellular and lipoprotein lipids, and 
it also lends itself to rapid sampling techniques such as fingertip prick collection and dried blood 
spotting (Armstrong et al., 2008).  While the use of whole blood in method development presents 
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a data-management challenge due to its complexity, it enables the examination of more lipid 
structures compared to isolated plasma or erythrocyte fractions.  This thesis presents a 
comprehensive acyl-specific lipidomic profiling method for whole blood.  The use of whole 
blood is validated and compared to lipidomic examinations of dried blood spots, plasma and 
erythrocyte fractions, as well as comparisons to traditional fatty acid profiling techniques.  
Additionally, there appears to only be one study (Uhl et al., 2013) using lipidomics to examine 
omega-3 supplementation and this was limited to a single dose of DHA (510 mg/day for 29 
days); lipidomic discrimination of acyl-species was done in plasma and erythrocyte fractions 
separately. As such, this thesis aims to adapt lipidomic analyses to human whole blood, and 
provide a more thorough analysis of lipid remodeling events that occur in human blood with 
varying doses of omega-3 HUFA supplementation over a twelve-week period.  Furthermore, this 
thesis aims to find appropriate experimental conditions through which a representation of the 
human whole blood lipidome can be achieved while minimizing sample runs and sample 
preparation. Specifically, the use dried blood spots will be examined as their use in research and 
clinical settings is increasing due to their minimally invasive nature, and their ease of storage and 
transport. Lipidomic discrimination of acyl species in dried blood spots has been validated in 
heel pricks of infants (Koulman et al., 2014), but not in an adult population. Moreover, this was 
limited to examinations of some phosphatidylcholine (PC), cholesteryl ester (CE), 
sphingomyelin (SM) and triacylglycerol (TAG) species while phosphatidylethanolamines (PE), 
phosphatidylserines (PS), phosphatidylinositols (PI), and sphingomyelins (SM) that are 
significant constituents of erythrocyte membranes (Wang and Gustafson, 1992) were excluded.  
The applications developed here can be extrapolated for the analysis of various biological 
samples, including other human and animal tissues.  
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Chapter 2 
Background 
2.1 Lipidomics 
Lipidomics is an emerging field of study that aims to study all of the molecular moieties 
that can be characterized as lipids (i.e. the lipidome) in their naturally-occurring state, including 
fatty acids, glycerolipids, glycerophospholipids, sterol lipids, sphingolipids, prenol lipids, 
saccharolipids and polyketides (Fahy et al., 2009).  This specialized discipline is part of the 
growing field of metabolomics, which together with transcriptomics, proteomics and genomics, 
constitute Systems Biology (Ellis et al., 2007).  Technological advances in the biological 
sciences have enabled the rapid growth of these disciplines.  Particularly, some of them have 
adopted methodological approaches that enable the identification and characterization of all of 
their subcomponents in a given sample (Schmelzer et al., 2007).  Lipidomic profiling, like in 
other ‘-omics’ fields, may be especially problematic in biological samples due to the dynamic 
ranges in concentrations and structures of lipid molecules.  Nevertheless, the growth of 
lipidomics and its applications has greatly been supported by the development of invaluable 
methods that incorporate MS and, more recently, HPLC. 
 
2.2 Principles of High-Performance Liquid Chromatography  
 HPLC, also known as high-pressure liquid chromatography, is an analytical method 
whereby a sample dissolved in a solvent is separated into its subcomponents based on physical 
and/or chemical interactions with mobile and stationary phases.  HPLC relies on the basis of 
pumping the liquid sample at high pressures (up to 6000 psi for HPLC) through a narrow 
column.  The column is lined in its interior surface with a solid compound, sometimes silica 
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beads of various sizes, which serves as the stationary phase.  As the sample is introduced into 
one end of the column, a predetermined solvent system continuously pumps (isocratic or 
gradient) solvents at specified flow rates to help guide the sample through the column; this is the 
mobile phase.  The nature of the constituents of the sample will cause them to interact differently 
with the mobile and stationary phases, where those with a higher affinity for the mobile phase 
will be eluted first.  As the compounds elute, different detectors employing various technologies 
are able to identify the constituents.  A common technique for compound identification involves 
the use of photodiode array to measure the wavelengths of light that pass through a sample.  
More robust technologies such as MS, however, enable the characterization of the molecular 
formulae of the compounds being detected.   
In HPLC, the nature of the compound or compounds of interest will largely dictate the 
solvent system, column, and detector to be used.  HPLC methods can be classified as normal-
phase- or reversed-phase.  Normal-phase HPLC was the first to be developed, and involves a 
non-polar mobile phase and a polar stationary phase.  In contrast, reversed-phase HPLC uses an 
aqueous solvent system and a non-polar surface lining the inside of the column.  Approximately 
75% of all HPLC methods currently employ a reverse-phase approach, due to its higher 
reproducibility (i.e. reduced inter-sample variability) and broader applicability compared to 
normal-phase HPLC (Waters, 2014).  Additionally, the use of a polar solvent system enables the 
use of materials such as formic acid, which improve chromatographic resolution by stimulating 
the molecular ionization process that is needed in MS.  While the use of single columns is most 
common in the literature, two-dimensional techniques that use two columns connected in tandem 
offer a considerable potential to increase peak capacity and resolution (Stoll et al., 2007).  While 
two columns of the same packing material can be used just to increase the total length of the 
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stationary phase (Byrdwell, 2011), columns of different stationary phase materials may be 
employed, enabling the separation of sample constituents based on multiple physical and/or 
chemical properties.  These significant advantages have driven the development of two-
dimensional liquid chromatography techniques, but a disadvantage is that sample run times can 
increase to hours to tens of hours (Stoll et al., 2007).  More recently, advances in HPLC 
technologies have enabled ultra-high performance liquid chromatography (UHPLC) applications 
to be developed (Varma et al., 2011).  The use of smaller particle-sized columns coupled with 
instruments that are capable of withstanding much higher pressures (up to 15000 psi) improve 
the chromatographic separation and resolution of compounds that would otherwise co-elute 
(Forcisi et al., 2013).  Additionally, adjustments may be made to chromatographic protocols to 
reduce sample run times and increase throughput (Plumb et al., 2005).  Moreover, nano-flow 
liquid chromatography techniques are emerging that offer improved sensitivity and can enable 
the analysis of compounds found in low abundance in complex matrices (Gama et al., 2013; 
Kirsch et al., 2008).  Nano-flow liquid chromatography also requires significantly less sample 
and mobile phase solvents compared to HPLC and UHPLC applications (Gama et al., 2013). 
 
2.3 Principles of Mass Spectrometry 
 Modern MS relies on three basic concepts: ion vaporization/creation, ion separation and 
ion detection (Matsuo and Seyama, 2000; Moreau, 2006).  Traditional mass spectrometers 
achieve ion creation through direct electron impact (EI), where the compounds of interest are 
bombarded with high-energy electrons.  This technique enabled the development and evaluation 
of extensive libraries (Ausloos et al., 1999; Dagan et al., 1995), which are still currently used 
(Lowenthal et al., 2013).  The development of ‘soft’ ionization techniques such as chemical 
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ionization (CI) followed, in which a gas (such as isobutane or acetonitrile) is ionized with an 
electron source and it is then allowed to interact with the analytes to transfer the charge.  For EI 
and CI, the analytes need to already be in the gas phase prior to ionization.  As a result, these 
ionization techniques are generally associated with gas chromatography methods.  The ionization 
and vaporization of liquids and solids was not possible until the development of techniques such 
as Electrospray Ionization (ESI) and Atmospheric Pressure Chemical Ionization (APCI) for 
liquids, and Matrix-Assisted Laser Desorption Ionization (MALDI) for solids (reviewed in detail 
by Isaac et al., 2007).  ESI and APCI largely rely on a nebulizing gas to convert liquids to a fine 
mist.  Ionization can take place either at the nebulizing source with the application of a high 
electrical current directly to the capillary (in the case of ESI), or via a corona discharge following 
mist formation (APCI).  The size of the newly formed droplets is gradually reduced as the 
solvent evaporates, until only the charged subcomponents of the original sample are left charged 
and in the gaseous phase.  Droplet evaporation is further stimulated by heating the capillary to 
several hundred degrees, usually 200-300°C (Banerjee et al., 2011).  Lastly, MALDI takes 
advantage of the physical properties of certain compounds to ablate when struck by a pulsed 
ultra-violet laser.  Specifically, the matrix materials commonly used in MALDI all have in 
common a conjugated pi-system that readily absorbs UV energy (Precup-Blaga et al., 2013).  
Upon ablation, the analytes are released from their solid state and are ionized, generally by 
protonation. 
For the ion separation step, multiple technologies such as a Quadrupole, Time of Flight 
(TOF), or Orbitrap may be used (Eliuk and Makarov, 2015).  To separate ions, they rely on the 
ratio of the molecular weight of analytes to their charge (known as mass to charge ratio, m/z).  
Quadrupole mass spectrometers consist of four cylindrical, parallel metal rods that are connected 
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as opposing pairs.  Very specific radio-electrical currents can be applied to each opposing pair, 
creating electrical fields that only allow certain ions to pass through to the detector.  TOF 
instruments operate by applying an electric field to ions, making them gain kinetic energy.  Ions 
with different m/z ratios gain different amounts of speed, and the TOF is able to measure very 
accurately the time when they hit the detector.  The first publications for quadrupole- and TOF- 
MS date back to the 1950s (Paul et al., 1958) and (Wiley and McLaren, 1955), respectively.  
These technologies generally employ the use of electron multipliers, Faraday cups, or 
photomultiplier conversion dynodes in order to detect ions.  More recently, developments in 
engineering and mathematical modeling led to the birth of orbitrap mass analyzers that enabled 
high-mass accuracy MS, providing information beyond nominal mass (Makarov, 2000).  The 
orbitrap is made up of two key components: a central spindle and a cylindrical electrode.  It is 
designed to trap ions by inducing an electrostatic field that causes ions to orbit around the 
spindle.  Ions with different m/z ratios orbit along and around the spindle with different 
rotational, radial, and axial frequencies, causing them to separate.  Moreover, ion detection in an 
orbitrap occurs by measuring the oscillation frequencies across the three axes and the image 
currents generated using the cylindrical electrode.  These frequencies are then converted to m/z 
ratio data via Fourier transformation. 
 Technological advances over the past few years have resulted in the exponential growth 
of the field of MS and its applications across the biological sciences (Careri, 2011).  Notably, 
hybrid instruments have been developed, and incorporate two or more of the techniques for ion 
separation described above (Yost and Boyd, 1990).  These have shown increased quantitative 
capabilities that are often sought for examinations of complex systems (Ståhlman et al., 2009).  
Popular hybrid instruments include the quadrupole-orbitrap, triple-quadrupole, Q-trap (linear ion 
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trap as the third quadrupole in triple-quadrupole instruments) and quadrupole-time of flight mass 
spectrometers, all of which take advantage of a first-pass quadrupole mass filter and enable the 
accurate characterization of very specific compounds.  These are landmarks of selected ion 
monitoring and some data-dependent acquisition methods (Hao et al., 2012).  Due to all of the 
instrument combinations that can be configured and that are currently commercially available, 
the full characterization of biological metabolomes is progressively more within reach. 
 
2.4 High-Performance Liquid Chromatography, Mass Spectrometry, and the Growth of 
Lipidomics Research in Biological Matrices 
 Although the study of lipids using MS tools has been ongoing since the early 1950s, the 
shift towards global lipid analysis or ‘lipidomics’ of biological systems has only taken place 
within the last decade or so.  Specifically, Han and Gross in 2003 were the first to use the term 
lipidomics. The evolution of the field since then has resulted in the emergence of various 
subdisciplines, but these are still within an -omics approach and rely heavily on MS. Particularly, 
the division of lipidomics can be generally interpreted in terms of methodological approaches to 
target specific lipid classes (e.g. sphingolipidomics and phospholipidomics deal with 
sphingolipids and phospholipids, respectively; Buré et al., 2013; Merrill et al., 2009), interests in 
specific lipids based on their metabolic activity (e.g. functional lipidomics, mediator lipidomics; 
Arita, 2012; Ferreri and Chatgilialoglu, 2012), and targeted lipidomics of specific biological 
tissues for lipid profiling (e.g. neurolipidomics; Han, 2007) and structural mapping (MALDI-
imaging lipidomics; Goto-Inoue et al., 2011). Furthermore, lipidomic methods within these 
specialized subdisciplines may take a targeted approach if there are specific lipids of interest 
within selected lipid classes (Isobe and Arita, 2014), or an untargeted approach in global lipid 
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screening applications (Godzien et al., 2015). Finally, some lipidomic profiling methods may 
take a form of an untargeted approach known as “shotgun” lipidomics (Han and Gross, 2003). 
Here, lipid extracts are directly infused into the ionization source of a mass spectrometer without 
prior chromatographic separation. Though this approach can generate MS data in acquisition 
times of just a few minutes, the resolution of isobaric lipid species in global lipidomics can be 
problematic due to the vast number of molecular moieties than may be present in biological 
samples.  
 The joint use of HPLC, ESI, and tandem MS form a well-suited method to determine the 
lipidomic profile of a system.  While complex proteins can have molecular weights in the range 
of kilo-Daltons (eg.  the molecular weight of actin is approximately 45 kDa; Rees and Young, 
1967), the weights of most mammalian cellular lipids are less than 1000 Da.  This is well within 
the scan range of most mass spectrometers.  Furthermore, lipids generally form singly-charged 
molecules in soft ionization techniques like ESI, which simplifies their identification based on 
their predicted precursor m/z ratios (Cassiday, 2014).  These characteristics enable lipidomic 
profiling to be possible in a virtually unlimited array of matrices, with or without prior 
chromatographic separation (Schuhmann et al., 2012).  Most lipidomic profiling methods take 
advantage of many mass spectrometers’ capabilities to perform tandem MS. Tandem MS relies 
on the generation of fragments from a precursor ion, and at least two rounds of ion separation.  In 
lipidomics, fragmentation of native lipids is often carried out in order to characterize their fatty 
acyl constituents.  Generally, tandem MS methods for fragmentation of acyl-containing lipids 
generate fragments that represent the loss of a fatty acyl chain.  For example, the fragmentation 
pattern for a TAG containing palmitate (C16:0), stearate (C18:0) and docosahexaenoate (C22:6n-
3) in positive ESI would reveal three peaks: one corresponding to the m/z ratio for a 16:0/18:0 
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diacylglycerol (loss of docosahexaenoate), one corresponding to a 16:0/22:6n-3 diacylglycerol 
(loss of stearate), and a third corresponding to a 18:0/22:6n-3 diacylglycerol (loss of palmitate).  
More elaborate tandem MS methods can go a step further and carry out MS/MS/MS.  In this 
manner, tandem MS can often take the form of MSn, with n being the number of ion separations 
performed with rounds of fragmentation in between each one.  Though there are several ways to 
perform fragmentation, most current mass spectrometers use collision-induced dissociation 
(CID).  In CID, ions are vibrationally excited with the application of a radiofrequency voltage 
while in the presence of a gas, such as nitrogen (Olsen et al., 2007).  The ions and the gas collide 
once a certain kinetic energy is reached, causing the dissociation of the precursor ion.  Less 
commonly used fragmentation methods include in-source fragmentation, where sufficient energy 
is applied in the ionization process to cause fragmentation within the mass spectrometer (Pais et 
al., 1997); and photodissociation, where the energy required for dissociation is supplied by the 
addition of a laser by an ultra-violet laser (Williams et al., 1990). 
As with other -omics disciplines, there are several challenges in lipidomics.  The 
development of the field of MS and related analytical tools has coincided with shift away from 
early applications of simple compound identification towards applications involving 
comprehensive qualitative and quantitative analyses (Eliuk and Makarov, 2015). Advances in 
technological instrumentation and software have played a vital role in moving the field forward, 
and this has been accompanied by the desire to do more to keep pushing the limits of our 
instruments. In a sense, instrumental solutions to current methodological problems become the 
limits of future applications.   
Comprehensive qualitative determinations have increased the demand on management of 
experimental data due to the thousands of molecular moieties that may be found in a biological 
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sample.  Though there are several emerging lipid-based mass spectrum databases and software 
solutions such as LipidBlast (Kind et al., 2013) LipidSearch (Peake et al., 2013) and LipidView 
(Simons and Arendt, 2010) that are well suited for identifying lipids, significant efforts need to 
be made to develop a comprehensive mass spectrometric method that generates data files which 
meet all of the criteria required by these programs (i.e. MS/MS spectra with sufficiently intense 
fragment ions; this may be an issue with fragmentation of phosphatidylcholine species following 
positive ESI: Lee et a., 2011).   
Accurate quantitation of all the lipids in a lipidomic profile is another considerable if not 
more daunting challenge.  Although the use of stable isotopes is widely accepted as the gold 
standard in quantitative MS (Snyder et al., 2015), this approach is not feasible in screening 
lipidomics applications since every analyte would have to have its own stable isotope.  Stable 
isotopes for each and every specific lipid are not available, and those that do exist can be costly.  
Surrogate internal standards that share similar physical and chemical characteristics to several of 
the compounds of interest may be used instead.  Specifically for lipidomics, exogenous lipids 
may be used as internal standards if factors such as the carbon length and degree of unsaturation 
of fatty acyl constituents, and phospholipid head group (if applicable) are taken into account 
(Koivusalo et al., 2001). Standardizing results to a single standard or standard curve is often 
employed. Although, this should be considered semi-quantitative analysis as the behaviour of 
lipids from multiple lipid classes after ESI cannot be normalized using a single lipid standard.  
  
2.5 Omega-3 Highly Unsaturated Fatty Acid Supplementation and Lipidomic Research 
 Over the past decades, the relationship between blood lipids and omega-3 highly 
unsaturated fatty acid (HUFA) intake has been examined extensively.  This has been greatly 
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influenced by early associations between the consumption of fish and positive health outcomes, 
such as reducing the risk of developing heart disease (Dyerberg and Band, 1979; Chowdhury et 
al., 2014).  Most of this research has used fatty acid compositional data derived from gas 
chromatography analyses, resulting in specific parent acyl lipid species information being lost 
and limited to the fatty acid composition of lipid classes through separation techniques such as 
thin layer chromatography (Xu et al., 2007).  Lipidomics can allow us to identify relationships 
between lipids, diet and health at the level of individual acyl species of complex lipids.  
Therefore, the metabolism of these very specific lipid molecules can be better characterized.  The 
emerging literature on analysis of native lipids containing omega-3 HUFA in biological samples 
include the analysis of single lipid classes of cell cultures (Ramanadham et al., 2000; Rucker et 
al., 2013), isolated tissues (Lamaziere et al., 2011; Murthy et al., 2002; Sjövall et al., 2015), 
plasma, erythrocytes and other circulating blood cells (Ottestad et al., 2012; Pacetti et al., 2004; 
Stanke-Labesque et al., 2008; Uhl et al., 2013).  Currently, there is no research available 
encompassing omega-3 HUFA supplementation and lipidomic profiling of acyl species in 
multiple lipid families in whole blood. 
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Chapter 3 
Rationale, Objectives and Hypotheses 
Fatty acid profiling techniques such as gas GC-FID, which form the basis for the lipid 
analyses of most of the available nutrition and health research, looks at the total fatty acid 
composition of biological tissues, and not the existing acyl species of the lipids.  Moreover, the 
effects of fish oil supplementation has been examined extensively in the past decades, revealing 
possible cardioprotective effects (Harris et al., 2013) and the important role of DHA in 
neurological function and fetal development (Larque et al., 2012) but changes in tissue lipids 
have been limited to GC-FID analyses.  Due to sample processing, significant information that 
may be of physiological relevance is lost.  This information could provide a more thorough 
understanding of biological membrane remodeling events, and metabolism of fatty acids and 
lipids. Notably, fatty acid compositional research has examined the different rates of 
incorporation of different HUFAs into cellular membranes (Holub et al., 2011).  However, the 
parent acyl-containing species information that is lost could provide insights with regards to 
recent versus long-term intake of omega-3 HUFA, or about their preferential incorporation into 
acyl-specific lipids. For instance, preliminary investigations in our laboratory have indicated that 
16:0/DHA phosphatidylcholine (PC) increases dramatically in the latter stages of pregnancy in 
the rat, with only modest increases in other DHA-containing acyl-specific lipids (such as 
18:0/DHA PC, 18:1/DHA PC; unpublished observations).  Additionally, a shift towards the use 
of whole blood in lipid research seems to be prevalent in recent literature.  This has been 
accompanied by investigations that have established associations between the lipid profiles of 
blood fractions (Metherel et al., 2012; Stark et al., 2015 (unpublished observations)).  The use of 
whole blood may provide a more comprehensive examination of an individual’s lipid profile.  
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Information from the analysis of whole blood can be used to draw conclusions about cellular 
bilayers and plasma lipoproteins, which can reveal important details about metabolism.  In 
addition, there is less sample processing involved with the use of whole blood.  Although recent 
developments in MS have highlighted the quantitative potential of MS methods (Serna et al., 
2015), many applications of traditional fatty acid compositional research have used qualitative 
approaches for practical purposes, such as the Omega-3 Index (percent weight of EPA + DHA in 
erythrocytes; Harris et al., 2004). This also highlights the distinction between quality vs. quantity 
of fat. As such, not all of the emerging lipidomic profiling methods are fully quantitative, but 
have qualitative characteristics (Bird et al., 2015). 
This thesis, therefore, aims to establish conditions for semi-quantitative lipidomic 
analysis of whole blood samples through HPLC-MS/MS that are fast, accurate and repeatable, 
and can be applied to whole blood stored in cryovials or on dried blood spot matrices. In 
addition, the molecular changes occurring in the human blood lipidome following fish oil 
supplementation at three different doses will be examined.  Techniques to manage and interpret 
the lipidomic data will also be explored at the preliminary level (e.g. different ways of 
normalizing mass spectrometric data, and the potential of various spectral libraries and/or 
software solutions).  Additionally, given the complexity of whole blood lipids, the methods from 
the proposed research have the potential to be readily adapted for the analysis of various 
biological samples if appropriate lipid volumes can be obtained.   
 
3.2 Objectives 
The present thesis involves the development and application of a novel lipidomic method 
employing UHPLC-MS/MS (see flow diagram: Figure 1).  The initial objective was to establish 
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an untargeted lipidomic method for the characterization of lipids in human whole blood using a 
UHPLC-MS/MS method on the front-end of a Quadrupole-Orbitrap hybrid mass spectrometer.  
This involved preliminary work using commercially-available lipid standards and the application 
of the method using lipid extracts from human whole blood that included serial dilution analyses 
to determine appropriate volumes of blood to be used in sample preparations.  Fine-tuning of 
chromatographic (ex. UHPLC column selection) and mass-spectrometric settings (ex. positive 
vs. negative mode) was also completed and the method was assessed in terms of its ability to 
detect, measure and report the most abundant lipids in human whole blood. 
Upon the development of a whole blood lipidomic method, two applications were 
examined.  The first application examined was the use of the method to determine the lipidomic 
profiles of liquid whole blood and dried blood spots (DBS) across individuals reporting low, 
medium and high levels of omega-3 fatty acid intake (n=3; 1F, 2M).  This involved examining 
the extraction efficiency of both matrices, and comparing the results against traditional fatty acid 
composition data as determined by GC-FID.  The second application and final objective was to 
characterize the changes that occur in the human whole blood lipidome with very specific dietary 
intakes of EPA+DHA using samples from a previous intervention trial.  Specific acyl specific 
lipids that incorporate EPA and DHA as well as the lipids that they displace in the lipidome were 
identified.  These changes were also tracked using neutral-lipid and polar-lipid thin-layer 
chromatography coupled to GC-FID in order to quantify total EPA and DHA content of specific 
lipid classes. 
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3.3 Hypotheses 
1. An HPLC-MS/MS method will be developed that can detect native PC, PE, PI, PS, 
cardiolipin (CL), CE, free fatty acid (FFA), and TAG acyl species in positive ESI mode. 
2. The relationship between increasing concentrations of lipids from blood lipid extracts and 
the observed instrument response will be positive and linear (data from serial dilutions of 
lipid extracts normalized to a single internal standard). 
3. Lipidomic analysis of lipid extracts from dried blood spots and whole blood will give 
comparable results in terms of normalized lipid abundances for all lipids, independent of 
the extraction time and omega-3 HUFA status. 
4. Increasing intake of EPA and DHA will increase EPA and DHA acyl species across all 
lipid classes. 
5. Palmitoyldocosahexaenoyl phosphatidylcholine (16:0/DHA PC) will be the most 
responsive acyl-specific lipid to supplementation of DHA, and will increase the most 
compared to other DHA-containing lipids with increasing doses of the supplement. 
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Figure 1.  Flow chart highlighting the main experiments in this thesis.  The steps for the development of the lipidomic profiling method 
are highlighted in Chapter 5, method validation in Chapter 6, application for profiling of dried blood spots in Chapter 7, whole blood 
lipidomics following omega-3 HUFA supplementation in Chapter 8, and blood fraction lipidomics in Chapter 9. Electrospray ionization 
mass-spectrometry (ESI-MS); phosphatidylcholine (PC); phosphatidylethanolamine (PE); phosphatidylinositol (PI); phosphatidylserine 
(PS); cardiolipin (CL); triacylglycerol (TAG); cholesteryl ester (CE); non-esterified fatty acid (NEFA); data-dependent acquisition 
(DDA); dried blood spot (DBS); highly unsaturated fatty acid (HUFA); gas chromatography-flame ionization detection (GC-FID).
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Direct Infusion ESI-MS of Lipid Standards
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NEFA
1. Instrument Setup
2. Blood Lipid Extract Serial Dilution
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Chapter 4 
Methodological Foundations 
4.1 Blood Collection, Separation and Preparation Procedures 
Venous blood was collected and stored as described previously (Metherel et al., 2013).  
Briefly, blood was collected from the antecubital vein by a trained technician into sterile 
vacutainers to which 200 µL 0.2M ethylenediaminetetraacetic acid (EDTA, Sigma-Aldrich) were 
added.  Aliquots of whole blood (500 µL) were collected in duplicate.  One of the aliquots was 
separated into plasma and erythrocyte fractions by centrifugation at 1734 rcf (Patterson, 2013).  
In addition, 50 µL of blood were applied to pre-washed (1:1 chloroform:methanol) 
chromatography paper strips (Analtech Inc., Neward, DE) onto an area of ~ 1-2 cm2 for dried 
blood spots.  Strips were allowed to air-dry and were then placed in separate test tubes and 
sealed.  All samples were then stored at -80°C until analysis.   
 
4.2 Lipid Extraction  
Total lipid extracts were obtained from whole blood, plasma and dried blood spots using 
a method according to Folch et al., 1957.  In brief, 50 µL of thawed blood or plasma, or a single 
dried blood spot were mixed with a solution of chilled 2:1 chloroform:methanol (v/v), and left at 
4°C for 24 hours.  Samples were vortexed, and 500 µL of 0.2M sodium-phosphate buffer were 
added to induce layer separation.  After inversion, samples were centrifuged for 5 minutes at 
1734 rcf.  The organic layer, which contains all of the lipids, was collected.  An additional 2 mL 
of chloroform were added to the aqueous layer.  Samples were re-vortexed, re-centrifuged, and 
the organic layer was collected and combined with the one obtained in the first extraction.  The 
methanol/water layer was discarded.  Samples were stored in chloroform at 4°C until further 
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analysis.  Lipids were extracted from erythrocytes using the method of Reed et al., 1960. Briefly, 
200 µL of thawed, weighed erythrocytes were added to chilled methanol and vortexed 
immediately.  One mL of chilled chloroform was added, and the samples were stored overnight 
at -80ºC to prevent ‘sticky pellet’.  Samples were then vortexed, centrifuged at 1734 rcf for 5 
minutes and the supernatant was collected in a separate test tube.  2 mL of chilled 1:1 
chloroform:methanol (v/v) were added to the pellet, samples were vortexed and centrifuged 
again at 1734 g.  The supernatant was combined with the one obtained from the first extraction, 
and 1.8 mL sodium phosphate buffer were added.  Samples were inverted twice and centrifuged 
at 1734 g for five minutes.  The chloroform layer, which contains all the lipids, was collected and 
the methanol/water layer was discarded.  Samples were stored in chloroform at 4ºC until 
analysis. 
 
4.3 High- and Ultra-High Performance Liquid Chromatography 
 HPLC and UHPLC settings were used on the front end of the mass spectrometer using a 
Dionex UPLC system.  Two reversed-phase columns were used during method development.  
Initially, a C18 Ascentis Express, 15cm x 2.1 mm x 2.7 µm (Sigma-Aldrich, St. Louis, MO) was 
used for the initial development of the method and was replaced by a similar column with 
smaller particle size (C18 Ascentis Express, 15cm x 2.1 mm x 2.0 µm) (Sigma-Aldrich, St. 
Louis, MO) to improve chromatographic resolution.  A binary solvent system was used (Bird et 
al., 2010; Hu et al., 2008; Peake et al., 2013) that consisted of mobile phase A: 60:40 
acetonitrile:water (v/v), 10 mM ammonium formate, and 0.1% formic acid; and mobile phase B: 
90:10 isopropanol:acetonitrile (v/v), 10 mM ammonium formate and 0.1% formic acid.  
Depending on the desired lipid amount, aliquots of samples were dried and re-suspended in 100 
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µL 65:35:5 acetonitrile:isopropanol:water (v/v/v) with 0.1% formic acid (hereafter referred to as 
HPLC sample solvent).  The autosampler used 5 µL aliquots for sample analysis.  A multi-step 
gradient was utilized (Hu et al., 2008), where from 0 – 1.5 minutes it was 32% B, from 1.5 – 4 
min 45% B, from 4 – 5 min 52% B, from 5 – 8 min 58% B, from 8 – 11 min 66% B, from 11 – 
14 min70% B, from 14 – 18 min 75% B, from 18 – 21 min 97% B, from 21 – 25 min 95% B was 
maintained, from 25 – 25.1 min B was decreased to 32%, and allowed to equilibrate until the 30 
min mark.  The flow was set to 260 µL/min, column temperature at 45°C, and tray temperature at 
4°C.   
 
4.4 Positive Electrospray Ionization-Mass Spectrometry and Tandem Mass Spectrometry 
The mass spectrometer was a Thermo Q-Exactive Quadrupole-Orbitrap (hereafter 
referred to as Q-Orbitrap) (Thermo-Fisher Scientific, Waltham, MA).  MS parameters were set 
as follows: Scan range: 200-2000 m/z; sheath gas flow rate: 35; spray voltage: +3.0 kV; capillary 
temperature: 300°C.  Full scan MS experiments used di-isooctyl phthalate, m/z ratio 391.28429, 
as a lock mass for mass shift corrections.  This is a common ESI contaminant, and was present in 
the sample solvent and in the mobile phase.  Untargeted, data-dependent acquisition methods 
were used for tandem MS experiments (Top1 and Top5, later specified depending on the 
experiment) unless otherwise stated.  An exclusion list of the m/z ratios of 25 common positive 
ESI contaminants was created and specified on the method.  The Q-Orbitrap’s quadrupole mass 
filter can use that information to remove the specified ions from the spectra, reducing the signal-
to-noise ratio.  The Thermo Xcalibur QualBrowser (Version 2.1; Thermo-Fisher Scientific, 
Waltham, MA) was used for extracting ion chromatograms using saved layouts, exporting 
tandem MS spectra, and integrating peak areas.  Chromeleon Xpress (Version 7.2; Thermo-
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Fisher Scientific, Waltham, MA) was used to monitor and control the Dionex UPLC settings.  
The tandem MS spectra for compounds of interest were exported from Xcalibur as .RAW files, 
converted to .MGF using ProteoWizard, and loaded into the NIST 2.0 program for identification 
with the LipidBlast (Kind, 2013) and LipidMAPS (Fahy et al., 2009) databases.   
Due to the thousands of lipids that may be identified within a single biological sample 
(Han and Gross, 2003), all MS experiments were untargeted in nature unless otherwise stated. 
Specifically, tandem mass spectrometry was performed in a data-dependent manner, where either 
the top 1 or top 5 most intense ions in the full MS spectrum at any given point in time were re-
directed for fragmentation. While increasing the number of top ions to fragment is an effective 
tool in the analysis of a complex sample, as the number of top N ions is increased in the MS 
method, the resulting full scan MS chromatograms decrease in peak resolution since the scanning 
frequency is inevitably reduced (Michalski et al., 2011). 
 
4.5 Thin Layer Chromatography to Separate Lipid Classes 
Thin layer chromatography was used to separate total lipid extracts into specific lipid 
classes prior to fatty acid composition analysis by GC-FID.  Both neutral and polar lipid 
separation techniques were used.  Total lipid extracts from plasma, erythrocytes and whole blood 
were dried and reconstituted into 50 µL of chloroform, loaded on to a thin layer chromatography 
plate (Silica Gel G, 20 x 20 cm, 250 um, Analtech Inc., Newark, DE) using a Hamilton syringe, 
and resolved in a mixture of 60:40:2 heptane:diethyl ether:glacial acetic acid (v/v/v) (Armstrong, 
2008).  FFA, TAG, and CE bands were scraped after spraying with 0.1% 2,7-dichlorofluorescin 
in methanol (w/v), visualizing under UV light, and comparing to external lipid standards.  Lipids 
were extracted from the scrapings twice with 2:1 chloroform:methanol (Folch, 1957) containing 
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1 µg/mL C 22:3n-3 ethyl ester standard (Nu-Check Prep, Elysian, MN, USA) and 50 µg/mL 
butyl-hydroxytoluene (BHT).   
Polar lipid thin layer chromatography plates (Silica Gel H, 20 x 20 cm, 250 um, Analtech 
Inc., Newardk, DE) were loaded with total lipid extracts reconstituted into 50 µL chloroform and 
applied to each plate using a Hamilton syringe.  A mobile phase consisting of 30:9:25:6:18 
chloroform:methanol:isopropanol:0.25% potassium chloride in water (w/v):triethylamine was 
used.  Phospholipids resolved in the following order: SM, PC, PS, PI, and PE from bottom to 
top.  Bands were scraped after visualizing with 0.1% 2,7-dichlorofluorescin in methanol (w/v) 
and comparing to external standards, lipids were extracted, derivatized to make fatty acid methyl 
esters and ran on the GC-FID using the protocol described in Section 4.6. 
 
4.6 Gas Chromatography – Flame Ionization Detection 
The lipid extracts in chloroform were dried under a stream of nitrogen gas.  One mL of 
14% BF3 in methanol and 300 µL of hexane were added, and samples were then placed on a 
heating block at 100°C for 1 hour to yield fatty acid methyl esters (Armstrong et al., 2008).  
Fatty acid methyl esters were collected, dried under a stream of nitrogen gas, and re-constituted 
into 50 µL hexane.  Samples were analyzed on a Varian 3900 gas chromatograph equipped with 
a DB-FFAP 15 m x 0.1 mm i.d.  x 0.1 µm film thickness, nitroterephthalic acid modified, 
polyethylene glycol, capillary column (J and W Scientific from Agilent Technologies, 
Mississauga, ON) and used hydrogen as the carrier gas.  One-µL aliquots were introduced by a 
Varian CP-8400 autosampler into the injector, which was heated to 250ºC and used a 25:1 split 
ratio.  The initial temperature was 150ºC with a 0.25-minute hold, followed by a 35ºC/min ramp 
to 200ºC.  An 8ºC/min ramp followed until 245ºC were reached, where the temperature was held 
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for 15 minutes.  The flame ionization detector temperature was set to 300ºC, air and nitrogen 
make-up gas flows were 300 mL/min and 45 mL/min, respectively, and the sampling frequency 
was 50 Hz.  Peaks were identified by retention time using an external standard mix (GLC-462, 
Nu-Check Prep, Elysian, MN, USA). 
 
4.7 Statistical Analyses 
 Concentrations of fatty acids in GC-FID experiments were determined using the C22:3n-
3 internal standard (to yield µg fatty acid/100 µL blood or plasma).  Erythrocyte fatty acid 
concentrations are expressed as µg fatty acid/200 mg erythrocytes.  The percent weight of each 
fatty acid in total fatty acid pools is also expressed.  In HPLC-MS and UHPLC-MS experiments, 
peak areas were normalized by dividing the area under the curve for each extracted ion 
chromatogram by the area under the curve for the di-17:0 PC internal standard and multiplying 
by 100.  Units for lipidomic data are expressed as arbitrary units (A.U.) and the data are therefore 
considered semi-quantitative, a method to express MS data (Lazaro et al., 1999).  Comparisons 
of whole blood and dried blood spot lipidomics, and the whole blood lipidomics at different 
intakes of omega-3 HUFA were assessed by one-way ANOVA and/or two-tailed Student’s t-
tests.  Post hoc tests were performed using Tukey’s Honestly Significant Difference test and 
statistical significance was inferred as p < 0.05 after a significant F-value as determined by the 
one-way ANOVA.  SPSS for Windows statistical software (release 11.5.1; SPSS Inc., Chicago, 
IL, USA) was used.  Data are presented as the mean ± standard deviation as indicated. 
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Chapter 5 
Development of an Untargeted Lipidomic Method for the Analysis of 
Human Whole Blood 
5.1 Introduction 
 Traditional fatty acid profiling techniques have provided insights with regards to lipid 
metabolism in vivo and in vitro, and have been used to support relationships between dietary fat 
intakes and disease risk (Mozaffarian et al., 2013, de Oliveira et al., 2014).  These techniques are 
generally gas chromatography-based, which require fatty acyl chains to be isolated from their 
parent lipids and be chemically derivatized for analysis (Metherel et al., 2013).  As a result, 
whether fatty acids come from glycerophospholipids, CE, TAG, or are part of other lipid pools, 
becomes unknown.  Techniques such as thin-layer chromatography can isolate specific lipid 
classes prior to fatty acid determination, but the specific acyl species of the original lipids 
remains unidentifiable.  More recently, the development of mass spectrometric and liquid 
chromatographic techniques have allowed for the identification of acyl specific species of 
complex lipids, but untargeted lipidomic analyses are typically limited to semi-quantitative if the 
appropriate precautions are taken.  Absolute quantitation using MS is widely known to be 
problematic (Pitt, 2009) and is usually restricted to targeted measurements with appropriate 
internal standards.  This chapter addresses the issues associated with the development of a semi-
quantitative lipidomic profiling method, and provides the foundation for the application of this 
method for the analysis of biological tissues.  For method validation, human whole blood was 
chosen over erythrocytes or plasma due to the fact that it is a more comprehensive sample.  It 
contains TAG and CE, which are predominant in plasma; and PE and PS, which are abundant in 
the erythrocyte bilayer. 
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5.2 Method Development 
5.2.1 Mass Spectrometry - Setting Instrument Conditions for Lipid Standards 
 In ESI-MS, compounds can ionize to form various molecular adducts with compounds 
such as ammonium, lithium, sodium, and potassium (Koivusalo et al., 2001).  The formation of 
these ions is largely dependent on two factors: the nature of the solvent in which the compounds 
are dissolved and the concentration of the solute.  As a result, a series of initial experiments were 
carried out in the Q-Orbitrap instrument to examine the molecular behavior of commercially-
available lipid standards with the ESI process.  Specifically, the standards tested were: 16:0 FFA, 
di-17:0 PC, di-17:0 PE, di-16:0 PI, di-16:0 PS, 17:0 CE, tri-17:0 TAG, tetra-18:2 CL, and free 
cholesterol at equivalent concentrations of 50 µg/100 µL in 1:1 methanol:water + 0.1% formic 
acid + 10mM ammonium formate.  These solutions were introduced into the mass spectrometer 
with a 10 µL Hamilton syringe (Hamilton Company, NV, USA) connected directly to the ESI 
source via fused-silica tubing, at a flow rate of 0.5 µL/min.  Since glycerolipids and cholesteryl 
esters are known to form stable cations (Weir et al., 2013; Murphy et al., 2011), the instrument 
was operated in positive ESI-mode with a spray voltage of +3.0 kV.  The spectra generated were 
visualized on real-time, mass-shift corrected using a lock mass, and saved over 1-minute 
acquisition periods.  By comparing blank runs against lipid standard runs, the most abundant 
molecular ions for the compounds tested were determined.  Based on the results from the Q-
Orbitrap, it was concluded that the most abundant molecular ion configuration using our solvent 
system for PC, PE, PI and PS is [M+H]+, while that for TAG, CE, and CL is [M+NH4]+ and free 
cholesterol [M+H-H2O]+.  The FFA standard was the only one that could not be detected in 
positive ESI mode.  This can be attributed to the chemical properties of this compound; the 
deprotonated form of a carboxylic acid (R-COO-) is more abundant than the protonated form (R-
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COOH) when in solution due to resonance stabilization of the negative charge by the oxygen 
atoms around the alpha-carbon.  However, by switching the spray voltage to -3.0kV to ionize the 
sample, an ion was observed at m/z 255.2324 (Figure 2, Spectrum A).  It was concluded that this 
represented the deprotonated form of 16:0 FFA, since its predicted m/z ratio is 255.2330 (delta 
0.583 ppm, lock mass correction with di-isooctyl phthalate was not applied).  As a result, 
samples need to be analyzed under negative ESI conditions in order to detect FFA.  Subsequent 
experiments were performed in positive ESI mode at the expense of not reporting FFA, which 
only make up approximately 6% of human blood acyl-containing lipids under normal conditions 
(Supporting data in Figure A.1, Appendix A). 
 
5.2.2 High Performance Liquid Chromatography – Resolving Lipid Standards 
 After having examined the molecular behavior of lipid standards with positive ESI in 
section 5.2.1, the next step was to use HPLC to separate the lipids prior to ionization.  This was 
necessary as whole blood is a complex matrix that contains a wide array of lipids of which many 
are isobaric compounds (i.e. share the same molecular formula and m/z ratio, but are different 
lipids; for example 16:0/20:4 PC and 18:2/18:2 PC are both 36:4 PC, C44H81NO8P if [M+H]+, 
m/z ratio 782.5694).  Chromatographic separation prior to ESI enables resolution of such 
compounds, enabling their characterization.  Previous reports (Bird et al., 2011; Hu et al., 2008; 
Peake et al., 2013) have used comparable HPLC techniques in order to achieve separation of 
lipids across all lipid classes.  These studies used a binary solvent system, multi-step HPLC 
gradient protocol, and a reversed-phased C18 column (method described in detail in Section 4.4).  
Moreover, in these studies lipids were also ionized and successfully detected in positive ESI 
mode.  The nine compounds that were tested in Section 5.2.1 were prepared again at a 
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concentration of 50 µg/100 µL in 65:35:5 acetonitrile:isopropanol:water (v/v/v) + 0.1% formic 
acid.  The mild acidity (pH ~ 4.7) of this solvent supports the protonation of lipids.  The samples 
were run with the 30-minute chromatographic protocol by Bird et al (Figure 4 A).  The mass 
spectrometer was operated in positive ESI mode (except for 16:0 FFA, this sample was run in 
negative ESI), used a lock mass, and Top1 data-dependent acquisition for tandem MS.  Figure 3 
shows the combined extracted ion chromatograms for the precursor ion m/z ratios with a ±0.01 
Da scan window of each of the nine lipids tested.  The individual extracted ion chromatograms 
were overlaid into a single chromatogram, hence each lipid was 100% abundant in their 
individual runs.  The overlay indicated all nine compounds were chromatographically unique 
with none of the peaks being wide or tailing, which indicates adequate selectivity by the 
stationary phase.  Tandem MS spectra were used to confirm the identities of the lipid standards.  
Moving forward, the behaviour of blood lipids was examined with the current chromatographic 
and mass spectrometric method over a range of native lipid concentrations. 
 
5.2.3 Untargeted HPLC-MS/MS and Serial Dilutions of Human Whole Blood 
After the successful detection of lipid standards and an indication that chromatographic 
separation was likely, the behavior of native lipids in human whole blood was examined.  A 
previous report (Koivusalo et al., 2001) has suggested that, for quantitative purposes, diluting 
lipids to an appropriate range is necessary in order to maintain a linear relationship between 
increasing sample concentration and the observed spectrum absolute intensity.  Specifically, the 
literature suggests that concentrations of up to 5 pmol/µL of phospholipid standards show a 
linear response.  At higher concentrations, however, a logarithmic relationship begins to be 
observed, losing the linear response needed for quantitation using internal standards.  A possible 
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explanation for the linear then logarithmic relationship with increasing lipid concentration 
involves lipid aggregation and micelle formation when using polar solvents.  The more 
concentrated lipid droplets may result in short chain acyl containing-molecules that are 
concentrated at the surface of the droplet, preventing ionization of long chain acyl-containing 
lipids that gather inside (Han et al., 2006).  Therefore, a series of dilutions from blood lipid 
extracts were assessed in order to determine an appropriate working concentration to minimize 
sequestering of lipids with the droplet.  Lipids were extracted from the blood of one participant 
in 100 µL aliquots, and diluted in chloroform to represent 25.0 µL, 20.0 µL, 15.0 µL, 10.0 µL, 
5.0 µL, 2.0 µL and 1.0 µL of blood.  Samples were dried, re-suspended in 100 µL 65:35:5 
acetonitrile:isopropanol:water (v/v/v) + 0.1% formic acid, and spiked with a 5.0 nmol/µL 
solution of di-17:0 PC.  Samples were run for Top5 data-dependent tandem MS acquisition.  The 
chromatogram obtained from the 10 µL dilution with the estimated elution times for the main 
lipid classes in blood and the full-scan MS summed ion spectrum from the chromatogram 
indicated the most abundant lipids in blood (Figure 5A and 5B).  The importance of 
chromatography when analyzing the lipidome of a complex biological sample are shown in this 
figure – isobaric species cannot be resolved due to the complexity of tandem MS spectra and 
algorithms would need to be developed in order to interpret this type of data.  The three most 
abundant ions, m/z 758.5698, 874.7851 and 666.6183 (identified as 16:0/18:2 PC [M+H]+, 
16:0/18:1/18:2 TAG [M+NH4]+, and 18:2 CE [M+NH4]+, respectively using tandem MS 
spectra), were used to compare the 7 dilutions from whole blood total lipids.  The areas for the 
chromatographic peaks of those three compounds were calculated across all of the dilutions, 
normalized to the area of the 17:0/17:0 PC standard, and plotted as shown in Figure 6.  
Interestingly, the dilution curves show a positive linear relationship between lipid concentration 
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and instrument response up to 5 nmol/µL (internal standard concentration; 0.983 ≤ R2 ≤ 0.992).  
These results contradict the logarithmic relationship of lipid standards at concentrations higher 
than 5 pmol/uL observed by Koivusalo et al., 2001.  This may be explained by the fact that this 
response was observed using triple-quadrupole and ion trap mass spectrometers, which may have 
limited dynamic ranges as compared with the Q-Orbitrap that was used presently.   
From these experiments, the 10 µL dilution was chosen as the most appropriate working 
concentration for future experiments.  Choosing a greater dilution factor may limit the detection 
and quantitation of lipids that are natively found in low abundance in blood while less diluted 
samples may result in co-elution of isobaric compounds and/or ion suppression.  In order to 
determine if the current method could characterize native lipids across all lipid classes, the 
tandem MS spectra generated for all compounds in the 10 µL dilution were examined.  
Approximately 4500 tandem MS spectra were generated from the analysis of a single lipid 
extract.  Upon examining approximately 250 of the spectra that had precursor ion masses in the 
range of what was expected for glycerolipids and cholesteryl esters (Tables A.1 through A.6, 
Appendix A), acyl-specific information was generated for PC, TAG and CE only.  Extracting ion 
profiles for the accurate masses of some known PE, PI and PS species revealed chromatographic 
peaks, but confirmation of actual acyl species could not be made as tandem MS spectrum were 
not available.  This was due to precursor ion intensities of these molecules being much lower 
than PC species, therefore the Top5 data-dependent setting did not select for PE, PI and PS ions.  
Without this selection, tandem MS analyses were not performed and the specific fatty acyls 
species could not be identified.  An inherent characteristic of PC that likely contributed to these 
results is its high native abundance in whole blood compared with other phospholipids.  While 
PC is a key structural component of chylomicron monolayers and erythrocyte bilayers, PE, PI 
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and PS are primarily found in erythrocytes in the inner part of the bilayer and in much smaller 
proportions (Leidl et al., 2008).  Furthermore, PC is well known to have ion-suppressing 
properties in positive ESI-MS, as it is highly ionizable (i.e. it ‘hogs’ the charge) and prevents 
other compounds from being ionized (Kim et al., 2008).  Therefore, additional measures were 
required in order to improve chromatographic separation and further resolve lipids. 
 
5.2.4 Development of the Chromatographic Method 
 In order to address the issues identified with the preliminary method, which included ion 
suppression and lipid co-elution, the multi-step gradient was examined and modified.  There was 
significant co-elution of peaks during minutes 12 to 17 (phospholipids) and between 22-24 (TAG 
and CE) (Figure 5A).  Therefore, the transition from Solvent A (more polar) to Solvent B (more 
non-polar) was modified to be slower throughout these times and shifted the original 30-minute 
gradient (Figure 4A, Bird et al., 2011) to a 47-minute protocol (Figure 4B) with reduced solvent 
ramps for phospholipids and TAG/CE.  New lipid extracts were prepared from whole blood 
samples using the 10 µL dilution that was determined in Section 5.2.3, and then run using the 
new chromatography gradient with the Top5 data-dependent setting.  The results from this 
experiment revealed tandem MS spectra for 16002 ions.  The fact that the number of tandem MS 
spectra generated here increased by over 3.5 fold compared with the ~4500 originally generated, 
tends to confirm that there was considerable ion suppression with the initial chromatographic 
settings.  Of the 16002 tandem MS spectra, approximately 450 were examined based on pre-
determined precursor accurate masses (Tables A.1 through A.7, Appendix A).  Remarkably, the 
fatty acyls of several PE and lyso-PC were identified in addition to the previously observed PC, 
TAG and CE.  Free cholesterol was also detected.  However, characterizing species of PS and PI 
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was still not possible.  Rather than making further alterations to the chromatographic gradient, 
switching to a UHPLC method was examined.  A column with similar phase, length and internal 
diameter, but with smaller particle sizes was used (15 cm x 2.1 mm x 2.7 µm vs. 15 cm x 2.1 
mm x 2.0 µm; Sigma Aldrich, C18 Ascentis Express). Pressures of up to 550 bar were reached 
under the same 260 µL/min flow and gradient system, achieving UHLPC conditions (Varma et 
al., 2011).  This resulted in increased resolution through visibly narrower peaks (Figure A.2 C, 
Appendix A), and more than 18600 tandem MS spectra successfully identified.  From these, 
approximately 600 were checked, and confirmed the acyl species of more PC, TAG, CE, PE, 
Plasmenyl PE, lyso-PC, and several new PS and SM.  Unfortunately, PI species could still not be 
resolved even under these conditions. 
 
5.2.5 Method Optimization for the Targeted Characterization of Phosphatidylinositol Acyl 
Species 
 In an attempt to characterize PI acyl species in a human blood sample, a modification was 
made to the tandem MS settings.  Instead of selecting untargeted Top5 data-dependent ions for 
fragmentation, the quadrupole mass filter capabilities of the Q-Orbitrap were used by specifying 
the m/z ratios of 5 compounds in a targeted inclusion list.  These selected-ion monitoring 
experiments only enable precursor ions with the desired m/z ratios to enter the higher-energy 
collisional dissociation (HCD) cell and be fragmented.  PI species that have been previously 
identified in human erythrocytes (Leidl et al., 2008) were targeted ([M+H]+ for all).  These 
included: 16:0/20:4 PI, m/z 859.5331; 18:0/18:2 PI, m/z 863.5644; 18:0/18:1 PI, m/z 865.5801; 
18:0/20:4 PI, m/z 887.5644; and 18:0/20:3 PI, m/z 889.5801.  Three technical replicates of one 
blood sample were prepared and diluted and ran with the UHPLC method in positive ESI with 
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the m/z inclusion list above.  The results from this experiment were ineffective even with the 
implementation of the m/z inclusion list as no tandem MS spectra were generated.  This suggests 
that PI ion suppression by highly-abundant co-eluting compounds such as PC occurred.  In 
addition to this, the detection of PI in positive ESI mode can be problematic due to its chemical 
structure, and a poor ability to hold a positive charge (Enriquez-Algeciras et al., 2013).  
Although the pure 16:0/16:0 PI standard tested in Sections 5.2.1 and 5.2.2 showed that it could 
be detected in positive ESI, previous reports have had success in detecting it using negative ESI 
(Koivusalo et al.  2001; Uhl et al., 2013).  To run these samples in negative ESI experiments, the 
spray voltage was set to -3.0kV and as flows and temperatures were kept the same as in positive 
ESI.  A new negative [M-H]- parent ion inclusion list was generated for the same 5 PI that were 
targeted before: 16:0/20:4 PI, m/z 857.5175; 18:0/18:2 PI, m/z 861.5488; 18:0/18:1 PI, m/z 
863.5645; 18:0/20:4 PI, m/z 885.5488; and 18:0/20:3 PI, m/z 887.5645.  A formic acid doublet 
with the formula C2H3O4 for the [2M-H]- molecular ion gave a strong signal at m/z 91.0031 and 
was chosen as the lock mass since the positive ESI lock mass (di-isooctyl phthalate, m/z 
391.28429) was not seen in full scan negative ESI MS.  Upon running the technical replicates, 
only one out the 5 compounds gave tandem MS spectra that allowed identification (18:0/20:4 
PI).  Although tandem MS spectra for compounds with the parent masses specified in the 
inclusion list were generated, fragmentation was not successful in creating daughter ions that 
were sufficiently intense, and left the precursor ion virtually intact.  For this reason, the 
normalized collision energy (NCE, the amount of energy applied in the HCD cell to fragment 
compounds) was increased from 17.5 to 40.  The three samples were run again, tandem MS 
spectra were generated at 5 time points throughout the chromatogram, and all 5 PI were 
confirmed. The chromatograms obtained from the same sample when run with either positive 
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(Figure 7A) or negative ESI (Figure 7B), and the tandem MS spectra obtained for m/z 857.5186 
(Figure 7C) that was used to identify it as 16:0/20:4 PI ([M-H]-).  Interestingly, it appears that 
phospholipids can be detected in both positive and negative ESI with the current methods, 
confirming previous reports on the zwitterionic nature of phospholipids (Koivusalo et al.  2001).  
Conversely, TAG and CE show poor ionization efficiencies in negative ESI based on the 
intensity of the peaks generated (Figure 7B).  These observations have been reported elsewhere 
(Sandra et al., 2010). 
 
5.2.6 Summary of Method, Limitations and Future Directions  
In conclusion, the positive ESI-UHPLC-MS/MS method developed enabled the acyl-
specific characterization of PC, PE, PS, TAG, CE, and SM in whole blood by taking a data-
dependent untargeted approach.  Together, these lipids constitute approximately 80% of human 
whole blood acyl-containing lipids (supporting data in Figure A.1, Appendix A).  Although the 
analysis of FFA and PI species requires negative ESI and a targeted inclusion list, this chapter 
has proven that these lipid classes can also be reported.  Further development of the mass 
spectrometric method may enable the analysis of all lipids from a single analytical run.  
Specifically, the Q-Orbitrap has the ability to alternate between positive and negative ESI within 
a single sample run.  However, it takes the instrument significantly more time to perform scans 
since the action of switching from positive to negative ESI or vice versa is not instantaneous.  
The decreased scanning frequency decreases the sharpness of the resulting chromatographic 
peaks, limiting the reliability of quantitation.  In addition, PI analyses are not well suited for 
untargeted or global analyses, as additional extraction steps are typically required to improve 
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recovery as they can have strong interactions with proteins and may require denaturation using 
acid treatment (Homeyman et al., 1983). 
One of the primary limitations of the current method is the inability to distinguish 
between omega-3, -6, -7, and -9 fatty acids.  Furthermore, cis- and trans- isomers cannot be 
discriminated, and the location of fatty acyls within the glycerol backbones of phospholipids and 
TAG cannot be reported at this point.  Further work is necessary in order to address these issues.  
Specifically, new methods have been developed for locating double bonds within fatty acids 
(Háková et al., 2015), their stereochemistry (Kuksis et al., 2005), and sn-1, sn-2, or sn-3 
arrangement in glycerolipids (Byrdwell, 2015).  Adaptations may be made to the current method 
in order to accommodate such modifications. 
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Figure 2.  Full-scan MS spectra for A. 16:0 free fatty acid; B. Free Cholesterol; C. di-16:0 phosphatidylserine; D. di-16:0 
phosphatidylinositol; E. di-17:0 phosphatidylcholine; F. di-17:0 phosphatidylethanolamine; G. tetra-18:2 cardiolipin; H. tri-17:0 
triacylglycerol; I. 17:0 cholesteryl ester; J. Blank injection.  Each spectrum highlights the molecular adducts observed for each lipid 
species.  The most abundant ion in each spectrum is represented by the configuration underneath the name of the compound. 
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Figure 3.  Extracted ion chromatograms for lipid standards.  A. FFA; B. FC; C. PS; D. PI; E. PC; F. PE; G. CL; H. TAG; I. CE.  Ion 
profiles were extracted by scanning for the most abundant molecular adducts for each lipid class as determined from Figure 2, within 
± 0.01 Da.  All of the lipid standards analyzed produced well-shaped chromatographic peaks, and are able to be extracted based on 
precursor ion accurate masses. 
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Figure 4.  A. Chromatographic protocol by Bird et al., 2011.  B. Updated chromatographic 
protocol optimized for lipidomic analysis of human whole blood.  Elution time ranges for 
phospholipids and triacylglycerols/cholesteryl esters are specified, highlighting the slower shift 
towards Solvent B in the updated protocol in order to resolve co-eluting lipids.  Solvent flow was 
set constant at 260 µL/min. 
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Figure 5.  A.  Full-scan MS chromatogram from 10 µL blood, using the multi-step protocol 
established by Bird et al., 2011.  The elution times for several confirmed lipids in blood are 
highlighted, and their relative abundances compared to a spiked di-17:0 PC standard.  B.  
Summed ion spectrum for the chromatogram in Figure 5 A, highlighting the most abundant 
lipids in human whole blood.   
A. 
B. 
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Figure 6.  Examination of instrument response with increasing concentration of lipids A.  
16:0/18:2 phosphatidylcholine (PC); B.  16:0/18:1/18:2 triacylglycerol (TAG); C.  18:2 
cholesteryl ester (CE).  Blood volumes were created by extracting from 100 µL using 2:1 
chloroform:methanol (v/v), and diluting with chloroform. 
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Figure 7.  Full-scan MS chromatograms for 10 µL blood lipid extract in A. positive ESI and B. negative ESI. The time intervals for 
elution of blood lipids are indicated, and highlights how different lipids have different ionization efficiencies e.g., TAG and CE are 
more efficiently ionized in positive ESI compared to negative ESI.  The arrows indicate the five instances where tandem MS was 
performed based on the specified inclusion list.  C. Tandem MS spectrum for m/z 857.5186, this ion’s accurate mass was included in 
the MS method’s inclusion list to ensure its fragmentation.  The resulting fragments were used to confirm the identity of this molecule 
as 16:0/20:4 phosphatidylinositol (PI). 
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Chapter 6 
Validation of an Untargeted Lipidomic Method for the Analysis of 
Human Whole Blood 
6.1 Introduction 
The development and refinement of an untargeted method capable of identifying over 
18000 spectra in the whole blood lipidome was based largely on chromatographic and MS 
settings.  In order validate the method, the tandem MS spectra generated needed to be 
qualitatively characterized.  This characterization is dependent on searches of mass spectra 
databases such as those developed and maintained by NIST.  However, lipidomic data in the 
NIST databases is limited therefore alternative databases must be accessed such as LipidBlast 
database (Kind et al., 2013) and LipidMAPS Mass Spectrometry tools (Fahy et al., 2008).   
 
6.2 Comprehensive Lipidomics of Human Whole Blood 
  A comprehensive characterization of all detectable acyl-containing lipids in a single 
blood sample was performed on a single 10 µL blood lipid extract equivalent run under Top5 
data-dependent conditions, positive ESI, and with the UHPLC gradient developed in Section 5.2.  
From this sample, approximately 400 tandem MS spectra were examined in detail from 18635 
tandem MS spectra generated.  Each spectrum was individually extracted, exported, and 
analyzed using the NIST2.0 program with the LipidBlast database (Kind et al., 2013) and 
LipidMAPS Mass Spectrometry tools (Fahy et al., 1008).  From this experiment, 219 lipids were 
identified in terms of their lipid group (i.e. total carbon atoms and C-C double bonds in acyl 
chains; e.g. PC 34:2 and TAG 52:3) based on accurate masses and chromatographic retention 
times by single MS.  Out of these 219 lipids, acyl specific data was generated for 163 lipids 
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across cholesteryl esters, PC, PE, PS, and TAG using tandem MS.  A list of 548 compounds was 
generated (full list in Tables B.1 through B.6, Appendix B) and includes the observed m/z ratio, 
identity, and area under the curve for each lipid.  Notably, only combinations of even-chained 
fatty acids were analyzed in this process.  While odd-chained fatty acids such as heptadecanoic 
acid (C17:0) and tricosanoic acid (C23:0) are present in blood, and more specifically in 
erythrocyte bilayers, they constitute less than 0.5% of total erythrocyte fatty acids by percent 
weight (Patterson et al., 2014).  The exclusion of odd-chained fatty acids from the analysis of 
tandem MS spectra made searches significantly less burdensome. 
The application of a lipidomic method for the analysis of biological samples generates 
complex and extensive amounts of data.  Though the current UHPLC-MS/MS method has 
demonstrated the capacity to provide data for hundreds of compounds, it can provide more 
accurate results if it is tailored to target specific lipids.  Traditional techniques such as thin-layer 
chromatography coupled with GC-FID or GC-MS may be better alternatives if the interest is in 
examining quantitative changes in total lipid pools.  Glycerophospholipids are discussed in 
Section 6.2.1, TAG in Section 6.2.2 and CE in Section 6.2.3. 
 
6.2.1 Glycerophospholipids 
Lipid group identification was possible for 49 PC, 33 PE, and 20 PS.  In order to detect 
these lipids, a list of all of the possible combinations of fatty acyls between di-12:0 to di-24:1 of 
lipid group molecular ion accurate masses was generated for PC, PE and PS (Table A.6, 
Appendix 6).  There were 91 lipid group accurate mass combinations for each of the three 
phospholipids (total of 273) that were extracted and integrated.  Many of these ion extractions, 
however, resulted in flat chromatograms below the limits of detection (LOD), shown as “<LOD” 
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for area under the curve (AUC) in Appendix B.  This indicates that phospholipids with fatty acyl 
configurations resulting in those lipid groups (i.e. di-24:1 PC à 48:2 PC) are either below the 
limit of detection of the current method, or are truly not present in the sample.  Furthermore, 
tandem MS spectral analyses confirmed 23 acyl species of PC, 3 lyso-PC, 17 PE and plasmenyl-
PE, and 5 PS.  The extracted ion profiles for the precursor ions of all of these lipids were 
integrated, and are shown in Appendix B organized by phospholipid class and ascending 
molecular weight.  By comparing the AUC of acyl-specific and non-acyl specific data, it can be 
concluded that this method can provide acyl-specific information for approximately 81% of PC, 
62% of PE and 70% of PS actually present in whole blood. 
 
6.2.2 Triacylglycerols 
As in Section 6.2.1, the sum of the peak areas for total confirmed TAG was calculated.  
In terms of total identifiable TAG by lipid group, the current method enabled the detection of 94 
TAG species out of 105 compounds that were searched for ([M+NH4]+ accurate masses, Table 
A.7, Appendix A).  Additionally, analysis of tandem MS spectra generated for this sample 
enabled the confirmation of 35 TAG acyl species, which constitute approximately 48% of total 
blood TAG.  This low proportion of TAG acyl species reported can be attributed to the structural 
complexity of TAG, and all of the fatty acyl combinations that may exist in a biological sample 
(sn-1, sn-2, sn-3 location; acyl chain length, unsaturation).  The accurate mass and molecular 
formula for a single TAG lipid group may be composed of at least 30 isobaric species (Figure 8).  
Since the ions that are generated from TAG fragmentation are direct indications of the molecular 
weights of the fatty acyls that constitute it, tandem MS spectra that were generated for co-eluting 
TAG revealed fragments for multiple species (Figure 9).  Although it was not possible to provide 
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the specific acyl composition for many TAG lipid groups, the fragments that were observed were 
analyzed and are shown in Table B.6, Appendix B.  This limits the number of fatty acyl 
combinations that make up that lipid group to 5 or less.  By doing this, the proportion of acyl-
specific data generated in terms of the total TAG pool increased from 48% to 90%. 
 
6.2.3 Cholesteryl Esters 
In contrast to glycerophospholipids and TAG, CE species analysis is relatively 
straightforward due to the fact that there is only one fatty acyl chain per CE molecule.  Here, the 
accurate masses of 20 cholesteryl esters were calculated and used to extract ion chromatograms.  
Interpreting CE spectra to confirm the identity of CE species relied primarily on full-scan MS 
and not tandem MS spectra.  Precisely, the spray voltage that was used to ionize the lipids as 
they eluted from the UHPLC column appears to have fragmented a large proportion of the ester 
bonds that held fatty acyls to their parent CE.  As a result, a large m/z 369.3516 ion, representing 
a cholesterol cation ([M+H-RCOOH]+) with molecular formula C27H45, was observed when each 
of the 20 CE ion profiles was extracted.  Fragmentation was accompanied by the neutral loss of 
fatty acyls.  For highly abundant CE species such as 18:2 CE, the precursor ion was fragmented 
both at the spray source and at the HCD cell, producing the cholesterol cation in both MS and 
tandem MS.  For less abundant CE species like 20:5 CE, fragmentation occurred only at the ion 
source, and the cholesterol fragment was only observed in MS since no tandem MS was 
generated.  As a result, the presence of m/z 369.3516 in full-scan MS was used as a diagnostic 
fragment when extracting ion profiles for all CE in order to confirm their identity.  Following 
identification, all 20 CE species were integrated and the absolute proportions of each are given in 
Table B.1, Appendix B.    
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6.3 Discussion and Conclusion 
 Overall, the current UHPLC-MS/MS method is capable of detecting acyl species of PC, 
PE, PS, TAG and CE by taking a data-dependent untargeted approach. Further development of 
the mass spectrometric method may enable the characterization of more than the 163 acyl-
specific lipids identified presently.  Specifically, some mass spectrometers have the ability to do 
fast polarity switching, which allows positive and negative ESI within the same analytical run 
(Yuan et al., 2012).  Fast polarity switching would allow PI and FFA species to be reported in 
our untargeted lipidomic method. Although the current UHPLC-MS/MS method is unable to 
determine the localization and stereochemistry of acyl-double bonds in native lipids or identify 
the sn-1, sn-2, sn-3 fatty acyl positions, difficulty resolving isobaric TAG species should be 
addressed first. several isobaric TAG species co-elute and limits the number of specific 
compounds that can be identified. While the current method used a single reversed-phase C18 
column, two-dimensional UHPLC (Byrdwell, 2011; Stoll et al., 2007) and/or nano-flow liquid 
chromatography (Gama et al., 2013) would likely improve chromatographic separation and 
decrease co-elution. Also, ionization of TAG via atmospheric pressure chemical ionization often 
yields better results than ESI  (Byrdwell, 2011; Byrdwell et al., 2001). Finally, the 
implementation of inclusion lists for the analysis of targeted lipids may improve peak resolution 
compared to the current Top5 data-dependent acquisition conditions. 
Despite the lipid identification challenges, the greatest challenge with the current 
lipidomic profiling method is data extraction and processing.  Although the LipidBlast database 
(Kind et al., 2013) and LipidMAPS consortium (Fahy et al., 2005, 2008) were used exhaustively 
for the identification of lipid acyl species, they are designed for targeted lipid profiling and do 
not have automatic experimental data processing tools.  As a result, each tandem MS spectrum 
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that was analyzed had to be individually extracted, converted to the appropriate file format, and 
imported into the NIST 2.0 software.  After the identification of each acyl species, peak areas 
had to be individually integrated, and the raw area under the curve values were manually typed 
in a blank spreadsheet.  Data-handling software solutions are beginning to emerge.  LipidSearch 
(Version 4.0; Thermo-Fisher Scientific, Waltham, MA, USA) offers lipid identification tools 
with an extensive library of more than 1.5 million lipid ions and predicted fragment ions, as well 
as peak alignment and integration options.  However, these software applications appear to rely 
on relatively crude search parameters and their ability to identify acyl species of specific lipids is 
limited.  For example, a preliminary use of a trial version of LipidSearch revealed that PC acyl 
species could not be discriminated because the relative abundances of fragment ions with acyl 
specific information were below the threshold specified in the search parameters.  The software 
was only able to detect the precursor [M+H]+ ion and the phosphocholine ion (m/z 184.0735; 
C5H15O4NP) and could only generate lipid group-specific data (i.e. total number of carbon atoms 
and C-C double bonds; e.g. PC 34:2).  The fragment ions that would be used to determine the 
acyl composition of PC species were less than 0.05% of the most abundant ion (the 
phosphocholine head fragment).  This phenomenon has been reported elsewhere (Lee et al., 
2011).  In the future, increasing the normalized collision energy (energy used to cause 
fragmentation), or operating the instrument in negative ESI mode may result in more abundant 
fragment ions, and potential enabling the detection of acyl species specific lipids by LipidSearch 
(Peake et al., 2015).  In spite of the limitations of the current method, the proportion of acyl 
species that were characterized is relatively comprehensive of the lipidome. The examination of 
native lipids in dried blood spots, and then in whole blood following fish oil supplementation 
promises to be highly informative and novel to the field.
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Figure 8.  Thirty of the acyl species of specific configurations of 56:8 triacylglycerol (TAG) 
lipid group (56 acyl-chain carbons, 8 C-C double bonds) with the same molecular weight.  The 
isobaric compounds shown here do not take into account configurations with odd-chain fatty 
acyls, sn-1, sn-2 or sn-3 localization, C-C double bond locations, or cis- and trans- conformation. 
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Figure 9.  A.  Tandem MS spectrum for the extracted ion profile of 52:0 triacylglycerol (TAG), m/z 880.8328.  This spectra reveals 
diacylglycerol (DAG) fragments corresponding to the losses of several fatty acids.  Eight combinations that give rise to isobaric TAG 
are shown B.  Tandem MS spectrum for the extracted ion profile of 52:3 TAG, m/z 874.7858.  In contrast to spectrum A., only three 
fragments are shown, meaning that there is one predominant species of TAG for 52:3 TAG which has fatty acids 16:0/18:1/18:2.  
450 500 550 600 650 700
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
el
at
iv
e 
A
bu
nd
an
ce
601.5197
577.5194
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
el
at
iv
e 
A
bu
nd
an
ce
579.5347
607.5658
551.5035
635.5974
523.4717495.4411
663.6262
450 500 550 600 650 700
m/z
575.5043
Loss of C18:0
Loss of C16:0
Loss of C14:0
Loss of C12:0
Loss of C20:0
Loss of 22:0
Loss of 24:0
Loss of C16:0
Loss of C18:1
Loss of C18:2
16:0/18:0/18:0
16:0/16:0/20:0
16:0/14:0/22:0
16:0/12:0/24:0
12:0/18:0/22:0
12:0/20:0/20:0
14:0/18:0/20:0
14:0/14:0/24:0
16:0/18:1/18:2
 49 
Chapter 7 
Semi-Quantitative Lipidomic Profiling of Human Whole Blood and 
Dried Blood Spots 
7.1 Introduction 
 Over the past years, there has been an increase in the use of whole blood in lipid literature 
and in clinical settings (Baylin et al., 2005; Doull et al., 2001).  While most of the research 
focuses on plasma, erythrocytes, and/or other circulating blood cells, the use of whole blood has 
several advantages (Risé et al., 2007).  Firstly, whole blood is a more complex sample and, as 
such, may be more informative.  Moreover, the isolation of erythrocytes and plasma requires 
blood to be collected via venipuncture, while applications such as the neonatal heel prick and 
fingertip prick dried-blood spotting are minimally invasive and require little training.  These 
techniques are regularly used to test for congenital diseases such as phenylketonuria, cystic 
fibrosis and sickle cell disease (Green et al., 1998; Health Quality Ontario, 2003).  Notably, 
whole blood has been used for the development of biomarkers that strongly correlate with the 
omega-3 fatty acid content of various mammalian tissues (Stark, 2008), which may be used to 
determine omega-3 fatty acid status using popular guidelines such as the Omega-3 Index (Harris 
et al., 2004).  These biomarkers have been validated in dried blood spots previously (Metherel et 
al., 2009).  Furthermore, the stability of fatty acids in dried blood spots has been examined in 
detail under optimal laboratory conditions (Metherel et al., 2013) and in fieldwork with limited 
resources (Nurhasan et al., 2015).  Currently, there are two reports from the same research group 
on lipidomic profiling of dried blood spots (Koulman et al., 2014; Prentice et al., 2015).  
Although no significant differences were observed between the lipidomic profiles of whole blood 
and dried blood spots in the validation work, these papers have several limitations.  Firstly, the 
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comparisons between dried blood spots and whole blood are qualitative.  The values given 
represent the proportion that specific lipids constitute in the sum of lipid intensities measured 
(i.e. the relative percent of lipids in the measured lipid pool).  Although this drawback does not 
limit the use of dried blood spots in applications where, for example, the ratio of one lipid to 
another is examined, it may conceal the possibility that the total sums for whole blood and dried 
blood spot ion intensities are different.  Moreover, both reports only present data for limited 
numbers of PC, SM, CE and TAG.  Though some PE data is presented in the electronic 
supplementary material, it is not discussed.  There may be a specific effect of spotting and drying 
blood on paper, or in the extraction of other lipid classes that are also present in blood, such as 
PS and PI.  These were not measured.  Lastly, lipidomic data is only reported in terms of lipid 
class and lipid grouping (i.e. PC 34:2).  While some assumptions are made with regards to what 
the fatty acyl constituents are, the researchers did not take advantage of the tandem MS spectra 
generated to examine possible effects that fatty acyl length and degree of unsaturation may have 
on dried blood spot lipidomic profiles. 
 In this chapter, the lipidomic profiles of dried blood spots and whole blood will be 
contrasted using the novel method that was developed.  Specifically, the lipidomic profiling 
method is employed to examine the use of dried blood spot technical replicates qualitatively and 
semi-quantitatively.  The extraction efficiency of lipids from dried blood spots is also examined.  
Finally, the use of dried blood spots for lipidomic profiling is validated using a small sample of 
adults (n=3) that reported frequent, sporadic, and no consumption of omega-3 highly unsaturated 
fatty acid-rich sources, such as fish or nutraceuticals. 
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7.2 Lipidomics of Whole Blood and Dried Blood Spot Technical Replicates 
 The blood of one, 23 year-old male participant was collected from the antecubital vein 
into an EDTA-lined vacutainer.  Ten whole blood technical replicates were aliquoted (500 µL 
each) stored in at -80ºC until analysis.  Additionally, ten dried blood spot technical replicates 
were prepared by pipetting 50 µL of fresh, unfrozen whole blood into pre-washed (1:1 
chloroform:methanol, v/v) chromatography paper strips, onto an area of approximately 1 cm2.  
The blood was allowed to air-dry for approximately one hour, and then stored in capped test 
tubes at -80ºC (Metherel et al., 2013).  Prior to analysis, whole blood samples were allowed to 
thaw at room temperature for 30 minutes.  Six 50 µL aliquots were transferred to 12 x 75 
disposable culture tubes, then 3 mL of 2:1 chloroform:methanol (v/v) were added in order to 
extract lipids as described in Chapter 4.  Similarly, six dried blood spots were taken out of 
storage, placed on 12 x 75 disposable culture tubes, and 3 mL of 2:1 chloroform:methanol (v/v) 
were added.  To examine the effect of extraction time, three out of the six whole blood samples 
and three dried blood spots were left in solvents for 24 hours (hereafter referred to as WB24 and 
DBS24, respectively).  The remaining three whole blood samples and dried blood spots were 
vortexed vigorously for 1 minute, then 500 µL of 0.2 M Na2PO4 in ddH2O were added in order to 
induce phase separation.  Samples were inverted twice and centrifuged at 1734 rcf for 5 minutes.  
The bottom chloroform layer containing the lipids was extracted, and 2 mL of fresh chloroform 
were added to the aqueous portion of the 6 samples.  All were vortexed and centrifuged again.  
The resulting organic phases were taken and combined with the first extracts.  These total lipid 
extracts for these whole blood and dried blood spot samples are hereafter referred to as WBi and 
DBSi, indicating that the lipids were extracted immediately following the addition of 
chloroform/methanol.  Total lipid extracts were dried fully under a stream of N2 gas, and 
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reconstituted into 1 mL of chloroform.  Based on the results from the blood dilution experiments 
performed in Chapter 5, a 100 µL aliquot was taken from the total lipid extracts, representing 10 
µL of blood.  The 100 µL samples were spiked with 500 pmol of a concentrated di-17:0 PC 
standard solution to allow semi-quantitative analyses and account for sample-to-sample 
variability.  Samples were then added to HPLC vials, dried fully under N2 gas, and re-suspended 
in 100 µL of the HPLC sample solvent.  The samples were then stored at 4ºC until analysis.  On 
the following day, lipids were extracted from WB24 and DBS24, aliquoted, and spiked with di-
17:0 PC as described above.  All samples were run with the chromatographic protocol developed 
in Chapter 5, and using Top5 data-dependent acquisition with positive ESI.  From the list of 
identifiable lipids reported in Appendix B, 11 acyl specific lipids were selected for the validation 
of dried blood spots (Table 1).  This list includes several PC with a range of acyl-chain lengths 
and levels of unsaturation, as well as a lyso- PC, two PE, a PS, a TAG, and a CE.  The dried 
blood spot samples that were extracted immediately following the addition of 
chloroform/methanol (DBSi) resulted in significantly lower recoveries compared with WBi, 
DBS24, and WB24 (p < 0.05 for all; Table 1).  The fact that there are no significant differences 
between the lipid recoveries of WBi and WB24 may be explained by the larger contact area of 
WB with the extraction solvents compared to DBS.  Since chloroform/methanol is added to 
whole blood while it is liquid, the resulting sample is a homogeneous mixture.  On the other 
hand, dried blood spots have a much smaller surface area since the lipids are contained within a 
~1 cm2 piece of chromatography paper, and do not solubilize as easily in the extraction solvents.  
It appears, however, that leaving the DBS samples in chloroform/methanol for 24 hours reverses 
this effect as no significant differences were observed between recoveries from DBS24, WBi or 
WB24.  Since these results are based on technical replicates of one volunteer’s blood, the next 
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step was to examine the lipidomic profiles of whole blood and dried blood spots from different 
individuals.   
 
6.3 Whole Blood and Dried Blood Spot Lipidomic Analysis of Humans with Low, 
Intermediate, and High Omega-3 Status 
 In order to confirm the validity of the results from the technical replicate experiments, a 
small sample of participants was recruited (n =3; 2M, 1F; aged 18 - 25).  These participants were 
asked about their regular diets; Participant 1 (P1) indicated consuming fish frequently (4-5 times 
per week), Participant 2 (P2) indicated taking a fish oil supplement containing 300 mg of 
EPA+DHA per capsule once per week and consumption of fish approximately once monthly, 
and Participant 3 (P3) reported no consumption of fish, fish oil, or omega-3 enriched foods.  
Venous blood was taken from the three participants from the antecubital vein into EDTA-lined 
vacutainers.  Blood was aliquoted and prepared into dried blood spots as explained in Section 
6.2.  Lipids were extracted from WB and DBS samples for each of the three participants 24 
hours after the addition of 2:1 chloroform:methanol (v/v).  Lipid extracts were diluted 
appropriately, spiked with 17:0/17:0 PC as an internal standard, and reconstituted in the HPLC 
sample solvent.  The samples were run with the UHPLC method developed in Chapter 5, using 
positive ESI and Top5 data-dependent acquisition for tandem MS.  In order to contrast and 
express the lipidomic data in terms of whole blood omega-3 highly unsaturated fatty acid status, 
a single 50 µL aliquot from the original whole blood samples was used to determine the fatty 
acid composition for the three participants.  This was done as described previously (Metherel et 
al., 2013).  In short, fatty acids were derivatized to fatty acid methyl esters using 1 mL 14% BF3 
in methanol and analyzed via GC-FID.  C 22:3n-3 was used as the internal standard (Nu-Check 
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Prep, Elysian, MN, USA).  Fatty acid composition data is presented in Table 4 as concentration 
and Table C.1, Appendix C as weight percent in total fatty acids.  The blood biomarker levels 
such as the % n-3 HUFA in total HUFA and the sum of the % of EPA+DHA reflected the high, 
medium, and low omega-3 HUFA intakes reported verbally by participants P1, P2, and P3, 
respectively.  After confirming the range in omega-3 HUFA status via GC-FID, lipidomic data 
was extracted for the 11 lipids examined in Section 6.2 as well as 11 HUFA-containing lipids for 
a total of 22 specific lipids (Table 2).  From the lipids examined, only 18:0/22:6 PS was 
significantly lower in DBS compared to WB (two-tailed Student’s t-test, p = 0.02), suggesting 
that PS species may not be extracted from DBS as efficiently as other lipids.  To explore this 
further, data for five additional PS species were extracted from the existing chromatograms 
(Table 3).  All PS species measured were significantly lower in DBS compared to WB samples 
(p < 0.05 for all comparisons).  This confirmed limited recoveries of PS species from dried blood 
spots.  Interestingly, all phospholipids have one acidic group (-OH) around the phosphorus atom, 
while PS residues have an additional carboxylic acid residue that makes PS species acidic 
compounds at physiological pH (Folch, 1948).  Hydrogen bonding between acidic compounds 
and the cellulose fibers within the chromatography paper used to collect DBS is known to occur 
(Sahin et al., 2008), and may explain the limited recoveries of PS observed. 
 
7.4 Conclusions, Limitations and Future Directions 
 Lipidomic profiling of dried blood spots can provide a reliable representation of the 
whole blood lipidome for PC, PE, TAG, and CE.  However it appears that lipid extraction from 
DBS requires extended periods of time.  Moreover, the recovery of PS appears to be limited even 
with the 24-hour extraction period.  The homogenization or sonication of DBS in the 
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chloroform/methanol may aid in increasing PS recoveries by increasing the surface area of the 
blood with the extraction solvents (Metherel et al., 2009).  Lipid extraction techniques employing 
different solvent systems (Koulman et al., 2014) or manipulating the pH of the extraction 
solvents may also result in higher PS recoveries from DBS.  Interestingly, the relationships 
between omega-3 HUFA in lipidomic profiles and fatty acid profiles may provide additional 
insights.  Specifically, the blood of P1 has the highest concentration of EPA (Table 4; 2.50 
µg/100µL whole blood) compared to P2 (2.19 µg/100 µL whole blood) and P3 (0.56 µg/100 µL 
whole blood), but 16:0/20:5 PC is highest in P2 (Table 2, 41.76 A.U.; P1 and P3 are 35.99 A.U. 
and 8.80 A.U., respectively).  EPA has been demonstrated to increase rapidly in response to 
recent intake (Metherel et al., 2009).  As such, certain acyl species of blood lipids such as 
16:0/20:5 PC may be an indicator of very recent omega-3 HUFA intake.  Other acyl species of 
blood lipids, such as erythrocyte membrane-associated phospholipids, may be better indicators 
for habitual, long-term intake; these take significantly longer periods of time to be remodeled 
compared to plasma lipids (Patterson et al., 2013).  Levels of 16:0/22:6 PC were considerably 
higher in P1 (106.03 A.U.) as compared with P2 (62.10 A.U.) and P3 (34.88 A.U.) suggesting it 
may be a marker of long term omega-3 HUFA intake.  To explore the relationship between 
dietary intake of omega-3 HUFA and acyl specific lipids, the lipidomic profiles of whole blood 
from humans with very defined dose intakes of EPA + DHA as part of a previous intervention 
trial (Patterson, 2012) were examined.  
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Table 1.  Lipidomic profiles of whole blood and dried blood spot technical replicates. 
   
Lipid Abundance 
(Arbitrary Units, Average ± SD) 
Observed m/z Lipid Adduct DBSi WBi DBS24 WB24 
496.3398 Lyso-16:0 PC [M+H]+ 42.9 ± 4.9a 96.5 ± 6.0b 103.0 ± 4.6b 92.4 ± 1.6b 
758.5694 16:0/18:2 PC [M+H]+ 381.6 ± 57.2a 1033.6 ± 95.7b 1110.7 ± 28.4b 1033.8 ± 36.0b 
782.5692 16:0/20:4 PC [M+H]+ 749.5 ± 97.5a 1319.0 ± 80.6b 1379.1 ± 42.5b 1232.8 ± 26.5b 
834.6006 18:0/22:6 PC [M+H]+ 13.5 ± 4.1a 28.0 ± 2.4b 30.0 ± 1.4b 28.1 ± 0.6b 
780.5534 16:0/20:5 PC [M+H]+ 29.2 ± 4.1a 58.0 ± 3.0b 61.1 ± 2.0b 53.0 ± 2.7b 
806.5691 16:0/22:6 PC [M+H]+ 51.7 ± 8.5a 130.5 ± 12.6b 137.5 ± 4.9b 131.3 ± 5.6b 
716.5221 16:0/18:2 PE [M+H]+ 6.3 ± 0.8a 11.9 ± 0.7b 13.0 ± 0.5b 12.0 ± 0.1b 
764.5221 16:0/22:6 PE [M+H]+ 11.7 ± 1.6a 20.8 ± 1.5b 22.7 ± 1.0b 21.0 ± 0.4b 
836.5432 18:0/22:6 PS [M+H]+ 37.1 ± 4.4a 54.9 ± 0.9b 48.6 ± 6.5b 57.5 ± 2.8b 
876.8011 16:0/18:1/18:1 TAG [M+NH4]+ 96.9 ± 28.9a 212.9 ± 14.3b 240.2 ± 9.7b 215.8 ± 9.0b 
666.6181 18:2 CE [M+NH4]+ 62.8 ± 11.4a 110.4 ± 7.4b 119.2 ± 11.2b 108.3 ± 3.1b 
m/z = mass to charge ratio.  DBSi = immediate lipid extraction from dried blood spots.  DBS24 = lipid extraction from dried 
blood spots 24 hours after the addition of extraction solvents.  WBi = immediate lipid extraction from whole blood.  WB24 = 
lipid extraction from whole blood 24 hours after the addition of extraction solvents. Phosphatidylcholine (PC); 
phosphatidylethanolamine (PE); phosphatidylserine (PS); triacylglycerol (TAG); cholesteryl ester (CE).  p ≤ 0.001 for all 
differences shown (except 18:0/22:6 PS, p < 0.05) after one-way ANOVA with Tukey post-hoc test. 
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Table 2.  Lipidomic profiles of whole blood and dried blood spots for high, intermediate, and low omega-3 HUFA 
status 
   Lipid Abundance (Arbitrary Units) Average ± SD  
Observed m/z Lipid Adduct HighWB MedWB LowWB HighDBS MedDBS LowDBS WBave DBSave 
496.3398 Lyso-16:0 PC [M+H]+ 90.89 78.77 100.31 88.77 62.79 91.43 90.0 ± 10.8 81.0 ± 15.8 
758.5694 16:0/18:2 PC [M+H]+ 1458.29 941.76 1045.18 1436.38 829.27 997.77 1148.4 ± 273.3 1087.8 ± 313.4 
780.5534 16:0/20:5 PC [M+H]+ 35.99 41.76 8.80 41.23 40.31 8.65 28.7 ± 17.8 30.0 ± 19.0 
782.5692 16:0/20:4 PC [M+H]+ 562.51 828.97 676.50 628.52 796.71 688.97 689.3 ± 133.7 704.7 ± 85.2 
806.5691 16:0/22:6 PC [M+H]+ 106.03 62.10 34.88 84.73 57.39 34.36 68.2 ± 36.3 60.1 ± 26.2 
808.5862 18:0/20:5 PC [M+H]+ 18.98 16.06 6.86 16.63 14.58 6.77 14.0 ± 6.3 12.7 ± 5.2 
832.5694 18:1/22:6 PC [M+H]+ 3.04 3.14 1.54 2.48 2.78 1.33 2.6 ± 0.9 2.2 ± 0.8 
834.6006 18:0/22:6 PC [M+H]+ 29.55 18.09 10.51 21.65 17.04 10.42 19.6 ± 9.9 16.5 ± 5.9 
716.5221 16:0/18:2 PE [M+H]+ 9.04 8.30 7.86 7.76 6.34 6.81 8.4 ± 0.6 7.0 ± 0.7 
764.5221 16:0/22:6 PE [M+H]+ 22.38 19.15 12.32 23.59 17.51 11.34 17.9 ± 5.2 17.4 ± 6.1 
722.5120 Plasmenyl-PE P16:0/20:5 [M+H]+ 3.20 2.14 0.58 2.62 1.74 0.58 2.0 ± 1.3 1.6 ± 1.0 
748.5277 Plasmenyl-PE P16:0/22:6 [M+H]+ 7.99 3.51 3.16 6.42 4.46 2.86 4.9 ± 2.7 4.6 ± 1.8 
752.5590 Plasmenyl-PE P18:0/20:4 [M+H]+ 27.86 32.95 33.54 25.33 27.22 29.88 31.5 ± 3.1 27.5 ± 2.3 
836.5432 18:0/22:6 PS [M+H]+ 43.23 40.20 28.58 23.66 13.38 11.36 37.3 ± 8.1a 16.2 ± 6.6b 
876.8011 16:0/18:1/18:1 TAG [M+NH4]+ 242.01 213.57 240.78 237.85 233.99 266.02 232.1 ± 16.1 246.0 ± 17.5 
894.7542 16:0/18:2/20:5 TAG [M+NH4]+ 1.41 2.31 0.50 1.21 2.58 0.57 1.4 ± 0.9 1.5 ± 1.0 
918.7036 16:0/18:2/22:6 TAG [M+NH4]+ 6.85 5.34 0.84 6.12 5.68 0.88 4.3 ± 3.1 4.2 ± 2.9 
920.7699 18:1/18:2/20:5 TAG [M+NH4]+ 6.88 5.41 0.85 6.10 5.74 0.89 4.4 ± 3.1 4.2 ± 2.9 
922.7859 16:0/18:1/22:6 TAG [M+NH4]+ 10.11 10.00 1.25 9.18 10.62 1.35 7.1 ± 5.1 7.1 ± 5.0 
666.6181 18:2 CE [M+NH4]+ 128.95 109.19 103.03 151.25 121.72 114.45 113.7 ± 13.5 129.1 ± 19.5 
688.6029 20:5 CE [M+NH4]+ 6.77 2.55 0.69 5.77 2.65 0.75 3.3 ± 3.1 3.1 ± 2.5 
714.6182 22:6 CE [M+NH4]+ 7.20 4.04 2.28 5.89 4.49 2.48 4.5 ± 2.5 4.3 ± 1.7 
High (P1), Med (P2) and Low (P3) represent omega-3 HUFA status, from fatty acid composition data generated with GC-FID.  
Full fatty acid profiles found in Appendix C.  Whole Blood (WB); Dried Blood Spot (DBS); Phosphatidylcholine (PC); 
phosphatidylethanolamine (PE); phosphatidylserine (PS); triacylglycerol (TAG); cholesteryl ester (CE).  a is significantly from b 
with p = 0.02 after a two-tailed Student’s t-test.   
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Table 3.  Lipidomic profiles of phosphatidylserine species in whole blood and dried blood spot for high, intermediate, and low 
omega-3 HUFA status 
   
Lipid Abundance 
(Arbitrary Units) Average ± SD 
 
Observed m/z Lipid Adduct HighWB MedWB LowWB HighDBS MedDBS LowDBS WBave DBSave 
790.5592 18:0/18:1 PS [M+H]+ 7.26 5.00 5.45 3.15 1.36 1.80 5.9 ± 1.2a 2.1 ± 0.9b 
814.5593 18:0/20:3 PS [M+H]+ 3.29 2.11 3.47 1.50 0.55 1.16 3.0 ± 0.7a 1.1 ± 0.5b 
812.5433 18:0/20:4 PS [M+H]+ 49.47 54.25 63.27 23.83 15.12 21.65 55.7 ± 7.0a 20.2 ± 4.5b 
837.5436 18:0/22:5 PS [M+H]+ 0.28 0.18 0.32 0.13 0.02 0.09 0.3 ± 0.1a 0.1 ± 0.1b 
836.5435 18:0/22:6 PS [M+H]+ 43.71 40.07 28.19 23.64 13.59 11.33 37.3 ± 8.1a 16.2 ± 6.6b 
m/z = mass to charge ratio.  Whole Blood (WB); Dried Blood Spot (DBS); Phosphatidylserine (PS).  High, Med and Low represent omega-3 
highly unsaturated status (HUFA), from fatty acid composition data generated with gas chromatography-flame ionization detection (GC-FID).  
Full fatty acid profiles found in Appendix C.  a is significantly from b with p < 0.05 after a two-tailed Student’s t-test.   
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Table 4.  Fatty Acid Composition – Concentrations in Whole Blood 
 
Whole Blood Total Lipids 
(µg fatty acid per 100 µL whole blood) 
Name P1 P2 P3 Average SD 
C 12:0 0.17 0.13 0.10 0.14 0.04 
C 14:0 1.76 2.15 1.55 1.82 0.30 
C 16:0 54.23 52.26 47.97 51.49 3.20 
C 17:0 0.81 0.75 0.63 0.73 0.09 
C 18:0 30.09 32.20 29.31 30.53 1.49 
C 20:0 0.78 0.93 0.82 0.84 0.08 
C 22:0 1.82 2.19 1.88 1.96 0.20 
C 23:0 0.46 0.52 0.41 0.46 0.05 
C 24:0 3.11 4.23 3.60 3.65 0.56 
SFAs 96.96 98.96 89.32 95.08 5.09 
C 12:1 0.01 0.01 0.01 0.01 <0.00 
C 14:1 0.07 0.07 0.03 0.06 0.03 
C 16:1 2.01 2.01 1.48 1.83 0.31 
C 18:1n-7 4.02 3.95 4.09 4.02 0.07 
C 18:1n-9 39.26 41.78 36.11 39.05 2.84 
C 20:1n-9 0.56 0.68 0.56 0.60 0.07 
C 22:1n-9 0.10 0.19 0.18 0.16 0.05 
C 24:1n-9 4.37 4.99 3.92 4.43 0.54 
MUFAs 51.16 54.27 46.81 50.75 3.75 
C 18:2n-6 63.34 47.80 45.05 52.06 9.86 
C 18:3n-6 0.14 0.83 0.25 0.41 0.37 
C 20:2n-6 0.65 0.52 0.51 0.56 0.08 
C 20:3n-6 2.56 3.15 2.54 2.75 0.35 
C 20:4n-6 20.30 26.20 23.00 23.17 2.95 
C 22:2n-6 0.20 0.22 0.21 0.21 0.01 
C 22:4n-6 1.72 2.59 3.31 2.54 0.80 
C 22:5n-6 0.62 0.92 0.99 0.84 0.19 
N-6 89.54 82.24 75.87 82.55 6.84 
C 18:3n-3 1.82 1.21 0.87 1.30 0.48 
C 20:3n-3 0.13 0.10 0.08 0.11 0.02 
C 20:5n-3 2.50 2.19 0.56 1.75 1.04 
C 22:5n-3 2.62 3.18 2.54 2.78 0.35 
C 22:6n-3 7.79 6.97 3.71 6.16 2.16 
N-3 14.87 13.66 7.77 12.10 3.80 
C 20:3n-9 0.17 0.31 0.18 0.22 0.08 
PUFAs 104.58 96.21 83.82 94.87 10.45 
HUFAs 38.42 45.63 36.93 40.32 4.65 
EPA+DHA 10.30 9.16 4.27 7.91 3.20 
Total 252.71 249.44 219.96 240.70 18.04 
Saturated fatty acids (SFAs); Mono-unsaturated fatty acids (MUFAs); Omega-6 fatty acids (N-
6); Omega-3 fatty acids (N-3); Polyunsaturated fatty acids (PUFAs); Highly unsaturated fatty 
acids (HUFAs); Eicosapentaenoic acid (EPA); Docosahexaenoic acid (DHA).  
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Chapter 8 
Lipidomic Profiling of Human Whole Blood Following Omega-3 Highly 
Unsaturated Fatty Acid Supplementation 
8.1 Introduction 
The fatty acid composition of blood before and after omega-3 HUFA supplementation 
has been examined extensively in the literature, although data on whole blood is relatively 
limited.  Previously, with acute supplementation and washout is has been observed that EPA 
increases and decreases rapidly in blood, while DHA changes appear to be more gradual 
(Metherel et al., 2009). Others have supported these observations, where the slow turnover of 
DHA in erythrocytes reflects long-term intake of omega-3 HUFA (Patterson et al., 2013). 
Though significant work has been done on the development of blood biomarkers that reflect 
short-term and long-term omega-3 HUFA intake using fatty acid compositional data (Browning 
et al., 2012) little work has been done examining the effect of omega-3 HUFA supplementation 
on acyl-specific blood lipids. Therefore, the location of omega-3 HUFA in complex blood lipids 
with different levels of fish oil intake was examined. To do so, blood samples from a previous 
intervention trial with tight dietary intakes of EPA and DHA (Patterson, 2012) were analyzed 
using the UHPLC-MS/MS method developed throughout Chapters 5 and 6 of this thesis. 
 
8.2 Methods 
8.2.1 Participants and Blood Samples 
Participants were recruited from the University of Waterloo area through flyers and 
emails. A screening fingertip prick sample was collected, and participants completed a semi-
quantitative food frequency questionnaire to assess EPA and DHA intakes. Individuals were 
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excluded if they were currently consuming supplements with EPA and DHA, or if fingertip prick 
whole blood revealed that EPA and DHA were greater than 3% of total fatty acids by weight 
percent. At baseline, anthropometric measures were collected along with a fasting venous blood 
sample from twenty individuals, and they were instructed to not consume any nutraceuticals or 
EPA/DHA-containing foods (anthropometric measures can be found in Patterson, 2012 Doctoral 
Thesis). The participants were provided with fish oil capsules and were instructed to take one 
capsule per day for four weeks (providing ~250 mg/day EPA+DHA), and then two capsules per 
day for the next four weeks (providing ~500 mg/day EPA+DHA).  After the eight-week period, a 
subset of five participants was asked to take four capsules per day for an additional four weeks 
(providing ~1000 mg/day EPA+DHA). Fasting venous blood samples were collected again after 
4 and 8 weeks for the 20 participants, and at week 12 for the subset of five. Blood samples were 
aliquoted in triplicates of 500 uL and stored at -80ºC until analysis. 
 
8.2.2 Fatty Acid Composition and Lipidomic Analyses 
 The fatty acid composition of whole blood, plasma phospholipids and erythrocytes was 
determined as described in Chapter 4 using in GC-FID in 2012 (Patterson, 2012). The samples 
that were used for lipidomic profiling remained frozen at -80ºC from the time of collection until 
preparation for UHPLC-MS/MS analysis. To test the quality and state of the samples after more 
than 2 years in storage, quantitative and qualitative fatty acid compositional data was generated 
for the whole blood of a subset of 3 participants from each of the four time points. There were no 
significant differences in the fatty acid profiles of the blood samples compared to the data from 
2012, suggesting that whole blood fatty acids may be stable in -80ºC storage for longer than 6 
months (Metherel et al., 2013). 
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Due to the complexity and extensiveness of the lipidomic data that can be generated with 
the current UHPLC-MS/MS method, and the issues associated with data processing, a list of 46 
target lipids was generated.  These were used to profile whole blood samples throughout the 
experiments in this chapter. Overall, the UHPLC-MS/MS method for lipidomic profiling of 
human whole blood developed in Chapter 5 identified 163 acyl specific lipids.  Individual acyl 
species of lipids were examined for individual lipids that made up the top 85% of the lipidome.  
The top 85% all of the detectable lipids (Appendix B) were determined by sorting in descending 
order the area under the curve (AUC).  This was done until the sum of these AUC constituted at 
least 85% of the total sum for all lipids within the lipid class to which they belong.  The specific 
lipids falling outside of the 85% made limited contributions to the overall lipidome (<0.01% to 
0.13% of total lipid AUC).  Providing acyl-specific data for the top 85% of lipids within a lipid 
class can provide information about specific molecules, yet still giving insights with regards to 
what may be happening to the entire lipid pool (Byrdwell, 2015b).  While data can be generated 
for hundreds of lipids and minor lipids can be highly bioactive (Ji et al., 2011), the targeted list 
of 46 provides a parsimonious but highly informative snapshot of the lipidome for screening 
purposes.   
 The sixty-five whole blood samples (20 baseline, 20 week 4, 20 week 8, and 5 week 12) 
were prepared for UHPLC-MS/MS analysis as described in Chapter 4.  Briefly, samples were 
removed from -80ºC storage, thawed, extracted twice using 2:1 chloroform:methanol (v/v), and 
spiked with di-17:0 PC in the HPLC sample solvent.  The 47-minute multi-step gradient was 
used with positive ESI and Top5 data-dependent acquisition.  The ion profiles for the 46 lipids 
that constituted the top 85% of total lipids were extracted and the peaks were integrated.  As in 
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previous chapters, the raw integrated data (area under the curve) were standardized by dividing 
them by the area under the curve for the internal standard (di-17:0 PC) and multiplying by 100. 
 
8.2.3 Thin Layer Chromatography and Adjustment of the Lipidomic Data 
The fatty acid composition of total PC, PE, PS, PI, SM, TAG, FFA and CE was 
determined by GC-FID after thin layer chromatography isolation as described in Chapter 4 for a 
subset of 3 participants at baseline, week 4, week 8 and week 12 of the supplementation period. 
Initially, this was done in order to contrast the acyl-specific lipidomic data derived from 
UHPLC-MS/MS analyses to fatty acid compositional data, as thin layer chromatography/GC-
FID fatty acid determinations are quantitatively robust (Firl et al., 2013). However, this fatty acid 
compositional data served a second purpose for standardization when the raw lipidomics data 
was inconsistent. While all of the semi-quantitative data generated in this thesis was standardized 
to a di-17:0 PC internal standard, there were significant differences in the responses that were 
observed for the standard peak in the lipidomic analyses that were completed. Due to instrument 
availability, the samples were run in three different sequences over the span of two weeks. Day-
to-day variation of absolute instrument responses are widely known for quantitative and semi-
quantitative MS methods in general, and may result from several factors such as instrument 
cleanliness, ion source flow rates, and state of the mass spectrometer’s vacuum (Pitt, 2009). 
Therefore, in order to analyze the lipidomic data and examine the effect of EPA and DHA 
supplementation over time, the data was normalized systematically to reflect the changes in 
specific lipid pool total concentrations generated through thin layer chromatography and GC-
FID.  As an example, the ratios between total PE between the four time points as determined by 
thin layer chromatography and GC-FID were applied to the lipidomic data from the UHPLC-
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MS/MS method.  Granted that using thin layer chromatography/ GC-FID data was effective for 
normalizing lipidomic data, generating it entails a considerable additional amount of analytical 
work that is not practical for routine analyses.   
 
8.3 Results 
Native lipid abundances of the top 85% abundant lipids are reported as A.U., were 
examined for the 20 participants over 8 weeks at intakes of 250 mg/day and 500 mg/day (Table 
5), and intakes of 250 mg/day, 500 mg/day and 1000 mg/day were examined in a subset of 5 
participants over 12 weeks (Table 6). Due to the nature of the semi-quantitative method, it is 
only possible to examine and compare specific lipid acyl species within lipid classes, but not 
between them. At baseline, the most abundant PC with DHA acyl species is 16:0/DHA PC, and 
that for EPA-containing species is 16:0/EPA PC.  Notably, these same species appear to be the 
most responsive to increasing doses of EPA+DHA within the PC pool. While there is some 
incorporation of dietary EPA and DHA into other lipids (like 18:0/DHA PC, 18:1/DHA PC, 
18:0/EPA PC), it appears that the bulk of these two fatty acids are going into palmitate-
containing PC. On average, 16:0/DHA PC and 16:0/EPA PC increase by 16.22 A.U. and 21.14 
A.U. respectively by week 8 compared to baseline in the group of 20 (Table 5; p < 0.001); and 
by 33.58 A.U. and 41.78 A.U. respectively by week 12 compared to baseline in the group of 5 
(Table 6; p < 0.05). Interestingly, these two lipids appear to change in a dose-response manner. 
The supplemented dose of EPA+DHA between weeks 4 and 8 was 500 mg/day, and between 
weeks 8 and 12 it was 1000 mg/day. This is reflected by the absolute increases in 16:0/DHA PC 
and 16:0/EPA PC at the end of weeks 8 and 12 compared to baseline values. While some 
incorporation of EPA and DHA does take place over time in PE acyl species, significantly higher 
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plasmenyl-PE P-16:0 EPA (most abundant species at baseline; p < 0.001) is only observed at 
week 12 compared to baseline. This lipid, like 16:0/DHA PC and 16:0/EPA PC appears to 
increase proportionally to the dose of EPA+DHA supplemented; there is an increase of 0.41 
A.U. at week 8 compared to baseline, and a further increase of 1.01 A.U. at week 12 compared to 
baseline in the subset of 5 participants (Table 6). In the contrary, 16:0/DHA PE, which is the 
most abundant DHA-containing acyl species in the PE pool at baseline is not different at any of 
the time points. Finally, there appears to be some incorporation of EPA and DHA into other lipid 
pools such as CE, TAG. No differences are observed in 18:0/DHA PS at any of the time points.  
Remarkably, the lipidomic data for PE species reveals flux of omega-6 HUFAs.  Specifically, PE 
species such as 16:0/20:4, 18:0/20:4 and Plasmenyl PE P-18:0/20:4 are significantly lower at 
week 12 compared to baseline. Furthermore, there is an increase in the proportion of 18:1/20:4 
PC species in the group of 20 participants at week 12.  
 
8.4 Discussion 
This study suggests that the PC pool is a major site for omega-3 HUFA incorporation in 
blood.  Notably, PC is a substantial component of both plasma lipoproteins and erythrocyte 
bilayers, but PE and PS are found primarily in the erythrocyte fraction (Figure 10; Table E.1, 
Appendix E).  In addition to previous reports (Metherel et al., 2009; Patterson et al., 2013), this 
supports that the plasma fraction is more responsive to changes in EPA and DHA dietary intake 
compared to erythrocytes.  Interestingly, these findings are further supported by the plasma 
phospholipid and erythrocyte total fatty acid composition data (Tables 7 and 8), and the whole 
blood lipid pool fatty acid composition data (Table 9; Tables D.1 through D.7, Appendix D).  
While plasma phospholipid EPA is significantly higher after four weeks of supplementation and 
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DHA after 8 weeks compared to baseline in the group of 20 and (p < 0.05 for both), erythrocyte 
EPA appears to only be significantly higher than baseline at week 8 and erythrocyte DHA is only 
different at week 12. Finally, the fatty acid composition data for total PE (Table 9) shows that 
there is no difference in total DHA in PE even after 12 weeks of supplementation, but total EPA 
in PE is over 3-fold higher at week 12 compared to baseline (p < 0.05). 
In addition to these observations that suggest slower turnover of omega-3 HUFA in 
erythrocytes membrane lipids compared to plasma phospholipids, three potential acyl-specific 
lipids were identified that reflect the doses of EPA and DHA being consumed through fish oil 
supplementation. These lipids are 16:0/DHA PC, 16:0/EPA PC, and plasmenyl-PE P-16:0/EPA. 
The difference in the absolute increase of these lipids to baseline was nearly a factor of 2 from 
week 8 to week 12, which is the factor by which the dose increased. Since PC is a major 
structural component of erythrocyte bilayers but also plasma lipoproteins, it was therefore 
expected that some acyl-specific PC molecule would reflect rapid changes in EPA+DHA intake. 
Although, it was interesting to see that plasmenyl-PE P-16:0/EPA, which is primarily associated 
with the erythrocyte bilayer (Nagan and Zoeller, 2001) also reflects recent intake. This finding 
supports previous reports (Patterson et al., 2014) on the faster flux of EPA in and out of 
erythrocyte membranes compared to DHA. However, it appears that EPA mobilization is fast in 
the PE pool as well which has not been reported previously. 
 
8.4 Conclusions, Limitations, and Future Directions 
 In conclusion, the lipidomic data supports previous findings of fast turnover of EPA and 
DHA in plasma, but slower in erythrocyte phospholipids (Metherel et al., 2009; Patterson et al., 
2014). Through the acyl-specific characterization of whole blood lipids from a previous 
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supplementation study with tight dietary control (Patterson, 2012), 16:0/DHA PC, 16:0/EPA PC, 
and plasmenyl-PE P-16:0/EPA were found to be very responsive to increasing intakes of 
EPA+DHA. Specifically, these lipids increased in a dose-dependent manner, and may be 
adequate indicators of frequent or habitual intake of EPA+DHA. Interestingly, the reduction that 
was observed in some omega-6 HUFA acyl specific PE like 16:0/20:4 PE, 18:0/20:4 PE and 
plasmenyl-PE P-18:0/20:4 suggests that phospholipid remodeling may be taking place possibly 
through the Lands Cycle (Lands, 1958). One of the main limitations of this study is that the 
current UHPLC-MS/MS analyses did not allow for direct comparisons to be made between lipid 
pools containing EPA and DHA acyl-specific lipids. This was due to the fact that only one 
internal standard (di-17:0 PC) was used to normalize the data. Since different lipids exhibit 
different electrical properties in ESI-MS that are intrinsic of their molecular configurations, they 
generate different absolute instrument responses that may only be normalized through the use of 
internal standards that share those same electrical properties (Koivusalo et al., 2001). Therefore, 
an internal standard for each lipid class is likely required. If the use of stable isotope standards 
for quantitation is not feasible or possible, multiple lipid standards may be used if factors such as 
the phospholipid head group, and fatty acyl length and degree of unsaturation are taken into 
account. Furthermore, the analyses performed in this study were only in whole blood. While 
some conclusions were made regarding PE acyl species and changes in erythrocyte membranes, 
erythrocyte PC cannot be distinguished from plasma PC at this point. This could provide more 
insights with regards to lipid bilayer remodeling with omega-3 HUFA supplementation. Future 
work should examine lipidomic changes of acyl-specific lipids across blood fractions. 
Additionally, it remains unknown whether specific enzymes that are involved in phospholipid 
remodeling processes such as phospholipase-A2 (Tanaka et al., 2010) and lyso-phospholipid 
 68 
acyltransferases (Shindou et al., 2013) are upregulated. Finally, though the participants that were 
part of this study consumed very tightly-controlled amounts of EPA+DHA, the supplementation 
period was only 8 weeks for the group of 20, and 12 weeks for the subgroup of 5. Lipidomic 
discrimination of complex lipids in a long-term supplementation study could reveal acyl-specific 
lipids that are remodeled slowly over the span of several months, and could therefore be 
validated as indicators of long-term omega-3 HUFA intake. Some of the DHA-containing PS and 
PE species that did not change in this study could be appropriate biomarkers but longer 
supplement intervention times are required. 
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Table 5.  Lipidomic Examination of Human Whole Blood Following Fish Oil Supplementation for 8 weeks. 
   
Lipid Abundance, n = 20  
(Arbitrary Units, Average ± SD) 
Observed m/z Lipid Adduct Baseline Week 4 Week 8 
760.5843 PC 16:0/18:1 [M+H]+ 284.60 ± 66.08 268.98 ± 55.75 303.04 ± 55.89 
758.5704 PC 16:0/18:2 [M+H]+ 560.84 ± 100.02 532.74 ± 113.35 550.66 ± 84.17 
782.5699 PC 16:0/20:4 [M+H]+ 414.37 ± 68.83 370.16 ± 94.38 381.85 ± 81.23 
780.5536 PC 16:0/20:5 [M+H]+ 12.47 ± 5.83a 19.53 ± 6.45b 33.61 ± 11.52c 
806.5693 PC 16:0/22:6 [M+H]+ 42.70 ± 9.57a 44.65 ± 14.94a 58.92 ± 14.30b 
788.6178 PC 18:0/18:1 [M+H]+ 64.09 ± 11.59 64.05 ± 14.12 73.15 ± 12.91 
786.6022 PC 18:0/18:2 [M+H]+ 223.78 ± 51.85 222.93 ± 55.13 207.94 ± 33.78 
810.6002 PC 18:0/20:4 [M+H]+ 89.19 ± 23.49 77.99 ± 24.94 73.32 ± 21.67 
808.5851 PC 18:0/20:5 [M+H]+ 3.93 ± 1.96a 6.90 ± 2.49b 12.45 ± 3.23c 
834.6009 PC 18:0/22:6 [M+H]+ 12.12 ± 3.12a 13.01 ± 3.83a 17.34 ± 3.67b 
808.5872 PC 18:1/20:4 [M+H]+ 24.69 ± 5.51a 22.91 ± 6.98a 31.66 ± 7.83b 
832.5853 PC 18:1/22:6 [M+H]+ 2.35 ± 0.69 2.34 ± 0.77 2.88 ± 0.91 
Total PC measured 1735.14 ± 206.07 1646.19 ± 299.48 1746.82 ± 218.10 
718.5380 PE 16:0/18:1 [M+H]+ 11.48 ± 1.72 11.16 ± 1.74 11.44 ± 1.87 
716.5227 PE 16:0/18:2 [M+H]+ 4.66 ± 1.20 4.38 ± 1.05 4.45 ± 1.18 
740.5227 PE 16:0/20:4 [M+H]+ 9.36 ± 1.64 8.46 ± 1.58 8.49 ± 1.17 
738.5069 PE 16:0/20:5 [M+H]+ 0.40 ± 0.16a 0.46 ± 0.15a 0.68 ± 0.14b 
764.5225 PE 16:0/22:6 [M+H]+ 5.83 ± 1.76 5.65 ± 1.65 6.63 ± 1.74 
768.5512 PE 18:0/20:4 [M+H]+ 8.73 ± 1.70 7.81 ± 1.65 7.78 ± 1.49 
742.5383 PE 18:1/18:2 [M+H]+ 5.42 ± 1.20 4.88 ± 1.19 5.05 ± 1.28 
766.5370 PE 18:1/20:4 [M+H]+ 6.49 ± 0.68 6.04 ± 1.15 6.14 ± 1.12 
724.5284 Plasmenyl-PE P-16:0/20:4 [M+H]+ 8.32 ± 2.33a 6.86 ± 1.44b 6.92 ± 1.22b 
722.5114 Plasmenyl-PE P-16:0/20:5 [M+H]+ 0.53 ± 0.20a 0.64 ± 0.16a 0.93 ± 0.17b 
750.5428 Plasmenyl-PE P-16:0/22:5 [M+H]+ 8.27 ± 1.94a 7.01 ± 1.44b 7.22 ± 1.20ab 
748.5273 Plasmenyl-PE P-16:0/22:6 [M+H]+ 1.94 ± 0.43 1.77 ± 0.41 2.01 ± 0.30 
752.5598 Plasmenyl-PE P-18:0/20:4 [M+H]+ 16.39 ± 3.23a 13.91 ± 2.94b 13.94 ± 2.84b 
Total PE measured 87.82 ± 13.05 79.02 ± 11.59 81.68 ± 10.74 
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790.5589 PS 18:0/18:1 [M+H]+ 1.26 ± 0.40 1.12 ± 0.31 1.37 ± 0.37 
812.5437 PS 18:0/20:4 [M+H]+ 11.46 ± 4.60 8.76 ± 3.11 15.40 ± 24.50 
836.5434 PS 18:0/22:6 [M+H]+ 6.33 ± 2.56 5.22 ± 1.55 6.07 ± 1.42 
Total PS measured 19.05 ± 6.45 15.10 ± 4.51 22.83 ± 25.06 
822.2553 TAG 14:0/16:0/18:1 [M+NH4]+ 17.81 ± 21.88 18.47 ± 19.21 22.72 ± 21.48 
852.8020 TAG 16:0/16:0/18:0 [M+NH4]+ 3.93 ± 2.79 3.85 ± 2.44 4.30 ± 4.23 
850.7812 TAG 16:0/16:0/18:1 [M+NH4]+ 37.85 ± 36.03 39.43 ± 40.30 49.05 ± 48.07 
876.7986 TAG 16:0/18:1/18:1 [M+NH4]+ 136.29 ± 70.90 133.32 ± 54.64 174.28 ± 98.11 
874.7862 TAG 16:0/18:1/18:2 [M+NH4]+ 151.41 ± 52.49 147.75 ± 37.68 174.16 ± 85.72 
872.7674 TAG 16:0/18:1/18:3 [M+NH4]+ 6.48 ± 4.37 6.51 ± 3.33 9.08 ± 6.14 
896.7700 TAG 16:0/18:1/20:5 [M+NH4]+ 1.31 ± 0.53 1.54 ± 0.69 1.72 ± 0.89 
922.7840 TAG 16:0/18:1/22:6 [M+NH4]+ 1.28 ± 0.73a 2.06 ± 1.02a 4.00 ± 2.25b 
872.7674 TAG 16:0/18:2/18:2 [M+NH4]+ 24.00 ± 10.31 25.70 ± 10.96 29.25 ± 15.49 
902.8143 TAG 18:0/18:1/18:2 [M+NH4]+ 11.56 ± 5.63 11.71 ± 3.78 15.97 ± 10.65 
902.8143 TAG 18:1/18:1/18:1 [M+NH4]+ 37.09 ± 16.34ab 35.88 ± 13.23a 48.78 ± 19.33b 
900.7988 TAG 18:1/18:1/18:2 [M+NH4]+ 49.64 ± 22.87 50.05 ± 20.63 58.51 ± 25.53 
898.7857 TAG 18:1/18:2/18:2 [M+NH4]+ 10.99 ± 7.95 12.30 ± 7.41 13.37 ± 8.64 
Total TAG measured 489.63 ± 205.52 488.57 ± 145.22 605.18 ± 293.02 
668.6340 CE 18:1 [M+NH4]+ 3.38 ± 0.78 3.62 ± 1.18 4.03 ± 0.90 
666.6185 CE 18:2 [M+NH4]+ 24.12 ± 4.23a 25.40 ± 4.72ab 28.51 ± 4.77b 
690.6186 CE 20:4 [M+NH4]+ 3.81 ± 1.98 3.04 ± 1.45 3.35 ± 1.52 
688.6029 CE 20:5 [M+NH4]+ 0.12 ± 0.15a 0.21 ± 0.13a 0.56 ± 0.29b 
714.6175 CE 22:6 [M+NH4]+ 0.28 ± 0.12a 0.36 ± 0.19a 0.58 ± 0.24b 
Total CE measured 31.72 ± 5.44a 32.64 ± 6.44ab 37.03 ± 6.44b 
Mass-to-charge ratio (m/z); Phosphatidylcholine (PC); Phosphatidylethanolamine (PE); Phosphatidylserine (PS); Triacylglycerol 
(TAG); Cholesteryl ester (CE); Highly unsaturated fatty acid (HUFA). Superscript differences highlight significantly different values 
after one-way ANOVA + Tukey HSD post-hoc test with p < 0.05. 
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Table 6.  Lipidomic Examination of Human Whole Blood Following Omega-3 HUFA Supplementation for 12 weeks. 
   
Lipid Abundance, n = 5 
(Arbitrary Units, Average ± SD) 
Observed m/z Lipid Adduct Baseline Week 4 Week 8 Week 12 
760.5843 PC 16:0/18:1 [M+H]+ 289.01 ± 92.38 261.43 ± 82.16 280.19 ± 68.53 226.57 ± 53.66 
758.5704 PC 16:0/18:2 [M+H]+ 502.44 ± 71.94 458.79 ± 83.41 503.39 ± 103.27 511.50 ± 134.15 
782.56994 PC 16:0/20:4 [M+H]+ 478.52 ± 22.61 425.96 ± 75.56 419.09 ± 45.96 392.48 ± 70.54 
780.5536 PC 16:0/20:5 [M+H]+ 11.23 ± 5.37a 16.33 ± 5.76a 31.19 ± 11.66a 53.01 ± 18.69b 
806.5693 PC 16:0/22:6 [M+H]+ 38.57 ± 9.31a 45.02 ± 16.37ab 51.53 ± 11.20ab 72.15 ± 22.81b 
788.6178 PC 18:0/18:1 [M+H]+ 70.42 ± 12.18 71.32 ± 16.98 76.02 ± 14.06 68.59 ± 16.17 
786.6022 PC 18:0/18:2 [M+H]+ 198.57 ± 44.16 202.80 ± 56.03 210.20 ± 54.40 220.51 ± 78.42 
810.6002 PC 18:0/20:4 [M+H]+ 106.56 ± 19.28 94.15 ± 25.70 88.72 ± 17.33 77.15 ± 22.70 
808.5851 PC 18:0/20:5 [M+H]+ 4.10 ± 1.69a 7.45 ± 3.03ab 13.07 ± 4.35bc 17.37 ± 6.57c 
834.6009 PC 18:0/22:6 [M+H]+ 10.97 ± 3.00a 14.38 ± 4.71ab 16.38 ± 4.22ab 19.84 ± 4.93b 
808.5872 PC 18:1/20:4 [M+H]+ 26.01 ± 4.41 27.34 ± 6.91 33.86 ± 5.15 31.35 ± 11.58 
832.5853 PC 18:1/22:6 [M+H]+ 1.99 ± 0.89 2.41 ± 1.03 2.43 ± 0.88 3.38 ± 1.53 
Total PC measured 1738.40 ± 203.36 1627.39 ± 349.09 1726.07 ± 294.73 1693.89 ± 415.26 
718.5380 PE 16:0/18:1 [M+H]+ 11.05 ± 1.24 10.89 ± 1.24 11.37 ± 1.08 12.27 ± 0.97 
716.5227 PE 16:0/18:2 [M+H]+ 4.08 ± 0.54 3.86 ± 0.47 3.85 ± 0.35 4.37 ± 0.24 
740.5227 PE 16:0/20:4 [M+H]+ 10.13 ± 0.83a 9.44 ± 0.77ab 9.41 ± 0.75ab 8.22 ± 0.92b 
738.5069 PE 16:0/20:5 [M+H]+ 0.40 ± 0.14a 0.47 ± 0.11a 0.67 ± 0.11a 1.22 ± 0.27b 
764.5225 PE 16:0/22:6 [M+H]+ 5.44 ± 1.49 5.53 ± 1.03 6.55 ± 1.07 5.97 ± 1.68 
768.5512 PE 18:0/20:4 [M+H]+ 9.70 ± 1.28a 8.93 ± 1.03a 8.80 ± 1.10a 6.72 ± 0.69b 
742.5383 PE 18:1/18:2 [M+H]+ 5.01 ± 0.61 4.16 ± 0.74 4.58 ± 0.58 5.32 ± 0.74 
766.5370 PE 18:1/20:4 [M+H]+ 6.77 ± 0.60 6.24 ± 0.53 6.30 ± 0.89 5.73 ± 0.65 
724.5284 Plasmenyl-PE P-16:0/20:4 [M+H]+ 8.30 ± 1.12 7.56 ± 1.47 7.15 ± 1.01 8.01 ± 0.80 
722.5114 Plasmenyl-PE P-16:0/20:5 [M+H]+ 0.48 ± 0.12a 0.61 ± 0.11ab 0.89 ± 0.15b 1.49 ± 0.22c 
750.5428 Plasmenyl-PE P-16:0/22:5 [M+H]+ 8.29 ± 1.04 7.69 ± 1.57 7.49 ± 0.86 8.19 ± 0.60 
748.5273 Plasmenyl-PE P-16:0/22:6 [M+H]+ 1.75 ± 0.29ab 1.69 ± 0.26a 1.90 ± 0.23ab 2.19 ± 0.20b 
752.5598 Plasmenyl-PE P-18:0/20:4 [M+H]+ 16.96 ± 0.54a 15.23 ± 0.81a 15.28 ± 1.91a 12.45 ± 0.98b 
Total PE measured 88.36 ± 7.28 82.30 ± 6.95 84.24 ± 7.70 82.15 ± 6.69 
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790.5589 PS 18:0/18:1 [M+H]+ 1.21 ± 0.45 0.99 ± 0.36 1.21 ± 0.49 1.60 ± 0.34 
812.5437 PS 18:0/20:4 [M+H]+ 10.82 ± 6.15 8.82 ± 1.82 10.45 ± 2.82 5.55 ± 2.87 
836.5434 PS 18:0/22:6 [M+H]+ 5.16 ± 2.72 5.44 ± 1.18 5.99 ± 1.42 5.06 ± 0.84 
Total PS measured 17.19 ± 6.90 15.26 ± 2.70 17.65 ± 4.51 12.21 ± 3.39 
822.2553 TAG 14:0/16:0/18:1 [M+NH4]+ 24.35 ± 36.74 22.91 ± 20.87 23.06 ± 16.66 10.73 ± 6.26 
852.8020 TAG 16:0/16:0/18:0 [M+NH4]+ 3.90 ± 3.81 4.98 ± 2.91 4.68 ± 3.49 2.46 ± 0.86 
850.7812 TAG 16:0/16:0/18:1 [M+NH4]+ 42.86 ± 58.06 44.40 ± 39.84 49.05 ± 39.09 22.20 ± 11.01 
876.7986 TAG 16:0/18:1/18:1 [M+NH4]+ 124.72 ± 95.30 138.93 ± 75.44 160.77 ± 76.83 106.05 ± 52.03 
874.7862 TAG 16:0/18:1/18:2 [M+NH4]+ 127.24 ± 35.68 145.20 ± 42.38 158.65 ± 45.95 138.78 ± 33.33 
872.7674 TAG 16:0/18:1/18:3 [M+NH4]+ 5.12 ± 2.23ab 5.86 ± 1.15ab 7.46 ± 2.04b 3.38 ± 1.38a 
896.7700 TAG 16:0/18:1/20:5 [M+NH4]+ 1.18 ± 0.49a 1.87 ± 0.80ab 1.92 ± 0.32ab 0.91 ± 0.20a 
922.7840 TAG 16:0/18:1/22:6 [M+NH4]+ 1.08 ± 0.75a 2.00 ± 0.98ab 3.09 ± 1.12b 2.21 ± 1.46ab 
872.7674 TAG 16:0/18:2/18:2 [M+NH4]+ 16.28 ± 2.52 23.78 ± 9.95 23.76 ± 10.19 22.19 ± 6.67 
902.8143 TAG 18:0/18:1/18:2 [M+NH4]+ 8.49 ± 4.77 10.98 ± 3.28 13.68 ± 5.59 5.64 ± 4.50 
902.8143 TAG 18:1/18:1/18:1 [M+NH4]+ 30.96 ± 10.20 33.26 ± 9.98 39.34 ± 14.90 34.55 ± 28.91 
900.7988 TAG 18:1/18:1/18:2 [M+NH4]+ 38.39 ± 11.01 46.12 ± 16.80 48.56 ± 15.67 51.98 ± 25.75 
898.7857 TAG 18:1/18:2/18:2 [M+NH4]+ 6.72 ± 2.60 11.58 ± 7.08 10.37 ± 5.19 12.61 ± 6.30 
Total TAG measured 431.28 ± 240.72 491.87 ± 164.07 544.40 ± 187.52 413.68 ± 136.89 
668.6340 CE 18:1 [M+NH4]+ 3.18 ± 0.73 3.30 ± 1.16 3.49 ± 1.22 4.97 ± 1.64 
666.6185 CE 18:2 [M+NH4]+ 22.76 ± 3.29 23.47 ± 5.12 26.27 ± 7.52 30.09 ± 8.45 
690.6186 CE 20:4 [M+NH4]+ 5.57 ± 2.60 4.08 ± 1.61 3.90 ± 1.10 4.30 ± 1.13 
688.6029 CE 20:5 [M+NH4]+ 0.11 ± 0.06a 0.28 ± 0.20ab 0.65 ± 0.38ab 0.84 ± 0.57b 
714.6175 CE 22:6 [M+NH4]+ 0.30 ± 0.12 0.47 ± 0.19 0.58 ± 0.20 0.33 ± 0.12 
Total CE measured 31.93 ± 5.77 31.61 ± 8.02 34.89 ± 9.90 40.53 ± 11.73 
Mass-to-charge ratio (m/z); Phosphatidylcholine (PC); Phosphatidylethanolamine (PE); Phosphatidylserine (PS); Triacylglycerol 
(TAG); Cholesteryl ester (CE); Highly unsaturated fatty acid (HUFA). Superscript differences highlight significantly different values 
after one-way ANOVA + Tukey HSD post-hoc test with p < 0.05. 
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Table 7. Concentration of EPA and DHA in Whole Blood, Plasma Phospholipids and 
Erythrocytes over 8 weeks of Omega-3 HUFA Supplementation (n = 20) 
Blood Fraction Fatty Acid Baseline Week 4 Week 8 
Whole Blood 
(µg fatty acid/100µL blood) 
EPA 0.80 ± 0.36a 1.64 ± 0.43b 2.68 ± 0.58c 
DHA 3.95 ± 0.75a 5.39 ± 1.05b 6.88 ± 1.26c 
Plasma Phospholipids 
(µg fatty acid/100µL plasma) 
EPA 0.72 ± 0.41a 1.22 ± 0.27b 2.09 ± 0.68c 
DHA 3.37 ± 0.70a 3.75 ± 0.75ab 4.28 ± 0.86b 
Erythrocytes 
(µg fatty acid/200mg cells) 
EPA 1.89 ± 0.65a 2.46 ± 0.59a 3.98 ± 1.00b 
DHA 13.61 ± 2.76 13.58 ± 3.35 15.08 ± 2.73 
Eicosapentaenoic acid (EPA); Docosahexaenoic acid (DHA); Highly Unsaturated Fatty Acid 
(HUFA). 
 
 
 
Table 8. Concentration of EPA and DHA in Whole Blood, Plasma Phospholipids and 
Erythrocytes over 12 weeks of Omega-3 HUFA Supplementation (n = 5) 
Blood Fraction Fatty Acid Baseline Week 4 Week 8 Week 12 
Whole Blood 
(µg fatty acid/100µL blood) 
EPA 0.89 ± 0.31a 1.74 ± 0.48ab 2.71 ± 0.87bc 4.11 ± 1.21c 
DHA 4.25 ± 0.90a 5.37 ± 0.73ab 6.16 ± 1.52ab 7.33 ± 1.11b 
Plasma Phospholipids 
(µg fatty acid/100µL plasma) 
EPA 0.77 ± 0.42a 1.19 ± 0.40ab 2.51 ± 1.17bc 2.81 ± 1.03c 
DHA 3.21 ± 1.07 3.83 ± 1.02 4.28 ± 1.59 5.37 ± 1.39 
Erythrocytes 
(µg fatty acid/200mg cells) 
EPA 1.72 ± 0.40a 2.21 ± 0.32ab 3.35 ± 0.87b 5.21 ± 0.84c 
DHA 11.86 ± 2.34ab 11.20 ± 1.82a 13.12 ± 2.29ab 15.29 ± 1.44b 
Eicosapentaenoic acid (EPA); Docosahexaenoic acid (DHA); Highly Unsaturated Fatty Acid 
(HUFA). 
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Table 9.  Fatty Acid Composition of Blood Phosphatidylethanolamines (n = 3) 
Concentration (µg fatty acid/100 µL whole blood) 
Fatty Acid Baseline Wk4 Wk8 Wk12 
C 14:0 0.44 ± 0.16 0.40 ± 0.09 0.23 ± 0.08 0.56 ± 0.37 
C 16:0 5.55 ± 0.92 5.32 ± 0.81 4.81 ± 0.37 4.97 ± 0.70 
C 18:0 5.95 ± 0.91 5.67 ± 1.42 5.71 ± 0.26 4.74 ± 0.99 
C 20:0 0.10 ± 0.01 0.11 ± 0.01 0.09 ± 0.01 0.19 ± 0.22 
C 22:0 0.06 ± 0.01 0.06 ± 0.01 0.06 ± <0.01 0.12 ± 0.11 
C 24:0 0.07 ± 0.02 0.08 ± 0.01 0.07 ± 0.02 0.17 ± 0.11 
SFAs 12.26 ± 1.93 11.87 ± 2.02 11.02 ± 0.20 10.89 ± 1.49 
C 12:1 <0.01 ± <0.01 0.03 ± 0.03 0.01 ± 0.01 0.03 ± 0.02 
C 14:1 0.02 ± 0.01 0.03 ± 0.01 0.02 ± 0.02 0.09 ± 0.05 
C 16:1 0.13 ± 0.06 0.19 ± 0.11 0.11 ± 0.06 0.34 ± 0.34 
C 18:1n-7 0.38 ± 0.09 0.37 ± 0.09 0.29 ± 0.04 0.41 ± 0.15 
C 18:1n-9 5.30 ± 1.62 4.63 ± 0.37 3.47 ± 0.49 3.79 ± 0.71 
C 20:1n-9 0.13 ± 0.02 0.13 ± 0.02 0.11 ± 0.01 0.18 ± 0.09 
C 22:1n-9 0.61 ± 0.06 0.59 ± 0.08 0.58 ± 0.03 0.82 ± 0.54 
C 24:1n-9 0.06 ± 0.02 0.05 ± 0.02 0.06 ± 0.02 0.06 ± 0.02 
MUFAs 6.63 ± 1.67 6.01 ± 0.40 4.64 ± 0.52 5.70 ± 1.76 
C 18:2n-6 1.46 ± 0.35 1.24 ± 0.10 1.20 ± 0.18 1.71 ± 0.95 
C 18:3n-6 0.03 ± <0.01 0.02 ± 0.01 0.02 ± <0.01 0.04 ± 0.03 
C 20:2n-6 0.07 ± 0.02 0.08 ± 0.01 0.07 ± <0.01 0.10 ± 0.03 
C 20:3n-6 0.26 ± 0.10 0.25 ± 0.04 0.26 ± 0.07 0.26 ± 0.07 
C 20:4n-6 4.18 ± 0.75 4.23 ± 0.73 4.25 ± 0.65 4.02 ± 0.28 
C 22:2n-6 0.05 ± <0.01 0.06 ± 0.02 0.04 ± <0.01 0.08 ± 0.04 
C 22:4n-6 1.20 ± 0.11 1.20 ± 0.21 1.12 ± 0.07 1.04 ± 0.14 
C 22:5n-6 0.17 ± 0.07 0.18 ± 0.03 0.16 ± 0.05 0.14 ± 0.02 
N-6 7.43 ± 1.24 7.26 ± 0.95 7.12 ± 0.87 7.38 ± 1.02 
C 18:3n-3 0.14 ± 0.04 0.15 ± 0.04 0.15 ± 0.01 0.17 ± 0.09 
C 20:3n-3 0.01 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.05 ± 0.03 
C 20:5n-3 0.12 ± 0.07a 0.18 ± 0.05a 0.27 ± 0.05a 0.45 ± 0.08b 
C 22:5n-3 0.62 ± 0.15a 0.68 ± 0.05ab 0.74 ± 0.05ab 0.84 ± 0.04b 
C 22:6n-3 0.82 ± 0.30 0.89 ± 0.19 1.02 ± 0.24 1.24 ± 0.20 
N-3 1.71 ± 0.54a 1.93 ± 0.31ab 2.20 ± 0.35ab 2.75 ± 0.31b 
C 20:3n-9 0.03 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 0.03 ± 0.01 
PUFAs 9.17 ± 1.79 9.21 ± 1.22 9.35 ± 1.21 10.17 ± 1.28 
HUFAs 7.42 ± 1.40 7.66 ± 1.08 7.87 ± 1.03 8.08 ± 0.53 
EPA+DHA 0.94 ± 0.36 1.07 ± 0.24 1.29 ± 0.30 1.69 ± 0.27 
Total 28.06 ± 3.31 27.09 ± 2.81 25.01 ± 1.62 26.76 ± 4.01 
Saturated fatty acids (SFAs); Mono-unsaturated fatty acids (MUFAs); Omega-6 fatty acids (N-6); Omega-3 fatty 
acids (N-3); Polyunsaturated fatty acids (PUFAs); Highly unsaturated fatty acids (HUFAs); Eicosapentaenoic acid 
(EPA); Docosahexaenoic acid (DHA). Superscript differences represent significantly different values after one-way 
ANOVA + Tukey HSD (p < 0.05). 
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Chapter 9 
Lipidomic Discrimination of Complex Lipids in Whole Blood, Plasma 
and Erythrocytes of Individuals with Low, Intermediate and High Levels 
of Omega-3 HUFA Intake 
9.1 Introduction 
 Lipidomic analyses of blood lipids and the response to omega-3 PUFA intervention have 
been examined (Patterson et al., 2014; Uhl et al., 2013), but a comprehensive assessment of 
plasma, erythrocyte and whole blood across individuals with different omega-3 HUFA status is 
needed. This is required as changes in response to dietary EPA and DHA are more rapid in 
plasma compared with erythrocytes, and DHA is slower to change than EPA (Metherel et al., 
2009; Patterson et al., 2012). The experiments in this chapter will expand on the examination of 
whole blood complex lipids that was carried out in Chapter 8, using the UHPLC-MS/MS acyl-
specific lipidomic profiling method developed in Chapter 5 to profile the whole blood, plasma 
and erythrocyte fractions of individuals across a range of omega-3 HUFA intakes. 
 
9.2 Methods 
9.2.1 Participants and Blood Samples 
 Volunteer participants were recruited from the University of Waterloo. An initial 
screening visit was performed where participants were asked about their consumption of fish, 
nutraceuticals containing EPA/DHA, or EPA/DHA-enriched foods. Initially, approximately 15 
volunteers attended this screening visit, and nine of them were asked to participate in the study 
based on their verbally reported consumption of EPA/DHA. Specifically, three of these 
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participants reported consuming either very little or no EPA/DHA-containing foods or 
supplements; three reported sporadic consumption of fish once or twice every two weeks; and 
three reported either high consumption of fish (more than twice per week) or regular 
consumption of EPA/DHA supplements. Five males and four females were recruited for this 
study; their anthropometric measures were assessed (Table 10). A single fasting venous blood 
sample was collected into one-10 mL EDTA-lined vacutainer by a phlebotomist at the 
volunteer’s convenience and all samples were collected within one week. After collection, three 
500 µL whole blood aliquots were separated and stored in cryovials at -80ºC until analysis. The 
remainder of the blood was separated into plasma and erythrocyte fractions by centrifugation at 
1734 rcf as described earlier (Patterson et al., 2013). Plasma and erythrocytes were separated into 
three 500 µL aliquots in cryovials and also stored at -80ºC until analysis. All participants 
provided informed written consent and the University of Waterloo Human Ethics Committee 
approved all protocols and procedures.   
 
9.2.2 Lipidomic and Fatty Acid Profiling Methods 
 Briefly, samples were removed from -80ºC storage, thawed, extracted twice using 2:1 
chloroform:methanol (v/v), and aliquoted for UHPLC-MS/MS or for derivatization to fatty acid 
methyl esters followed by GC-FID (only whole blood was used for fatty acid composition 
determinations). The lipidomic sample lipid extracts were spiked with di-17:0 PC in the HPLC 
sample solvent.  The 47-minute multi-step gradient as described in Chapter 5 was used with 
positive ESI and Top5 data-dependent acquisition.  Only the ion profiles for complex lipids 
containing either omega-3 or omega-6 HUFAs were extracted and the peaks were integrated.  As 
in previous chapters, the raw integrated data (area under the curve) were standardized by 
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dividing them by the area under the curve for the internal standard (di-17:0 PC) and multiplying 
by 100. The whole blood lipid extract aliquot that was separated for fatty acid composition was 
dried under a stream of N2 gas, and fatty acid methyl esters were generated after methylation in 1 
mL 14% BF3 in methanol at 100ºC (Metherel et al., 2009). Samples were then analyzed via GC-
FID.  C 22:3n-3 was used as the internal standard (Nu-Check Prep, Elysian, MN, USA). 
 
9.2.3 Statistical Analyses 
 The normalized lipidomic data (A.U.) for the lipids examined (complete list in Table E.1, 
Appendix E) was correlated with whole blood total DHA concentration and whole blood total 
EPA concentration using Pearson’s correlation. The resulting correlation coefficients were sorted 
in decreasing order, and the correlations with the top 5 r-values (that ranged from 0.76 to 0.99 
and p value of < 0.01) were used to create scatterplots. 
 
9.3 Results 
 The lipidomic examination of complex lipids in whole blood, plasma and erythrocytes 
revealed that the plasma fraction is rich in PC, CE and TAG; the erythrocyte fraction is rich in 
PC, PE, plasmenyl-PE and PS; and whole blood is comprehensive of all these lipids (Figure 10). 
The correlation analyses that were performed and the resulting scatterplots of the top 5 most 
strongly correlated complex lipids with total DHA and EPA in whole blood are shown in Figure 
11. In each of the scatterplots, the slopes of the lines of best fit have been included to highlight 
the complex lipids where EPA and DHA appear to be localized with increasing EPA and DHA 
status. The slopes of the lines for lipids that were previously identified as highly responsive to 
EPA+DHA intake in Chapter 8 are less steep in the erythrocyte lipidomics vs. DHA and EPA 
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scatterplots compared to the plasma lipidomics vs. DHA and EPA scatterplots. The best fit lines 
for scatterplots of total DHA concentration in whole blood against 16:0/DHA PC and 16:0/EPA 
PC in blood fractions have the steepest slopes across whole blood (15.51, 17.77; respectively), 
plasma (24.66, 15.68; respectively) and erythrocytes (2.97, 4.03; respectively) compared to all 
other PC species. Interestingly, some of the complex lipids that correlated the most strongly with 
total DHA in whole blood did not have DHA in them, but rather EPA or in one case, a negative 
association with docosatetraenoic acid (C22:4n-6; erythrocyte lipidomics scatterplot). Likewise, 
some DHA-containing complex lipids like 18:0/DHA PC were found to be strongly correlated 
with total EPA in whole blood. These relationships highlight the close interplay between EPA 
and DHA in metabolism and incorporation into complex lipids. 
 
9.4 Discussion and Conclusion 
Three acyl-specific lipids, 16:0/DHA PC, 16:0/EPA PC and plasmenyl-PE P-16:0/EPA 
were identified as being highly responsive to the dietary manipulation in a dose-response manner 
in Chapter 8. In addition, previous findings in our laboratory suggest a slower turnover of 
omega-3 HUFA in erythrocytes as compared with plasma (Metherel et al., 2009; Patterson et al., 
2012).  , The present study examined the lipidomic profiles of HUFA-containing complex lipids 
in whole blood, plasma and erythrocytes from nine individuals that reported consuming various 
levels of fish, EPA/DHA-enriched foods, or EPA/DHA-containing supplements. Rather than rely 
on dietary records or food frequency questionnaires, which is subject to error (Patterson et al., 
2012), the absolute concentrations of EPA and DHA in whole blood were determined to indicate 
omega-3 status and correlated with lipidomic data. This was done to examine acyl-specific 
complex lipids where EPA and DHA may be localized when total concentrations of EPA and 
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DHA are increased in blood. Notably, the experiments performed here revealed that 16:0/DHA 
PC and 16:0/EPA PC appear to preferentially incorporate and retain DHA and EPA compared to 
other PC species in both plasma and erythrocyte fractions, as total DHA and EPA concentrations 
increase in whole blood.  
To our knowledge, this study is the first to examine a range of intakes of EPA and DHA 
through fatty acid compositional data (derived from GC-FID) and examinations of acyl-
containing complex lipids (through UHPLC-MS/MS) at the same time to identify the specific 
acyl-specific complex lipids across blood fractions that were the most responsive to increasing 
concentrations of DHA and EPA in whole blood. Although whole blood biomarkers have been 
previously identified and reflect dietary intake of EPA+DHA (Patterson et al., 2012) no direct 
associations can be made at this point regarding specific amounts of EPA and DHA that were 
consumed by the participants and the lipidomic responses in blood fractions.  One of the 
limitations of this study is that the data is cross sectional and insights on incorporation are 
limited to static time points and rate of change and kinetic turnover cannot be discussed. 
Additionally, the use of a single PC internal standard (di-17:0 PC) prevents direct comparisons to 
be made between different lipid pools (i.e. comparing the slopes of the lines for 16:0/DHA PC 
vs. 16:0/DHA PE in a given blood fraction). Future research should examine the effect of tightly-
controlled intakes of EPA+DHA in acyl-specific lipids in blood fractions, as well as examining 
dose-responsive lipids over an extended period of time. Further work is also necessary to shift 
this semi-quantitative method to a quantitative lipidomics method, possibly through the use of 
multiple internal standards. 
In conclusion, it appears that 16:0/DHA PC and 16:0/EPA PC are the most abundant 
DHA- and EPA-containing PC species (respectively) across all blood fractions. It also appears 
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16:0/DHA PC and 16:0/EPA PC to be very responsive in plasma compared to erythrocytes, and 
seem to increase the most as DHA and EPA increase in the diet as determined by levels of DHA 
and EPA in whole blood. This work provides the foundation for the potential use of acyl-specific 
complex lipids as biomarkers for omega-3 HUFA status. 
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Table 10. Anthropometric Measures for the Nine Participants of the Blood Fraction 
Lipidomics Study 
 Males (n = 5) Females (n = 4) 
Anthropometric Measures Average ± Standard Deviation 
Age (years) 22.75 ± 1.53 23.47 ± 6.07 
Height (cm) 177.88 ± 5.57 167.93 ± 7.04 
Mass (kg) 80.58 ± 16.17 63.08 ± 7.04 
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Figure 10. Whole blood, plasma and erythrocyte total ion current (TIC) full-scan MS 
chromatograms. Phosphatidylcholine (PC); Phosphatidylethanolamine (PE); Phosphatidylserine 
(PS); Plasmenyl-Phosphatidylethanolamine (PE-P); Cholesteryl ester (CE); Triacylglycerol 
(TAG). 
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Figure 11. Scatterplots of the acyl-specific HUFA-containing lipids that were correlated the 
most strongly with either total DHA (left) or EPA (right) concentrations in whole blood 
determined by GC-FID. A. Whole lipidomics vs. DHA concentration in whole blood B. Plasma 
lipidomics vs. DHA concentration in whole blood C. Erythrocyte lipidomics vs. DHA 
concentration in whole blood D. Whole lipidomics vs. EPA concentration in whole blood E. 
Plasma lipidomics vs. EPA concentration in whole blood F. Erythrocyte lipidomics vs. EPA 
concentration in whole blood.  Phosphatidylcholine (PC); Phosphatidylethanolamine (PE); 
Phosphatidylserine (PS); Plasmenyl-Phosphatidylethanolamine (PE-P); Cholesteryl ester (CE); 
Triacylglycerol (TAG). 
 
A.  D.  
B.  E.  
C.  F.  
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Chapter 10 
Discussion and Conclusion 
10.1 General Discussion 
 Previous studies have characterized the lipidomes of cellular systems (Bird et al., 2011; 
Hermansson et al., 2005; Ramanadham et al., 2000) and mammalian tissues (Lamaziere et al., 
2011; Murthy et al., 2002; Sandra et al., 2010; Sjövall et al., 2015).  Though some of this work 
has examined the lipid remodeling effects of omega-3 highly unsaturated fatty acid 
supplementation, little work has been done on blood.  This thesis presents a thorough 
examination of human blood native lipids following omega-3 HUFA supplementation, while 
outlining all of the steps and limitations associated with the development of a UHPLC-MS/MS 
lipidomic profiling method. 
 In line with the stated hypotheses (Chapter 4), a method was developed to detect acyl 
species of PC, PE, PS, CE, and TAG in positive ESI mode.  The method ended up being 
UHPLC-MS/MS rather than HPLC-MS/MS, and determination of PI, FFA, and CL were not 
possible.  The relationship between increasing concentrations of lipids from blood lipid extracts 
and the observed instrument response was confirmed to be positive and linear at the sample 
dilutions tested.  The lipidomic profiles of whole and dried blood spots provided comparable 
lipid abundances when dried blood spot lipid extraction was extended to a 24-hour protocol, with 
the exception of persistent low PS recoveries.  Increasing EPA and DHA intakes were positively 
associated with increasing EPA and DHA in several but not all acyl species of lipids, as changes 
in PS were not observed.  Finally, 16:0/DHA PC was highly responsive to DHA 
supplementation, however, other acyl specific species responsive to fish oil intervention were 
also identified. 
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 Although there are several limitations associated with the current lipidomic profiling 
method that are highlighted in Chapters 5 and 6, its use enabled the validation of dried blood 
spots for lipidomic profiling, and the characterization of lipid remodeling events in acyl-specific 
complex lipids following supplementation of EPA and DHA. While some work is necessary in 
order to fully validate the use of dried blood spots for lipidomic profiling, the present 
observations show that the analysis of PC, PE, TAG and CE species in a single analytical run is 
possible. In dried blood spots, the significantly decreased recoveries of PS species needs to be 
examined further, and modifications to the mass spectrometric method are needed in order to 
examine PI and FFA species. Using blood samples that were collected under tight dietary control 
of EPA+DHA intake, three specific whole blood lipids (16:0/DHA PC, 16:0/EPA PC and 
plasmenyl-PE P-16:0/EPA) that are very responsive to supplementation in a dose-dependent 
manner were identified. Additionally, 16:0/DHA PC and 16:0/EPA PC were shown to have the 
steepest slopes when correlated against omega-3 HUFA status across the whole blood, 
erythrocytes, and plasma fractions.  Therefore, 16:0/DHA PC and 16:0/EPA PC have potential to 
be developed into biomarkers of omega-3 HUFA intake.  However further work with short term 
and long term omega-3 HUFA interventions are needed to confirm the 16:0/DHA PC and 
16:0/EPA PC response, but also screen for other informative acyl specific lipids.  Biomarkers for 
recent vs. long term omega-3 HUFA would be useful in observational studies, as well as 
determining adherence and compliance to omega-3 HUFA intervention in clinical trials.  Also, 
by identifying specific acyl lipids and their unique chemistry, alternative methodology could be 
developed that provide rapid and cost efficient results required for clinical screening.  
 Due to the tens of thousands of lipids that can be detected in a biological system using 
MS (Han and Gross, 2003), and the painstaking steps of the current workflow for lipid 
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identification and integration, it was neither practical nor productive to characterize the entire 
lipidome of the samples that were examined in this thesis. The focus on the characterization of 
the top 85% of lipids in whole blood (Chapter 8) may serve as the basis for future untargeted 
lipidomic analyses of other whole blood samples.  This approach could be automated into 
software and greatly increase the analytical throughput by minimizing the current challenge of 
data processing. In particular, using a top 85% approach to identify lipids combined with a set of 
internal standards that enabled comprehensive quantitation would be a breakthrough in lipidomic 
data processing.  Further work is necessary to establish quantitative lipidomic profiling methods 
(i.e. internal standards) and comprehensive lipid class determinations in a single analytical run 
(i.e. challenge of detecting PI and FFA in positive ESI) using UHPLC-MS/MS.  The use of thin 
layer chromatography/ GC-FID data to control for day-to-day UHPLC-MS/MS variation may 
have potential in the development and assessment of a quantitative lipidomic method as 
lipidomic data could be expressed relative to quantified lipid classes.  Additional work is also 
required to ensure lipid extraction techniques are comprehensive across lipid classes (i.e. low PS 
recovery from dried blood spot sampling matrix).  
 
10.2 Conclusion 
A comprehensive lipidomic profiling method was developed for the analysis of acyl-
specific complex lipids in human whole blood. Over 500 lipids were identified based on accurate 
masses of parent lipid species, and confirming acyl-specific species was achieved for 163 of 
these lipids.  Through this method, the use of dried blood spots was validated for lipidomic 
profiling of PC, PE, CE and TAG.  Additionally, the current UHPLC-MS/MS method was used 
to examine the lipidomic changes that occur in human whole blood following very specific 
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intakes of EPA+DHA from samples of a previous intervention trial (Patterson, 2012).  16:0/DHA 
PC and 16:0/EPA PC appear to have potential as omega-3 HUFA biomarkers. In addition, novel 
techniques in quantitation and data processing were explored at the preliminary level that 
included GC-FID quantitative corrections and a top 85% lipid identification approach.   The 
extrapolation of the current lipidomic profiling method for analysis of other biological samples is 
possible; additional work is needed to establish appropriate instrument conditions, as these 
would be tailored specifically for the sample of interest. 
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Figure A.1.  Lipid Pool Composition of Human Whole Blood after Folch Lipid Extraction. 
Distribution of total fatty acids in whole blood across the predominant lipid pools.  Data 
represents the percent weight of total fatty acids in each pool divided by the total fatty acid 
concentration of whole blood.  Lipids were extracted using 2:1 chloroform:methanol as 
described previously (Folch et al., 1957). Lipid classes from lipid extracts (n = 12) were 
separated with thin layer chromatography, lipids were extracted, derivatized to fatty acid methyl 
esters with 14% BF3 in methanol, and analyzed using gas chromatography-flame ionization 
detection.  C22:3n-3 methyl ester was used for quantitation. 
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Figure A.2.  A.10 µL blood lipid extract run with Bird et al., 2011 chromatographic protocol.  
B.10 µL blood lipid extract run with optimized chromatographic protocol.  C.  10 µL blood lipid 
extract run with optimized chromatographic protocol and 2.0 µm C18 column. 
 
A.   
C.   
B.   
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Table A.1.  Matrix for the Determination of Acyl-Specific Phosphatidylcholine m/z ratios 
 
Acyl Chains C12:0 C14:0 C16:0 C16:1 C18:0 C18:1 C18:2 C18:3 C20:0 C20:1 C20:2 
C12:0 622.4442 650.4755 678.5068 676.4912 706.5381 704.5225 702.5068 700.4912 734.5694 732.5538 730.5381 
C14:0 650.4755 678.5068 706.5381 704.5225 734.5694 732.5538 730.5381 728.5225 762.6007 760.5851 758.5694 
C16:0 678.5068 706.5381 734.5694 732.5538 762.6007 760.5851 758.5694 756.5538 790.6320 788.6164 786.6007 
C16:1 676.4912 704.5225 732.5538 730.5381 760.5851 758.5694 756.5538 754.5381 788.6164 786.6007 784.5851 
C18:0 706.5381 734.5694 762.6007 760.5851 790.6320 788.6164 786.6007 784.5851 818.6633 816.6477 814.6320 
C18:1 704.5225 732.5538 760.5851 758.5694 788.6164 786.6007 784.5851 782.5694 816.6477 814.6320 812.6164 
C18:2 702.5068 730.5381 758.5694 756.5538 786.6007 784.5851 782.5694 780.5538 814.6320 812.6164 810.6007 
C18:3 700.4912 728.5225 756.5538 754.5381 784.5851 782.5694 780.5538 778.5381 812.6164 810.6007 808.5851 
C20:0 734.5694 762.6007 790.6320 788.6164 818.6633 816.6477 814.6320 812.6164 846.6946 844.6790 842.6633 
C20:1 732.5538 760.5851 788.6164 786.6007 816.6477 814.6320 812.6164 810.6007 844.6790 842.6633 840.6477 
C20:2 730.5381 758.5694 786.6007 784.5851 814.6320 812.6164 810.6007 808.5851 842.6633 840.6477 838.6320 
C20:3 728.5225 756.5538 784.5851 782.5694 812.6164 810.6007 808.5851 806.5694 840.6477 838.6320 836.6164 
C20:4 726.5069 754.5381 782.5694 780.5538 810.6007 808.5851 806.5694 804.5538 838.6320 836.6164 834.6007 
C20:5 724.4912 752.5225 780.5538 778.5381 808.5851 806.5694 804.5538 802.5381 836.6164 834.6007 832.5851 
C22:0 762.6007 790.6320 818.6633 816.6477 846.6946 844.6790 842.6633 840.6477 874.7259 872.7103 870.6946 
C22:1 760.5851 788.6164 816.6477 814.6320 844.6790 842.6633 840.6477 838.6320 872.7103 870.6946 868.6790 
C22:2 758.5694 786.6007 814.6320 812.6164 842.6633 840.6477 838.6320 836.6164 870.6946 868.6790 866.6633 
C22:4 754.5381 782.5694 810.6007 808.5851 838.6320 836.6164 834.6007 832.5851 866.6633 864.6477 862.6320 
C22:5 752.5225 780.5538 808.5851 806.5694 836.6164 834.6007 832.5851 830.5694 864.6477 862.6320 860.6164 
C22:6 750.5068 778.5381 806.5694 804.5538 834.6007 832.5851 830.5694 828.5538 862.6320 860.6164 858.6007 
C24:0 790.6320 818.6633 846.6946 844.6790 874.7259 872.7103 870.6946 868.6790 902.7572 900.7416 898.7259 
C24:1 788.6164 816.6477 844.6790 842.6633 872.7103 870.6946 868.6790 866.6633 900.7416 898.7259 896.7103 
 
Acyl Chains C20:3 C20:4 C20:5 C22:0 C22:1 C22:2 C22:4 C22:5 C22:6 C24:0 C24:1 
C12:0 728.5225 726.5069 724.4912 762.6007 760.5851 758.5694 754.5381 752.5225 750.5068 790.6320 788.6164 
C14:0 756.5538 754.5381 752.5225 790.6320 788.6164 786.6007 782.5694 780.5538 778.5381 818.6633 816.6477 
C16:0 784.5851 782.5694 780.5538 818.6633 816.6477 814.6320 810.6007 808.5851 806.5694 846.6946 844.6790 
C16:1 782.5694 780.5538 778.5381 816.6477 814.6320 812.6164 808.5851 806.5694 804.5538 844.6790 842.6633 
C18:0 812.6164 810.6007 808.5851 846.6946 844.6790 842.6633 838.6320 836.6164 834.6007 874.7259 872.7103 
C18:1 810.6007 808.5851 806.5694 844.6790 842.6633 840.6477 836.6164 834.6007 832.5851 872.7103 870.6946 
C18:2 808.5851 806.5694 804.5538 842.6633 840.6477 838.6320 834.6007 832.5851 830.5694 870.6946 868.6790 
C18:3 806.5694 804.5538 802.5381 840.6477 838.6320 836.6164 832.5851 830.5694 828.5538 868.6790 866.6633 
C20:0 840.6477 838.6320 836.6164 874.7259 872.7103 870.6946 866.6633 864.6477 862.6320 902.7572 900.7416 
C20:1 838.6320 836.6164 834.6007 872.7103 870.6946 868.6790 864.6477 862.6320 860.6164 900.7416 898.7259 
C20:2 836.6164 834.6007 832.5851 870.6946 868.6790 866.6633 862.6320 860.6164 858.6007 898.7259 896.7103 
C20:3 834.6007 832.5851 830.5694 868.6790 866.6633 864.6477 860.6164 858.6007 856.5851 896.7103 894.6946 
C20:4 832.5851 830.5694 828.5538 866.6633 864.6477 862.6320 858.6007 856.5851 854.5694 894.6946 892.6790 
C20:5 830.5694 828.5538 826.5381 864.6477 862.6320 860.6164 856.5851 854.5694 852.5538 892.6790 890.6633 
C22:0 868.6790 866.6633 864.6477 902.7572 900.7416 898.7259 894.6946 892.6790 890.6633 930.7885 928.7729 
C22:1 866.6633 864.6477 862.6320 900.7416 898.7259 896.7103 892.6790 890.6633 888.6477 928.7729 926.7572 
C22:2 864.6477 862.6320 860.6164 898.7259 896.7103 894.6946 890.6633 888.6477 886.6320 926.7572 924.7416 
C22:4 860.6164 858.6007 856.5851 894.6946 892.6790 890.6633 886.6320 884.6164 882.6007 922.7259 920.7103 
C22:5 858.6007 856.5851 854.5694 892.6790 890.6633 888.6477 884.6164 882.6007 880.5851 920.7103 918.6946 
C22:6 856.5851 854.5694 852.5538 890.6633 888.6477 886.6320 882.6007 880.5851 878.5694 918.6946 916.6790 
C24:0 896.7103 894.6946 892.6790 930.7885 928.7729 926.7572 922.7259 920.7103 918.6946 958.8198 956.8042 
C24:1 894.6946 892.6790 890.6633 928.7729 926.7572 924.7416 920.7103 918.6946 916.6790 956.8042 954.7885 
 
 
Matrix used for the identification of precursor [M+H]+m/z ratios for phosphatidylcholines with specific fatty acyl 
chains. The intersection between a fatty acid across the top row and down the first column would reveal its m/z ratio. 
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Table A.2.  Matrix for the Determination of Acyl-Specific Phosphatidylethanolamine m/z 
ratios 
 
Acyl Chains C12:0 C14:0 C16:0 C16:1 C18:0 C18:1 C18:2 C18:3 C20:0 C20:1 C20:2 
C12:0 580.3973 608.4286 636.4599 634.4442 664.4912 662.4755 660.4599 658.4442 692.5225 690.5068 688.4912 
C14:0 608.4286 636.4599 664.4912 662.4755 692.5225 690.5068 688.4912 686.4755 720.5538 718.5381 716.5225 
C16:0 636.4599 664.4912 692.5225 690.5068 720.5538 718.5381 716.5225 714.5068 748.5851 746.5694 744.5538 
C16:1 634.4442 662.4755 690.5068 688.4912 718.5381 716.5225 714.5068 712.4912 746.5694 744.5538 742.5381 
C18:0 664.4912 692.5225 720.5538 718.5381 748.5851 746.5694 744.5538 742.5381 776.6164 774.6007 772.5851 
C18:1 662.4755 690.5068 718.5381 716.5225 746.5694 744.5538 742.5381 740.5225 774.6007 772.5851 770.5694 
C18:2 660.4599 688.4912 716.5225 714.5068 744.5538 742.5381 740.5225 738.5068 772.5851 770.5694 768.5538 
C18:3 658.4442 686.4755 714.5068 712.4912 742.5381 740.5225 738.5068 736.4912 770.5694 768.5538 766.5381 
C20:0 692.5225 720.5538 748.5851 746.5694 776.6164 774.6007 772.5851 770.5694 804.6477 802.6320 800.6164 
C20:1 690.5068 718.5381 746.5694 744.5538 774.6007 772.5851 770.5694 768.5538 802.6320 800.6164 798.6007 
C20:2 688.4912 716.5225 744.5538 742.5381 772.5851 770.5694 768.5538 766.5381 800.6164 798.6007 796.5851 
C20:3 686.4755 714.5068 742.5381 740.5225 770.5694 768.5538 766.5381 764.5225 798.6007 796.5851 794.5694 
C20:4 684.4599 712.4912 740.5225 738.5068 768.5538 766.5381 764.5225 762.5068 796.5851 794.5694 792.5538 
C20:5 682.4442 710.4755 738.5068 736.4912 766.5381 764.5225 762.5068 760.4912 794.5694 792.5538 790.5381 
C22:0 720.5538 748.5851 776.6164 774.6007 804.6477 802.6320 800.6164 798.6007 832.6790 830.6633 828.6477 
C22:1 718.5381 746.5694 774.6007 772.5851 802.6320 800.6164 798.6007 796.5851 830.6633 828.6477 826.6320 
C22:2 716.5225 744.5538 772.5851 770.5694 800.6164 798.6007 796.5851 794.5694 828.6477 826.6320 824.6164 
C22:4 712.4912 740.5225 768.5538 766.5381 796.5851 794.5694 792.5538 790.5381 824.6164 822.6007 820.5851 
C22:5 710.4755 738.5068 766.5381 764.5225 794.5694 792.5538 790.5381 788.5225 822.6007 820.5851 818.5694 
C22:6 708.4599 736.4912 764.5225 762.5068 792.5538 790.5381 788.5225 786.5068 820.5851 818.5694 816.5538 
C24:0 748.5851 776.6164 804.6477 802.6320 832.6790 830.6633 828.6477 826.6320 860.7103 858.6946 856.6790 
C24:1 746.5694 774.6007 802.6320 800.6164 830.6633 828.6477 826.6320 824.6164 858.6946 856.6790 854.6633 
 
Acyl Chains C20:3 C20:4 C20:5 C22:0 C22:1 C22:2 C22:4 C22:5 C22:6 C24:0 C24:1 
C12:0 686.4755 684.4599 682.4442 720.5538 718.5381 716.5225 712.4912 710.4755 708.4599 748.5851 746.5694 
C14:0 714.5068 712.4912 710.4755 748.5851 746.5694 744.5538 740.5225 738.5068 736.4912 776.6164 774.6007 
C16:0 742.5381 740.5225 738.5068 776.6164 774.6007 772.5851 768.5538 766.5381 764.5225 804.6477 802.6320 
C16:1 740.5225 738.5068 736.4912 774.6007 772.5851 770.5694 766.5381 764.5225 762.5068 802.6320 800.6164 
C18:0 770.5694 768.5538 766.5381 804.6477 802.6320 800.6164 796.5851 794.5694 792.5538 832.6790 830.6633 
C18:1 768.5538 766.5381 764.5225 802.6320 800.6164 798.6007 794.5694 792.5538 790.5381 830.6633 828.6477 
C18:2 766.5381 764.5225 762.5068 800.6164 798.6007 796.5851 792.5538 790.5381 788.5225 828.6477 826.6320 
C18:3 764.5225 762.5068 760.4912 798.6007 796.5851 794.5694 790.5381 788.5225 786.5068 826.6320 824.6164 
C20:0 798.6007 796.5851 794.5694 832.6790 830.6633 828.6477 824.6164 822.6007 820.5851 860.7103 858.6946 
C20:1 796.5851 794.5694 792.5538 830.6633 828.6477 826.6320 822.6007 820.5851 818.5694 858.6946 856.6790 
C20:2 794.5694 792.5538 790.5381 828.6477 826.6320 824.6164 820.5851 818.5694 816.5538 856.6790 854.6633 
C20:3 792.5538 790.5381 788.5225 826.6320 824.6164 822.6007 818.5694 816.5538 814.5381 854.6633 852.6477 
C20:4 790.5381 788.5225 786.5068 824.6164 822.6007 820.5851 816.5538 814.5381 812.5225 852.6477 850.6320 
C20:5 788.5225 786.5068 784.4912 822.6007 820.5851 818.5694 814.5381 812.5225 810.5068 850.6320 848.6164 
C22:0 826.6320 824.6164 822.6007 860.7103 858.6946 856.6790 852.6477 850.6320 848.6164 888.7416 886.7259 
C22:1 824.6164 822.6007 820.5851 858.6946 856.6790 854.6633 850.6320 848.6164 846.6007 886.7259 884.7103 
C22:2 822.6007 820.5851 818.5694 856.6790 854.6633 852.6477 848.6164 846.6007 844.5851 884.7103 882.6946 
C22:4 818.5694 816.5538 814.5381 852.6477 850.6320 848.6164 844.5851 842.5694 840.5538 880.6790 878.6633 
C22:5 816.5538 814.5381 812.5225 850.6320 848.6164 846.6007 842.5694 840.5538 838.5381 878.6633 876.6477 
C22:6 814.5381 812.5225 810.5068 848.6164 846.6007 844.5851 840.5538 838.5381 836.5225 876.6477 874.6320 
C24:0 854.6633 852.6477 850.6320 888.7416 886.7259 884.7103 880.6790 878.6633 876.6477 916.7729 914.7572 
C24:1 852.6477 850.6320 848.6164 886.7259 884.7103 882.6946 878.6633 876.6477 874.6320 914.7572 912.7416 
 
 
Matrix used for the identification of precursor [M+H]+m/z ratios for phosphatidylethanolamines with specific fatty 
acyl chains. The intersection between a fatty acid across the top row and down the first column would reveal its m/z 
ratio. 
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Table A.3.  Matrix for the Determination of Acyl-Specific Phosphatidylserine m/z ratios 
 
Acyl Chains C12:0 C14:0 C16:0 C16:1 C18:0 C18:1 C18:2 C18:3 C20:0 C20:1 C20:2 
C12:0 624.3871 652.4184 680.4497 678.4341 708.4810 706.4654 704.4497 702.4341 736.5123 734.4967 732.4810 
C14:0 652.4184 680.4497 708.4810 706.4654 736.5123 734.4967 732.4810 730.4654 764.5436 762.5280 760.5123 
C16:0 680.4497 708.4810 736.5123 734.4967 764.5436 762.5280 760.5123 758.4967 792.5749 790.5593 788.5436 
C16:1 678.4341 706.4654 734.4967 732.4810 762.5280 760.5123 758.4967 756.4810 790.5593 788.5436 786.5280 
C18:0 708.4810 736.5123 764.5436 762.5280 792.5749 790.5593 788.5436 786.5280 820.6062 818.5906 816.5749 
C18:1 706.4654 734.4967 762.5280 760.5123 790.5593 788.5436 786.5280 784.5123 818.5906 816.5749 814.5593 
C18:2 704.4497 732.4810 760.5123 758.4967 788.5436 786.5280 784.5123 782.4967 816.5749 814.5593 812.5436 
C18:3 702.4341 730.4654 758.4967 756.4810 786.5280 784.5123 782.4967 780.4810 814.5593 812.5436 810.5280 
C20:0 736.5123 764.5436 792.5749 790.5593 820.6062 818.5906 816.5749 814.5593 848.6375 846.6219 844.6062 
C20:1 734.4967 762.5280 790.5593 788.5436 818.5906 816.5749 814.5593 812.5436 846.6219 844.6062 842.5906 
C20:2 732.4810 760.5123 788.5436 786.5280 816.5749 814.5593 812.5436 810.5280 844.6062 842.5906 840.5749 
C20:3 730.4654 758.4967 786.5280 784.5123 814.5593 812.5436 810.5280 808.5123 842.5906 840.5749 838.5593 
C20:4 728.4498 756.4810 784.5123 782.4967 812.5436 810.5280 808.5123 806.4967 840.5749 838.5593 836.5436 
C20:5 726.4341 754.4654 782.4967 780.4810 810.5280 808.5123 806.4967 804.4810 838.5593 836.5436 834.5280 
C22:0 764.5436 792.5749 820.6062 818.5906 848.6375 846.6219 844.6062 842.5906 876.6688 874.6532 872.6375 
C22:1 762.5280 790.5593 818.5906 816.5749 846.6219 844.6062 842.5906 840.5749 874.6532 872.6375 870.6219 
C22:2 760.5123 788.5436 816.5749 814.5593 844.6062 842.5906 840.5749 838.5593 872.6375 870.6219 868.6062 
C22:4 756.4810 784.5123 812.5436 810.5280 840.5749 838.5593 836.5436 834.5280 868.6062 866.5906 864.5749 
C22:5 754.4654 782.4967 810.5280 808.5123 838.5593 836.5436 834.5280 832.5123 866.5906 864.5749 862.5593 
C22:6 752.4497 780.4810 808.5123 806.4967 836.5436 834.5280 832.5123 830.4967 864.5749 862.5593 860.5436 
C24:0 792.5749 820.6062 848.6375 846.6219 876.6688 874.6532 872.6375 870.6219 904.7001 902.6845 900.6688 
C24:1 790.5593 818.5906 846.6219 844.6062 874.6532 872.6375 870.6219 868.6062 902.6845 900.6688 898.6532 
 
Acyl Chains C20:3 C20:4 C20:5 C22:0 C22:1 C22:2 C22:4 C22:5 C22:6 C24:0 C24:1 
C12:0 730.4654 728.4498 726.4341 764.5436 762.5280 760.5123 756.4810 754.4654 752.4497 792.5749 790.5593 
C14:0 758.4967 756.4810 754.4654 792.5749 790.5593 788.5436 784.5123 782.4967 780.4810 820.6062 818.5906 
C16:0 786.5280 784.5123 782.4967 820.6062 818.5906 816.5749 812.5436 810.5280 808.5123 848.6375 846.6219 
C16:1 784.5123 782.4967 780.4810 818.5906 816.5749 814.5593 810.5280 808.5123 806.4967 846.6219 844.6062 
C18:0 814.5593 812.5436 810.5280 848.6375 846.6219 844.6062 840.5749 838.5593 836.5436 876.6688 874.6532 
C18:1 812.5436 810.5280 808.5123 846.6219 844.6062 842.5906 838.5593 836.5436 834.5280 874.6532 872.6375 
C18:2 810.5280 808.5123 806.4967 844.6062 842.5906 840.5749 836.5436 834.5280 832.5123 872.6375 870.6219 
C18:3 808.5123 806.4967 804.4810 842.5906 840.5749 838.5593 834.5280 832.5123 830.4967 870.6219 868.6062 
C20:0 842.5906 840.5749 838.5593 876.6688 874.6532 872.6375 868.6062 866.5906 864.5749 904.7001 902.6845 
C20:1 840.5749 838.5593 836.5436 874.6532 872.6375 870.6219 866.5906 864.5749 862.5593 902.6845 900.6688 
C20:2 838.5593 836.5436 834.5280 872.6375 870.6219 868.6062 864.5749 862.5593 860.5436 900.6688 898.6532 
C20:3 836.5436 834.5280 832.5123 870.6219 868.6062 866.5906 862.5593 860.5436 858.5280 898.6532 896.6375 
C20:4 834.5280 832.5123 830.4967 868.6062 866.5906 864.5749 860.5436 858.5280 856.5123 896.6375 894.6219 
C20:5 832.5123 830.4967 828.4810 866.5906 864.5749 862.5593 858.5280 856.5123 854.4967 894.6219 892.6062 
C22:0 870.6219 868.6062 866.5906 904.7001 902.6845 900.6688 896.6375 894.6219 892.6062 932.7314 930.7158 
C22:1 868.6062 866.5906 864.5749 902.6845 900.6688 898.6532 894.6219 892.6062 890.5906 930.7158 928.7001 
C22:2 866.5906 864.5749 862.5593 900.6688 898.6532 896.6375 892.6062 890.5906 888.5749 928.7001 926.6845 
C22:4 862.5593 860.5436 858.5280 896.6375 894.6219 892.6062 888.5749 886.5593 884.5436 924.6688 922.6532 
C22:5 860.5436 858.5280 856.5123 894.6219 892.6062 890.5906 886.5593 884.5436 882.5280 922.6532 920.6375 
C22:6 858.5280 856.5123 854.4967 892.6062 890.5906 888.5749 884.5436 882.5280 880.5123 920.6375 918.6219 
C24:0 898.6532 896.6375 894.6219 932.7314 930.7158 928.7001 924.6688 922.6532 920.6375 960.7627 958.7471 
C24:1 896.6375 894.6219 892.6062 930.7158 928.7001 926.6845 922.6532 920.6375 918.6219 958.7471 956.7314 
 
 
Matrix used for the identification of precursor [M+H]+ m/z ratios for phosphatidylserines with specific fatty acyl 
chains. The intersection between a fatty acid across the top row and down the first column would reveal its m/z ratio. 
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Table A.4.  Matrix for the Determination of Acyl-Specific Phosphatidylinositol m/z ratios 
 
Acyl Chains C12:0 C14:0 C16:0 C16:1 C18:0 C18:1 C18:2 C18:3 C20:0 C20:1 C20:2 
C12:0 699.4079 727.4392 755.4705 753.4549 783.5018 781.4862 779.4705 777.4549 811.5331 809.5175 807.5018 
C14:0 727.4392 755.4705 783.5018 781.4862 811.5331 809.5175 807.5018 805.4862 839.5644 837.5488 835.5331 
C16:0 755.4705 783.5018 811.5331 809.5175 839.5644 837.5488 835.5331 833.5175 867.5957 865.5801 863.5644 
C16:1 753.4549 781.4862 809.5175 807.5018 837.5488 835.5331 833.5175 831.5018 865.5801 863.5644 861.5488 
C18:0 783.5018 811.5331 839.5644 837.5488 867.5957 865.5801 863.5644 861.5488 895.6270 893.6114 891.5957 
C18:1 781.4862 809.5175 837.5488 835.5331 865.5801 863.5644 861.5488 859.5331 893.6114 891.5957 889.5801 
C18:2 779.4705 807.5018 835.5331 833.5175 863.5644 861.5488 859.5331 857.5175 891.5957 889.5801 887.5644 
C18:3 777.4549 805.4862 833.5175 831.5018 861.5488 859.5331 857.5175 855.5018 889.5801 887.5644 885.5488 
C20:0 811.5331 839.5644 867.5957 865.5801 895.6270 893.6114 891.5957 889.5801 923.6583 921.6427 919.6270 
C20:1 809.5175 837.5488 865.5801 863.5644 893.6114 891.5957 889.5801 887.5644 921.6427 919.6270 917.6114 
C20:2 807.5018 835.5331 863.5644 861.5488 891.5957 889.5801 887.5644 885.5488 919.6270 917.6114 915.5957 
C20:3 805.4862 833.5175 861.5488 859.5331 889.5801 887.5644 885.5488 883.5331 917.6114 915.5957 913.5801 
C20:4 803.4706 831.5018 859.5331 857.5175 887.5644 885.5488 883.5331 881.5175 915.5957 913.5801 911.5644 
C20:5 801.4549 829.4862 857.5175 855.5018 885.5488 883.5331 881.5175 879.5018 913.5801 911.5644 909.5488 
C22:0 839.5644 867.5957 895.6270 893.6114 923.6583 921.6427 919.6270 917.6114 951.6896 949.6740 947.6583 
C22:1 837.5488 865.5801 893.6114 891.5957 921.6427 919.6270 917.6114 915.5957 949.6740 947.6583 945.6427 
C22:2 835.5331 863.5644 891.5957 889.5801 919.6270 917.6114 915.5957 913.5801 947.6583 945.6427 943.6270 
C22:4 831.5018 859.5331 887.5644 885.5488 915.5957 913.5801 911.5644 909.5488 943.6270 941.6114 939.5957 
C22:5 829.4862 857.5175 885.5488 883.5331 913.5801 911.5644 909.5488 907.5331 941.6114 939.5957 937.5801 
C22:6 827.4705 855.5018 883.5331 881.5175 911.5644 909.5488 907.5331 905.5175 939.5957 937.5801 935.5644 
C24:0 867.5957 895.6270 923.6583 921.6427 951.6896 949.6740 947.6583 945.6427 979.7209 977.7053 975.6896 
C24:1 865.5801 893.6114 921.6427 919.6270 949.6740 947.6583 945.6427 943.6270 977.7053 975.6896 973.6740 
 
Acyl Chains C20:3 C20:4 C20:5 C22:0 C22:1 C22:2 C22:4 C22:5 C22:6 C24:0 C24:1 
C12:0 805.4862 803.4706 801.4549 839.5644 837.5488 835.5331 831.5018 829.4862 827.4705 867.5957 865.5801 
C14:0 833.5175 831.5018 829.4862 867.5957 865.5801 863.5644 859.5331 857.5175 855.5018 895.6270 893.6114 
C16:0 861.5488 859.5331 857.5175 895.6270 893.6114 891.5957 887.5644 885.5488 883.5331 923.6583 921.6427 
C16:1 859.5331 857.5175 855.5018 893.6114 891.5957 889.5801 885.5488 883.5331 881.5175 921.6427 919.6270 
C18:0 889.5801 887.5644 885.5488 923.6583 921.6427 919.6270 915.5957 913.5801 911.5644 951.6896 949.6740 
C18:1 887.5644 885.5488 883.5331 921.6427 919.6270 917.6114 913.5801 911.5644 909.5488 949.6740 947.6583 
C18:2 885.5488 883.5331 881.5175 919.6270 917.6114 915.5957 911.5644 909.5488 907.5331 947.6583 945.6427 
C18:3 883.5331 881.5175 879.5018 917.6114 915.5957 913.5801 909.5488 907.5331 905.5175 945.6427 943.6270 
C20:0 917.6114 915.5957 913.5801 951.6896 949.6740 947.6583 943.6270 941.6114 939.5957 979.7209 977.7053 
C20:1 915.5957 913.5801 911.5644 949.6740 947.6583 945.6427 941.6114 939.5957 937.5801 977.7053 975.6896 
C20:2 913.5801 911.5644 909.5488 947.6583 945.6427 943.6270 939.5957 937.5801 935.5644 975.6896 973.6740 
C20:3 911.5644 909.5488 907.5331 945.6427 943.6270 941.6114 937.5801 935.5644 933.5488 973.6740 971.6583 
C20:4 909.5488 907.5331 905.5175 943.6270 941.6114 939.5957 935.5644 933.5488 931.5331 971.6583 969.6427 
C20:5 907.5331 905.5175 903.5018 941.6114 939.5957 937.5801 933.5488 931.5331 929.5175 969.6427 967.6270 
C22:0 945.6427 943.6270 941.6114 979.7209 977.7053 975.6896 971.6583 969.6427 967.6270 1007.7522 1005.7366 
C22:1 943.6270 941.6114 939.5957 977.7053 975.6896 973.6740 969.6427 967.6270 965.6114 1005.7366 1003.7209 
C22:2 941.6114 939.5957 937.5801 975.6896 973.6740 971.6583 967.6270 965.6114 963.5957 1003.7209 1001.7053 
C22:4 937.5801 935.5644 933.5488 971.6583 969.6427 967.6270 963.5957 961.5801 959.5644 999.6896 997.6740 
C22:5 935.5644 933.5488 931.5331 969.6427 967.6270 965.6114 961.5801 959.5644 957.5488 997.6740 995.6583 
C22:6 933.5488 931.5331 929.5175 967.6270 965.6114 963.5957 959.5644 957.5488 955.5331 995.6583 993.6427 
C24:0 973.6740 971.6583 969.6427 1007.7522 1005.7366 1003.7209 999.6896 997.6740 995.6583 1035.7835 1033.7679 
C24:1 971.6583 969.6427 967.6270 1005.7366 1003.7209 1001.7053 997.6740 995.6583 993.6427 1033.7679 1031.7522 
 
 
Matrix used for the identification of precursor [M+H]+m/z ratios for phosphatidylinositols with specific fatty acyl 
chains. The intersection between a fatty acid across the top row and down the first column would reveal its m/z ratio. 
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Table A.5.  Matrix for the Determination of Acyl-Specific Phosphatidylglycerol m/z ratios 
 
Acyl Chains C12:0 C14:0 C16:0 C16:1 C18:0 C18:1 C18:2 C18:3 C20:0 C20:1 C20:2 
C12:0 611.3919 639.4232 667.4545 665.4388 695.4858 693.4701 691.4545 689.4388 723.5171 721.5014 719.4858 
C14:0 639.4232 667.4545 695.4858 693.4701 723.5171 721.5014 719.4858 717.4701 751.5484 749.5327 747.5171 
C16:0 667.4545 695.4858 723.5171 721.5014 751.5484 749.5327 747.5171 745.5014 779.5797 777.5640 775.5484 
C16:1 665.4388 693.4701 721.5014 719.4858 749.5327 747.5171 745.5014 743.4858 777.5640 775.5484 773.5327 
C18:0 695.4858 723.5171 751.5484 749.5327 779.5797 777.5640 775.5484 773.5327 807.6110 805.5953 803.5797 
C18:1 693.4701 721.5014 749.5327 747.5171 777.5640 775.5484 773.5327 771.5171 805.5953 803.5797 801.5640 
C18:2 691.4545 719.4858 747.5171 745.5014 775.5484 773.5327 771.5171 769.5014 803.5797 801.5640 799.5484 
C18:3 689.4388 717.4701 745.5014 743.4858 773.5327 771.5171 769.5014 767.4858 801.5640 799.5484 797.5327 
C20:0 723.5171 751.5484 779.5797 777.5640 807.6110 805.5953 803.5797 801.5640 835.6423 833.6266 831.6110 
C20:1 721.5014 749.5327 777.5640 775.5484 805.5953 803.5797 801.5640 799.5484 833.6266 831.6110 829.5953 
C20:2 719.4858 747.5171 775.5484 773.5327 803.5797 801.5640 799.5484 797.5327 831.6110 829.5953 827.5797 
C20:3 717.4701 745.5014 773.5327 771.5171 801.5640 799.5484 797.5327 795.5171 829.5953 827.5797 825.5640 
C20:4 715.4545 743.4858 771.5171 769.5014 799.5484 797.5327 795.5171 793.5014 827.5797 825.5640 823.5484 
C20:5 713.4388 741.4701 769.5014 767.4858 797.5327 795.5171 793.5014 791.4858 825.5640 823.5484 821.5327 
C22:0 751.5484 779.5797 807.6110 805.5953 835.6423 833.6266 831.6110 829.5953 863.6736 861.6579 859.6423 
C22:1 749.5327 777.5640 805.5953 803.5797 833.6266 831.6110 829.5953 827.5797 861.6579 859.6423 857.6266 
C22:2 747.5171 775.5484 803.5797 801.5640 831.6110 829.5953 827.5797 825.5640 859.6423 857.6266 855.6110 
C22:4 743.4858 771.5171 799.5484 797.5327 827.5797 825.5640 823.5484 821.5327 855.6110 853.5953 851.5797 
C22:5 741.4701 769.5014 797.5327 795.5171 825.5640 823.5484 821.5327 819.5171 853.5953 851.5797 849.5640 
C22:6 739.4545 767.4858 795.5171 793.5014 823.5484 821.5327 819.5171 817.5014 851.5797 849.5640 847.5484 
C24:0 779.5797 807.6110 835.6423 833.6266 863.6736 861.6579 859.6423 857.6266 891.7049 889.6892 887.6736 
C24:1 777.5640 805.5953 833.6266 831.6110 861.6579 859.6423 857.6266 855.6110 889.6892 887.6736 885.6579 
 
Acyl Chains C20:3 C20:4 C20:5 C22:0 C22:1 C22:2 C22:4 C22:5 C22:6 C24:0 C24:1 
C12:0 717.4701 715.4545 713.4388 751.5484 749.5327 747.5171 743.4858 741.4701 739.4545 779.5797 777.5640 
C14:0 745.5014 743.4858 741.4701 779.5797 777.5640 775.5484 771.5171 769.5014 767.4858 807.6110 805.5953 
C16:0 773.5327 771.5171 769.5014 807.6110 805.5953 803.5797 799.5484 797.5327 795.5171 835.6423 833.6266 
C16:1 771.5171 769.5014 767.4858 805.5953 803.5797 801.5640 797.5327 795.5171 793.5014 833.6266 831.6110 
C18:0 801.5640 799.5484 797.5327 835.6423 833.6266 831.6110 827.5797 825.5640 823.5484 863.6736 861.6579 
C18:1 799.5484 797.5327 795.5171 833.6266 831.6110 829.5953 825.5640 823.5484 821.5327 861.6579 859.6423 
C18:2 797.5327 795.5171 793.5014 831.6110 829.5953 827.5797 823.5484 821.5327 819.5171 859.6423 857.6266 
C18:3 795.5171 793.5014 791.4858 829.5953 827.5797 825.5640 821.5327 819.5171 817.5014 857.6266 855.6110 
C20:0 829.5953 827.5797 825.5640 863.6736 861.6579 859.6423 855.6110 853.5953 851.5797 891.7049 889.6892 
C20:1 827.5797 825.5640 823.5484 861.6579 859.6423 857.6266 853.5953 851.5797 849.5640 889.6892 887.6736 
C20:2 825.5640 823.5484 821.5327 859.6423 857.6266 855.6110 851.5797 849.5640 847.5484 887.6736 885.6579 
C20:3 823.5484 821.5327 819.5171 857.6266 855.6110 853.5953 849.5640 847.5484 845.5327 885.6579 883.6423 
C20:4 821.5327 819.5171 817.5014 855.6110 853.5953 851.5797 847.5484 845.5327 843.5171 883.6423 881.6266 
C20:5 819.5171 817.5014 815.4858 853.5953 851.5797 849.5640 845.5327 843.5171 841.5014 881.6266 879.6110 
C22:0 857.6266 855.6110 853.5953 891.7049 889.6892 887.6736 883.6423 881.6266 879.6110 919.7362 917.7205 
C22:1 855.6110 853.5953 851.5797 889.6892 887.6736 885.6579 881.6266 879.6110 877.5953 917.7205 915.7049 
C22:2 853.5953 851.5797 849.5640 887.6736 885.6579 883.6423 879.6110 877.5953 875.5797 915.7049 913.6892 
C22:4 849.5640 847.5484 845.5327 883.6423 881.6266 879.6110 875.5797 873.5640 871.5484 911.6736 909.6579 
C22:5 847.5484 845.5327 843.5171 881.6266 879.6110 877.5953 873.5640 871.5484 869.5327 909.6579 907.6423 
C22:6 845.5327 843.5171 841.5014 879.6110 877.5953 875.5797 871.5484 869.5327 867.5171 907.6423 905.6266 
C24:0 885.6579 883.6423 881.6266 919.7362 917.7205 915.7049 911.6736 909.6579 907.6423 947.7675 945.7518 
C24:1 883.6423 881.6266 879.6110 917.7205 915.7049 913.6892 909.6579 907.6423 905.6266 945.7518 943.7362 
 
Matrix used for the identification of precursor [M+H]+m/z ratios for phosphatidylglycerols with specific fatty acyl 
chains. The intersection between a fatty acid across the top row and down the first column would reveal its m/z ratio. 
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Table A.6 Predicted Glycerophospholipid Precursor Accurate Masses# 
 
Accurate Mass, m/z [M+H]+ 
Lipid Group Phosphatidylcholines Phosphatidylethanolamines Phosphatidylserines 
24:0 622.4442 580.3973 624.3871 
24:1 620.4286 578.3817 622.3715 
24:2 618.4130 576.3661 620.3559 
26:0 650.4755 608.4286 652.4184 
26:1 648.4599 606.4130 650.4028 
26:2 646.4443 604.3974 648.3872 
28:0 678.5068 636.4599 680.4497 
28:1 676.4912 634.4443 678.4341 
28:2 674.4756 632.4287 676.4185 
30:0 706.5381 664.4912 708.4810 
30:1 704.5225 662.4756 706.4654 
30:2 702.5069 660.4600 704.4498 
30:3 700.4913 658.4444 702.4342 
30:4 698.4757 656.4288 700.4186 
32:0 734.5694 692.5225 736.5123 
32:1 732.5538 690.5069 734.4967 
32:2 730.5382 688.4913 732.4811 
32:3 728.5226 686.4757 730.4655 
32:4 726.5070 684.4601 728.4499 
32:5 724.4914 682.4445 726.4343 
32:6 722.4758 680.4289 724.4187 
34:0 762.6007 720.5538 764.5436 
34:1 760.5851 718.5382 762.5280 
34:2 758.5695 716.5226 760.5124 
34:3 756.5539 714.5070 758.4968 
34:4 754.5383 712.4914 756.4812 
34:5 752.5227 710.4758 754.4656 
34:6 750.5071 708.4602 752.4500 
34:7 748.4915 706.4446 750.4344 
36:0 790.6320 748.5851 792.5749 
36:1 788.6164 746.5695 790.5593 
36:2 786.6008 744.5539 788.5437 
36:3 784.5852 742.5383 786.5281 
36:4 782.5696 740.5227 784.5125 
36:5 780.5540 738.5071 782.4969 
36:6 778.5384 736.4915 780.4813 
36:7 776.5228 734.4759 778.4657 
38:0 818.6633 776.6164 820.6062 
30:1 816.6477 774.6008 818.5906 
38:2 814.6321 772.5852 816.5750 
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38:3 812.6165 770.5696 814.5594 
38:4 810.6009 768.5540 812.5438 
38:5 808.5853 766.5384 810.5282 
38:6 806.5697 764.5228 808.5126 
38:7 804.5541 762.5072 806.4970 
40:0 846.6946 804.6477 848.6375 
40:1 844.6790 802.6321 846.6219 
40:2 842.6634 800.6165 844.6063 
40:3 840.6478 798.6009 842.5907 
40:4 838.6322 796.5853 840.5751 
40:5 836.6166 794.5697 838.5595 
40:6 834.6010 792.5541 836.5439 
40:7 832.5854 790.5385 834.5283 
40:8 830.5698 788.5229 832.5127 
40:9 828.5542 786.5073 830.4971 
42:0 874.7259 832.6790 876.6688 
42:1 872.7103 830.6634 874.6532 
42:2 870.6947 828.6478 872.6376 
42:3 868.6791 826.6322 870.6220 
42:4 866.6635 824.6166 868.6064 
42:5 864.6479 822.6010 866.5908 
42:6 862.6323 820.5854 864.5752 
42:7 860.6167 818.5698 862.5596 
42:8 858.6011 816.5542 860.5440 
42:9 856.5855 814.5386 858.5284 
42:10 854.5699 812.5230 856.5128 
42:11 852.5543 810.5074 854.4972 
44:0 902.7572 860.7103 904.7001 
44:1 900.7416 858.6947 902.6845 
44:2 898.7260 856.6791 900.6689 
44:3 896.7104 854.6635 898.6533 
44:4 894.6948 852.6479 896.6377 
44:5 892.6792 850.6323 894.6221 
44:6 890.6636 848.6167 892.6065 
44:7 888.6480 846.6011 890.5909 
44:8 886.6324 844.5855 888.5753 
44:9 884.6168 842.5699 886.5597 
44:10 882.6012 840.5543 884.5441 
44:11 880.5856 838.5387 882.5285 
44:12 878.5700 836.5231 880.5129 
46:0 930.7885 888.7416 932.7314 
46:1 928.7729 886.7260 930.7158 
46:2 926.7573 884.7104 928.7002 
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46:3 924.7417 882.6948 926.6846 
46:4 922.7261 880.6792 924.6690 
46:5 920.7105 878.6636 922.6534 
46:6 918.6949 876.6480 920.6378 
46:7 916.6793 874.6324 918.6222 
48:0 958.8198 916.7729 960.7627 
48:1 956.8042 914.7573 958.7471 
48:2 954.7886 912.7417 956.7315 
#Matrix for the identification of precursor m/z ratios for phosphatidylcholine, phosphatidylethanolamine and 
phosphatidylserine lipid groups (non-acyl specific). 
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Table A.7 Predicted Triacylglycerol Precursor Accurate Masses# 
Lipid Group Accurate Mass, m/z [M+NH4]+ 
42:0 740.6763 
42:1 738.6606 
42:2 736.6450 
44:0 768.7076 
44:1 766.6919 
44:2 764.6763 
44:3 762.6606 
46:0 796.7467 
46:1 794.7232 
46:2 792.7076 
46:3 790.6919 
46:4 788.6763 
48:0 824.7720 
48:1 822.2553 
48:2 820.7436 
50:0 852.8020 
50:1 850.7812 
50:2 848.7726 
52:0 880.8328 
52:1 878.8175 
52:2 876.7986 
52:3 874.7862 
52:4 872.7674 
52:5 870.7514 
54:0 908.8641 
54:1 906.8534 
54:2 904.8312 
54:3 902.8143 
54:4 900.7988 
54:5 898.7857 
54:6 896.7463 
54:7 894.7069 
56:0 936.8954 
56:1 934.8797 
56:2 932.8641 
56:3 930.8484 
56:4 928.8328 
56:5 926.7880 
56:6 924.8015 
56:7 922.7840 
56:8 920.7164 
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58:0 964.9267 
58:1 962.9110 
58:10 944.7702 
58:11 942.7545 
58:12 940.7389 
58:2 960.8954 
58:3 958.8797 
58:4 956.8641 
58:5 954.8484 
58:6 952.8328 
58:7 950.8171 
58:8 948.8015 
58:9 946.7858 
60:0 992.9580 
60:1 990.9423 
60:10 972.8015 
60:11 970.7858 
60:12 968.7702 
60:13 966.7545 
60:2 988.9267 
60:3 986.9110 
60:4 984.8954 
60:5 982.8797 
60:6 980.8641 
60:7 978.8484 
60:8 976.8328 
60:9 974.8171 
62:0 1020.9893 
62:1 1018.9737 
62:10 1000.8333 
62:11 998.8177 
62:12 996.8021 
62:2 1016.9581 
62:3 1014.9425 
62:4 1012.9269 
62:5 1010.9113 
62:6 1008.8957 
62:7 1006.8801 
62:8 1004.8645 
62:9 1002.8489 
64:0 1049.0206 
64:1 1047.0050 
64:10 1028.8646 
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64:11 1026.8490 
64:12 1024.8334 
64:2 1044.9894 
64:3 1042.9738 
64:4 1040.9582 
64:5 1038.9426 
64:6 1036.9270 
64:7 1034.9114 
64:8 1032.8958 
64:9 1030.8802 
66:0 1077.0519 
66:1 1075.0363 
66:10 1056.8959 
66:11 1054.8803 
66:2 1073.0207 
66:3 1071.0051 
66:4 1068.9895 
66:6 1064.9583 
66:7 1062.9427 
66:8 1060.9271 
66:9 1058.9115 
#Matrix for the identification of precursor m/z ratios for triacylglycerol lipid groups (non-acyl specific). 
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Table B.1 Comprehensive Lipidomics of Cholesterol and Cholesteryl Ester Species in Whole 
Blood 
m/z Ratio Molecular Adduct Lipid Area Under the Curve 
369.3516 [M+H-H2O]+ Free Cholesterol 44074511 
640.6027 [M+NH4]+ CE 16:1 1941979 
642.6183 [M+NH4]+ CE 16:0 17929076 
664.6027 [M+NH4]+ CE 18:3 18726347 
666.6183 [M+NH4]+ CE 18:2 1471637361 
668.6340 [M+NH4]+ CE 18:1 146302004 
670.6496 [M+NH4]+ CE 18:0 21039879 
688.6027 [M+NH4]+ CE 20:5 34869072 
690.6183 [M+NH4]+ CE 20:4 330830276 
692.6340 [M+NH4]+ CE 20:3 17734717 
694.6496 [M+NH4]+ CE 20:2 54850605 
696.6653 [M+NH4]+ CE 20:1 14691256 
698.6809 [M+NH4]+ CE 20:0 3560071 
714.6183 [M+NH4]+ CE 22:6 55135656 
716.6340 [M+NH4]+ CE 22:5 4879891 
718.6496 [M+NH4]+ CE 22:4 20319563 
724.6966 [M+NH4]+ CE 22:1 5505764 
726.7122 [M+NH4]+ CE 22:0 1903873 
752.7279 [M+NH4]+ CE 24:1 3760657 
754.7435 [M+NH4]+ CE 24:0 514724 
Mass-to-charge ratio (m/z); Cholesteryl ester (CE). 
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Table B.2 Comprehensive Lipidomics of Phosphatidylcholine Species in Whole Blood 
m/z Ratio Molecular Adduct Lipid Lipid Group Area under the Curve 
496.3399 [M+H]+ lyso-16:0 PC  1054184678 
522.3556 [M+H]+ lyso-18:1 PC  246445199 
524.3710 [M+H]+ lyso-18:0 PC  381953150 
618.4130 [M+H]+  PC 24:2 5293777 
620.4286 [M+H]+  PC 24:1 8683479 
622.4442 [M+H]+  PC 24:0 283579 
646.4443 [M+H]+  PC 26:2 <LOD 
648.4599 [M+H]+  PC 26:1 13869347 
650.4755 [M+H]+  PC 26:0 <LOD 
674.4756 [M+H]+  PC 28:2 <LOD 
676.4912 [M+H]+  PC 28:1 <LOD 
678.5068 [M+H]+  PC 28:0 1032753 
698.4757 [M+H]+  PC 30:4 <LOD 
700.4913 [M+H]+  PC 30:3 356366 
702.5069 [M+H]+  PC 30:2 2850946 
704.5225 [M+H]+  PC 30:1 11496406 
706.5381 [M+H]+  PC 30:0 130414318 
722.4758 [M+H]+  PC 32:6 2216626 
724.4914 [M+H]+  PC 32:5 4335569 
726.5070 [M+H]+  PC 32:4 1801215 
728.5226 [M+H]+  PC 32:3 5977234 
730.5378 [M+H]+ PC 14:0/18:2 
PC 32:2 
43413080 
730.5378 [M+H]+  18711386 
732.5538 [M+H]+  PC 32:1 
456884323 
732.5538 [M+H]+ PC 16:0/16:1 401103023 
734.5694 [M+H]+  PC 32:0 
736489764 
734.5694 [M+H]+ PC 16:0/16:0 673269675 
748.4915 [M+H]+  PC 34:7 <LOD 
750.5071 [M+H]+  PC 34:6 4904911 
752.5227 [M+H]+  PC 34:5 13563503 
754.5383 [M+H]+  PC 34:4 50472182 
756.5539 [M+H]+  PC 34:3 300224436 
758.5695 [M+H]+  PC 34:2 
13540304839 
758.5695 [M+H]+ PC 16:0/18:2 13085851102 
760.5843 [M+H]+ PC 16:0/18:1 
PC 34:1 
6792037828 
760.5843 [M+H]+  8603126442 
762.6007 [M+H]+  PC 34:0 2272134454 
776.5228 [M+H]+  PC 36:7 <LOD 
778.5384 [M+H]+  PC 36:6 <LOD 
780.5537 [M+H]+ PC 16:0/20:5 
PC 36:5 
566524647 
780.5537 [M+H]+  798112731 
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782.5693 [M+H]+ PC 18:2/18:2 
PC 36:4 
234439064 
782.5696 [M+H]+  12013187125 
782.5699 [M+H]+ PC 16:0/20:4 11232517157 
784.5255 [M+H]+ PC 18:1/18:2 
PC 36:3 
1384783855 
784.5852 [M+H]+  4276038119 
784.5858 [M+H]+ PC 16:0/20:3 783986453 
786.6008 [M+H]+  
PC 36:2 
5684295432 
786.6021 [M+H]+ PC 18:1/18:1 735455506 
786.6022 [M+H]+ PC 18:0/18:2 4381677582 
788.6164 [M+H]+  PC 36:1 
2408553034 
788.6178 [M+H]+ PC 18:0/18:1 1656390362 
790.6320 [M+H]+  PC 36:0 246908217 
804.5541 [M+H]+  PC 38:7 584316889 
806.5697 [M+H]+  PC 38:6 
1225689021 
806.5701 [M+H]+ PC 16:0/22:6 849451102 
808.5853 [M+H]+  
PC 38:5 
1681214263 
808.5862 [M+H]+ PC 18:0/20:5 200965596 
808.5872 [M+H]+ PC 18:1/20:4 828143821 
810.6008 [M+H]+ PC 18:0/20:4 
PC 38:4 
1866759061 
810.6009 [M+H]+  2476911499 
810.6028 [M+H]+ PC 18:1/20:3 62773961 
812.6165 [M+H]+  PC 38:3 
474034308 
812.6178 [M+H]+ PC 18:0/20:3 341037865 
814.6321 [M+H]+  PC 38:2 157403704 
816.6477 [M+H]+  PC 38:1 25828217 
818.6633 [M+H]+  PC 38:0 3604768 
828.5542 [M+H]+  PC 40:9 71745446 
830.5698 [M+H]+  PC 40:8 77675246 
832.5848 [M+H]+ PC 18:1/22:6 
PC 40:7 
43263364 
832.5854 [M+H]+  266831772 
834.6010 [M+H]+  PC 40:6 
325786223 
834.6014 [M+H]+ PC 18:0/22:6 247551540 
836.6166 [M+H]+  PC 40:5 111124185 
838.6322 [M+H]+  PC 40:4 
73202889 
838.6367 [M+H]+ PC 18:0/22:4 24522523 
840.6478 [M+H]+  PC 40:3 2306992 
842.6634 [M+H]+  PC 40:2 <LOD 
844.6790 [M+H]+  PC 40:1 <LOD 
846.6946 [M+H]+  PC 40:0 <LOD 
852.5543 [M+H]+  PC 42:11 <LOD 
854.5699 [M+H]+  PC 42:10 <LOD 
856.5855 [M+H]+  PC 42:9 19768308 
858.6011 [M+H]+  PC 42:8 8440167 
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860.6167 [M+H]+  PC 42:7 3124636 
862.6323 [M+H]+  PC 42:6 24941042 
864.6479 [M+H]+  PC 42:5 <LOD 
866.6635 [M+H]+  PC 42:4 <LOD 
868.6791 [M+H]+  PC 42:3 <LOD 
870.6947 [M+H]+  PC 42:2 <LOD 
872.7103 [M+H]+  PC 42:1 <LOD 
874.7259 [M+H]+  PC 42:0 <LOD 
878.5700 [M+H]+  PC 44:12 <LOD 
880.5856 [M+H]+  PC 44:11 8639161 
882.6012 [M+H]+  PC 44:10 <LOD 
884.6168 [M+H]+  PC 44:9 <LOD 
886.6324 [M+H]+  PC 44:8 <LOD 
888.6480 [M+H]+  PC 44:7 <LOD 
890.6636 [M+H]+  PC 44:6 <LOD 
892.6792 [M+H]+  PC 44:5 <LOD 
894.6948 [M+H]+  PC 44:4 <LOD 
896.7104 [M+H]+  PC 44:3 <LOD 
898.7260 [M+H]+  PC 44:2 <LOD 
900.7416 [M+H]+  PC 44:1 <LOD 
902.7572 [M+H]+  PC 44:0 <LOD 
916.6793 [M+H]+  PC 46:7 <LOD 
918.6949 [M+H]+  PC 46:6 <LOD 
920.7105 [M+H]+  PC 46:5 <LOD 
922.7261 [M+H]+  PC 46:4 <LOD 
924.7417 [M+H]+  PC 46:3 <LOD 
926.7573 [M+H]+  PC 46:2 <LOD 
928.7729 [M+H]+  PC 46:1 <LOD 
930.7885 [M+H]+  PC 46:0 <LOD 
954.7886 [M+H]+  PC 48:2 <LOD 
956.8042 [M+H]+  PC 48:1 <LOD 
958.8198 [M+H]+  PC 48:0 <LOD 
Mass-to-charge ratio (m/z); Phosphatidylcholine (PC); Limit of detection (LOD). 
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Table B.3. Comprehensive Lipidomics of Phosphatidylethanolamine and Plasmenyl-
Phosphatidylethanolamine Species in Whole Blood 
m/z Ratio Molecular Adduct Lipid Lipid Group Area Under the Curve 
576.3661 [M+H]+  PE 24:2 <LOD 
578.3817 [M+H]+  PE 24:1 <LOD 
580.3973 [M+H]+  PE 24:0 1866840 
604.3974 [M+H]+  PE 26:2 <LOD 
606.4130 [M+H]+  PE 26:1 <LOD 
608.4286 [M+H]+  PE 26:0 3519976 
632.4287 [M+H]+  PE 28:2 <LOD 
634.4443 [M+H]+  PE 28:1 7990002 
636.4599 [M+H]+  PE 28:0 <LOD 
656.4288 [M+H]+  PE 30:4 <LOD 
658.4444 [M+H]+  PE 30:3 <LOD 
660.4600 [M+H]+  PE 30:2 <LOD 
662.4756 [M+H]+  PE 30:1 <LOD 
664.4912 [M+H]+  PE 30:0 <LOD 
680.4289 [M+H]+  PE 32:6 <LOD 
682.4445 [M+H]+  PE 32:5 <LOD 
684.4601 [M+H]+  PE 32:4 <LOD 
686.4757 [M+H]+  PE 32:3 <LOD 
688.4913 [M+H]+  PE 32:2 <LOD 
690.5069 [M+H]+  PE 32:1 63548261 
692.5225 [M+H]+  PE 32:0 11690609 
706.4446 [M+H]+  PE 34:7 <LOD 
708.4602 [M+H]+  PE 34:6 <LOD 
710.4758 [M+H]+  PE 34:5 <LOD 
712.4914 [M+H]+  PE 34:4 <LOD 
714.5070 [M+H]+  PE 34:3 1027096 
716.5226 [M+H]+  PE 34:2 
140866889 
716.5322 [M+H]+ PE 16:0/18:2 115800324 
718.5380 [M+H]+ PE 16:0/18:1 
PE 34:1 
316732311 
718.5382 [M+H]+  352269192 
720.5538 [M+H]+  PE 34:0 62109295 
722.5094 [M+H]+ Plasmenyl-PE P-16:0/20:5  28813754 
724.5284 [M+H]+ Plasmenyl-PE P-16:0/20:4  235265833 
730.5733 [M+H]+ Plasmenyl-PE P-18:0/18:1 54946073 
734.4759 [M+H]+  PE 36:7 <LOD 
736.4915 [M+H]+  PE 36:6 <LOD 
738.5069 [M+H]+ PE 16:0/20:5 
PE 36:5 
17290571 
738.5071 [M+H]+  19289309 
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740.5227 [M+H]+  PE 36:4 
332524679 
740.5247 [M+H]+ PE 16:0/20:4 267961188 
742.5381 [M+H]+ PE 18:1/18:2 
PE 36:3 
138352337 
742.5383 [M+H]+  269068248 
744.5539 [M+H]+  PE 36:2 
218373496 
744.5897 [M+H]+ PE 18:1/18:1 86650818 
746.5690 [M+H]+ PE 18:0/18:1 
PE 36:1 
111455765 
746.5695 [M+H]+  220162562 
748.5298 [M+H]+ Plasmenyl-PE P-16:0/22:6  75173546 
748.5851 [M+H]+  PE 36:0 5036671 
750.5428 [M+H]+ Plasmenyl-PE P-16:0/22:5  142621474 
752.5598 [M+H]+ Plasmenyl-PE P-18:0/20:4  445638736 
762.5072 [M+H]+  PE 38:7 39960549 
764.5228 [M+H]+  PE 38:6 
296147456 
764.5229 [M+H]+ PE 16:0/22:6 259526686 
766.5370 [M+H]+ PE 18:1/20:4 
PE 38:5 
213226059 
766.5384 [M+H]+  300220305 
768.5512 [M+H]+ PE 18:0/20:4 
PE 38:4 
291632129 
768.5540 [M+H]+  397548274 
770.5696 [M+H]+  PE 38:3 57089712 
772.5852 [M+H]+  PE 38:2 147731642 
774.6008 [M+H]+  PE 38:1 113010509 
776.6164 [M+H]+  PE 38:0 10404390 
780.5911 [M+H]+ Plasmenyl-PE P-18:0/22:4 106184046 
786.5073 [M+H]+  PE 40:9 <LOD 
788.5229 [M+H]+  PE 40:8 44500366 
790.5385 [M+H]+  PE 40:7 131989503 
792.5541 [M+H]+  PE 40:6 56883074 
794.5697 [M+H]+  PE 40:5 59570445 
796.5853 [M+H]+  PE 40:4 89050243 
798.6009 [M+H]+  PE 40:3 35482485 
800.6165 [M+H]+  PE 40:2 <LOD 
802.6321 [M+H]+  PE 40:1 <LOD 
804.6477 [M+H]+  PE 40:0 27820806 
810.5074 [M+H]+  PE 42:11 <LOD 
812.5230 [M+H]+  PE 42:10 <LOD 
814.5386 [M+H]+  PE 42:9 <LOD 
816.5542 [M+H]+  PE 42:8 <LOD 
818.5698 [M+H]+  PE 42:7 <LOD 
820.5854 [M+H]+  PE 42:6 26330221 
822.6010 [M+H]+  PE 42:5 <LOD 
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824.6166 [M+H]+  PE 42:4 16589395 
826.6322 [M+H]+  PE 42:3 9659705 
828.6478 [M+H]+  PE 42:2 <LOD 
830.6634 [M+H]+  PE 42:1 <LOD 
832.6790 [M+H]+  PE 42:0 <LOD 
836.5231 [M+H]+  PE 44:12 <LOD 
838.5387 [M+H]+  PE 44:11 <LOD 
840.5543 [M+H]+  PE 44:10 <LOD 
842.5699 [M+H]+  PE 44:9 <LOD 
844.5855 [M+H]+  PE 44:8 <LOD 
846.6011 [M+H]+  PE 44:7 <LOD 
848.6167 [M+H]+  PE 44:6 <LOD 
850.6323 [M+H]+  PE 44:5 <LOD 
852.6479 [M+H]+  PE 44:4 <LOD 
854.6635 [M+H]+  PE 44:3 <LOD 
856.6791 [M+H]+  PE 44:2 <LOD 
858.6947 [M+H]+  PE 44:1 <LOD 
860.7103 [M+H]+  PE 44:0 <LOD 
874.6324 [M+H]+  PE 46:7 <LOD 
876.6480 [M+H]+  PE 46:6 <LOD 
878.6636 [M+H]+  PE 46:5 <LOD 
880.6792 [M+H]+  PE 46:4 <LOD 
882.6948 [M+H]+  PE 46:3 <LOD 
884.7104 [M+H]+  PE 46:2 <LOD 
886.7260 [M+H]+  PE 46:1 <LOD 
888.7416 [M+H]+  PE 46:0 <LOD 
912.7417 [M+H]+  PE 48:2 <LOD 
914.7573 [M+H]+  PE 48:1 <LOD 
916.7729 [M+H]+  PE 48:0 <LOD 
Mass-to-charge ratio (m/z); Phosphatidylethanolamine (PE); Limit of detection (LOD). 
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Table B.4 Comprehensive Lipidomics of Phosphatidylserine Species in Whole Blood 
m/z Ratio Molecular Adduct Lipid Lipid Group Area Under the Curve 
620.3559 [M+H]+  PS 24:2 <LOD 
622.3715 [M+H]+  PS 24:1 <LOD 
624.3871 [M+H]+  PS 24:0 <LOD 
648.3872 [M+H]+  PS 26:2 <LOD 
650.4028 [M+H]+  PS 26:1 <LOD 
652.4184 [M+H]+  PS 26:0 650991 
676.4185 [M+H]+  PS 28:2 <LOD 
678.4341 [M+H]+  PS 28:1 <LOD 
680.4497 [M+H]+  PS 28:0 420877 
700.4186 [M+H]+  PS 30:4 <LOD 
702.4342 [M+H]+  PS 30:3 <LOD 
704.4498 [M+H]+  PS 30:2 <LOD 
706.4654 [M+H]+  PS 30:1 <LOD 
708.4810 [M+H]+  PS 30:0 661455 
724.4187 [M+H]+  PS 32:6 <LOD 
726.4343 [M+H]+  PS 32:5 <LOD 
728.4499 [M+H]+  PS 32:4 <LOD 
730.4655 [M+H]+  PS 32:3 <LOD 
732.4811 [M+H]+  PS 32:2 <LOD 
734.4967 [M+H]+  PS 32:1 <LOD 
736.5123 [M+H]+  PS 32:0 822370 
750.4344 [M+H]+  PS 34:7 <LOD 
752.4500 [M+H]+  PS 34:6 <LOD 
754.4656 [M+H]+  PS 34:5 <LOD 
756.4812 [M+H]+  PS 34:4 <LOD 
758.4968 [M+H]+  PS 34:3 1357458 
760.5124 [M+H]+  PS 34:2 <LOD 
762.5280 [M+H]+  PS 34:1 5189348 
764.5436 [M+H]+  PS 34:0 14408944 
778.4657 [M+H]+  PS 36:7 16740318 
780.4813 [M+H]+  PS 36:6 <LOD 
782.4969 [M+H]+  PS 36:5 <LOD 
784.5125 [M+H]+  PS 36:4 <LOD 
786.5281 [M+H]+  PS 36:3 <LOD 
788.5437 [M+H]+  PS 36:2 30759943 
790.5593 [M+H]+  PS 36:1 
77869885 
790.5593 [M+H]+ PS 18:0/18:1 65018065 
792.5749 [M+H]+  PS 36:0 <LOD 
806.4970 [M+H]+  PS 38:7 <LOD 
808.5126 [M+H]+  PS 38:6 <LOD 
810.5282 [M+H]+  PS 38:5 67450286 
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812.5438 [M+H]+  PS 38:4 
788138088 
812.5553 [M+H]+ PS 18:0/20:4 738414886 
814.5512 [M+H]+ PS 18:0/20:3 
PS 38:3 
28998762 
814.5594 [M+H]+  133024430 
816.5750 [M+H]+  PS 38:2 8024747 
818.5906 [M+H]+  PS 38:1 <LOD 
820.6062 [M+H]+  PS 38:0 <LOD 
830.4971 [M+H]+  PS 40:9 <LOD 
832.5127 [M+H]+  PS 40:8 <LOD 
834.5283 [M+H]+  PS 40:7 <LOD 
836.5407 [M+H]+ PS 18:0/22:6 
PS 40:6 
543442262 
836.5439 [M+H]+  564797028 
838.5588 [M+H]+ PS 18:0/22:5 
PS 40:5 
2344653 
838.5595 [M+H]+  148621873 
840.5751 [M+H]+  PS 40:4 67518015 
842.5907 [M+H]+  PS 40:3 <LOD 
844.6063 [M+H]+  PS 40:2 <LOD 
846.6219 [M+H]+  PS 40:1 <LOD 
848.6375 [M+H]+  PS 40:0 <LOD 
854.4972 [M+H]+  PS 42:11 <LOD 
856.5128 [M+H]+  PS 42:10 <LOD 
858.5284 [M+H]+  PS 42:9 <LOD 
860.5440 [M+H]+  PS 42:8 <LOD 
862.5596 [M+H]+  PS 42:7 11896503 
864.5752 [M+H]+  PS 42:6 <LOD 
866.5908 [M+H]+  PS 42:5 <LOD 
868.6064 [M+H]+  PS 42:4 <LOD 
870.6220 [M+H]+  PS 42:3 <LOD 
872.6376 [M+H]+  PS 42:2 <LOD 
874.6532 [M+H]+  PS 42:1 <LOD 
876.6688 [M+H]+  PS 42:0 <LOD 
880.5129 [M+H]+  PS 44:12 <LOD 
882.5285 [M+H]+  PS 44:11 <LOD 
884.5441 [M+H]+  PS 44:10 <LOD 
886.5597 [M+H]+  PS 44:9 <LOD 
888.5753 [M+H]+  PS 44:8 <LOD 
890.5909 [M+H]+  PS 44:7 <LOD 
892.6065 [M+H]+  PS 44:6 <LOD 
894.6221 [M+H]+  PS 44:5 <LOD 
896.6377 [M+H]+  PS 44:4 <LOD 
898.6533 [M+H]+  PS 44:3 <LOD 
900.6689 [M+H]+  PS 44:2 <LOD 
902.6845 [M+H]+  PS 44:1 <LOD 
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904.7001 [M+H]+  PS 44:0 <LOD 
918.6222 [M+H]+  PS 46:7 <LOD 
920.6378 [M+H]+  PS 46:6 16454351 
922.6534 [M+H]+  PS 46:5 6851312 
924.6690 [M+H]+  PS 46:4 <LOD 
926.6846 [M+H]+  PS 46:3 <LOD 
928.7002 [M+H]+  PS 46:2 <LOD 
930.7158 [M+H]+  PS 46:1 <LOD 
932.7314 [M+H]+  PS 46:0 <LOD 
956.7315 [M+H]+  PS 48:2 <LOD 
958.7471 [M+H]+  PS 48:1 <LOD 
960.7627 [M+H]+  PS 48:0 <LOD 
Mass-to-charge ratio (m/z); Phosphatidylserine (PS); Limit of detection (LOD). 
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Table B.5 Comprehensive Lipidomics of Sphingomyelin Species in Whole Blood 
m/z Ratio Molecular Adduct Lipid Lipid Group Area Under the Curve 
703.5755 [M+H]+  SM 34:1 2373406140 
725.5565 [M+Na]+  SM 34:1 376987084 
701.5595 [M+H]+  SM 34:2 194385143 
731.6069 [M+H]+  SM 36:1 247459601 
729.5918 [M+H]+  SM 36:2 717627881 
Mass-to-charge ratio (m/z); Sphingomyelin (SM). 
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Table B.6 Comprehensive Lipidomics of Triacylglycerol Species in Whole Blood 
m/z Ratio Molecular Adduct Lipid Lipid Group Area Under the Curve 
736.6450 [M+NH4]+  TAG 42:2 4186014 
738.6606 [M+NH4]+  TAG 42:1 17664651 
740.6763 [M+NH4]+  TAG 42:0 46929040 
762.6606 [M+NH4]+  TAG 44:3 3430004 
764.6763 [M+NH4]+  TAG 44:2 31060791 
766.6919 [M+NH4]+ TAG 12:0/14:1/18:0 
TAG 44:1 
 
766.6919 [M+NH4]+ TAG 14:0/14:0/16:1  
766.6919 [M+NH4]+ TAG 14:0/14:1/16:0  
766.6919 [M+NH4]+  92627876 
768.7076 [M+NH4]+ TAG 12:0/14:0/18:0 
TAG 44:0 
 
768.7076 [M+NH4]+ TAG 14:0/14:0/16:0  
768.7076 [M+NH4]+  146311692 
788.6763 [M+NH4]+  TAG 46:4 17338363 
790.6919 [M+NH4]+  TAG 46:3 23758702 
792.7076 [M+NH4]+ TAG 12:0/14:1/18:2 
TAG 46:2 
 
792.7076 [M+NH4]+ TAG 12:0/16:1/18:1  
792.7076 [M+NH4]+ TAG 14:0/16:1/16:1  
792.7076 [M+NH4]+ TAG 14:1/16:0/16:1  
792.7076 [M+NH4]+  132990657 
794.7232 [M+NH4]+ TAG 12:0/16:1/18:0 
TAG 46:1 
 
794.7232 [M+NH4]+ TAG 14:0/16:0/16:1 115479784 
794.7232 [M+NH4]+  275697544 
796.7467 [M+NH4]+ TAG 12:0/16:0/18:0 
TAG 46:0 
 
796.7467 [M+NH4]+ TAG 14:0/16:0/16:0  
796.7467 [M+NH4]+  349068286 
820.7436 [M+NH4]+ TAG 12:0/18:1/18:1 
TAG 48:2 
 
820.7436 [M+NH4]+ TAG 14:0/14:0/20:2  
820.7436 [M+NH4]+ TAG 14:0/16:0/18:2  
820.7436 [M+NH4]+ TAG 14:0/16:1/18:1 78240364 
820.7436 [M+NH4]+ TAG 14:1/16:0/18:1  
820.7436 [M+NH4]+ TAG 16:0/16:1/16:1  
820.7436 [M+NH4]+  363551003 
822.2553 [M+NH4]+ TAG 14:0/16:0/18:1 
TAG 48:1 
236386132 
822.2553 [M+NH4]+ TAG 16:0/16:0/16:1 127001336 
822.2553 [M+NH4]+  515410069 
824.7720 [M+NH4]+ TAG 12:0/16:0/20:0 
TAG 48:0 
 
824.7720 [M+NH4]+ TAG 12:0/18:0/18:0  
824.7720 [M+NH4]+ TAG 14:0/14:0/20:0  
824.7720 [M+NH4]+ TAG 14:0/16:0/18:0  
824.7720 [M+NH4]+ TAG 16:0/16:0/16:0 137360765 
824.7720 [M+NH4]+  413048012 
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848.7726 [M+NH4]+ TAG 14:0/18:1/18:1 
TAG 50:2 
 
848.7726 [M+NH4]+ TAG 16:0/16:0/18:2  
848.7726 [M+NH4]+ TAG 16:0/16:1/18:1  
848.7726 [M+NH4]+ TAG 16:1/16:0/18:0  
848.7726 [M+NH4]+ TAG 16:1/16:1/18:0  
848.7726 [M+NH4]+  1065347409 
850.7812 [M+NH4]+ TAG 14:0/16:0/20:1 
TAG 50:1 
 
850.7812 [M+NH4]+ TAG 16:0/16:0/18:1 398027936 
850.7812 [M+NH4]+  479183927 
852.8020 [M+NH4]+ TAG 14:0/18:0/20:0 
TAG 50:0 
 
852.8020 [M+NH4]+ TAG 16:0/16:0/18:0 503657742 
852.8020 [M+NH4]+  95674075 
870.7514 [M+NH4]+ TAG 16:0/18:2/18:3 
TAG 52:5 
 
870.7514 [M+NH4]+ TAG 16:1/18:1/18:3  
870.7514 [M+NH4]+ TAG 16:1/18:2/18:2 31525771 
870.7514 [M+NH4]+  302425017 
872.7674 [M+NH4]+ TAG 16:0/18:1/18:3 
TAG 52:4 
302184166 
872.7674 [M+NH4]+ TAG 16:0/18:2/18:2 600636961 
872.7674 [M+NH4]+ TAG 16:1/18:1/18:2 219315443 
872.7674 [M+NH4]+  1152786133 
874.7862 [M+NH4]+ TAG 16:0/18:1/18:2 
TAG 52:3 
2695509654 
874.7862 [M+NH4]+ TAG 16:1/18:1/18:1 272298752 
874.7862 [M+NH4]+  3093089589 
876.7986 [M+NH4]+ TAG 14:0/18:1/20:1 
TAG 52:2 
81396930 
876.7986 [M+NH4]+ TAG 16:0/18:1/18:1 2870568710 
876.7986 [M+NH4]+  2917011757 
878.8175 [M+NH4]+ TAG 14:0/18:1/20:0 
TAG 52:1 
15355180 
878.8175 [M+NH4]+ TAG 16:0/18:0/18:1 155316559 
878.8175 [M+NH4]+  192326441 
880.8328 [M+NH4]+ TAG 12:0/16:0/22:0 
TAG 52:0 
 
880.8328 [M+NH4]+ TAG 14:0/16:0/18:0  
880.8328 [M+NH4]+ TAG 16:0/18:0/18:0  
880.8328 [M+NH4]+  65781339 
894.7069 [M+NH4]+ TAG 14:0/18:2/22:5 
TAG 54:7 
 
894.7069 [M+NH4]+ TAG 16:0/18:2/20:5  
894.7069 [M+NH4]+ TAG 18:1/18:3/18:3 17147086 
894.7069 [M+NH4]+ TAG 18:2/18:2/18:3 24418374 
894.7069 [M+NH4]+  147616344 
896.7463 [M+NH4]+ TAG 14:0/18:1/22:5 
TAG 54:6 
 
896.7463 [M+NH4]+ TAG 16:0/18:1/20:5 67166181 
896.7463 [M+NH4]+ TAG 16:0/18:2/20:4  
896.7463 [M+NH4]+ TAG 18:1/18:2/18:3 156879087 
896.7463 [M+NH4]+ TAG 18:2/18:2/18:2 40560451 
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896.7463 [M+NH4]+  484025594 
898.7857 [M+NH4]+ TAG 16:0/16:0/22:5 
TAG 54:5 
 
898.7857 [M+NH4]+ TAG 16:0/18:1/20:4 134277520 
898.7857 [M+NH4]+ TAG 16:0/18:2/20:3  
898.7857 [M+NH4]+ TAG 18:1/18:1/18:3 205752055 
898.7857 [M+NH4]+ TAG 18:1/18:2/18:2 426220158 
898.7857 [M+NH4]+  909030524 
900.7988 [M+NH4]+ TAG 16:0/18:1/20:3 
TAG 54:4 
172551468 
900.7988 [M+NH4]+ TAG 18:1/18:1/18:2 1563813145 
900.7988 [M+NH4]+  2203244769 
902.8143 [M+NH4]+ TAG 16:0/18:1/20:2 
TAG 54:3 
 
902.8143 [M+NH4]+ TAG 18:0/18:1/18:2 258388211 
902.8143 [M+NH4]+ TAG 18:1/18:1/18:1 1338600628 
902.8143 [M+NH4]+  2265063290 
904.8312 [M+NH4]+ TAG 16:0/18:0/20:2 
TAG 54:2 
 
904.8312 [M+NH4]+ TAG 16:0/18:1/20:1  
904.8312 [M+NH4]+ TAG 18:0/18:1/18:1  
904.8312 [M+NH4]+  1225901399 
906.8534 [M+NH4]+ TAG 16:0/16:1/22:0 
TAG 54:1 
 
906.8534 [M+NH4]+ TAG 16:0/18:0/20:1  
906.8534 [M+NH4]+ TAG 16:0/18:1/20:0  
906.8534 [M+NH4]+ TAG 16:1/18:0/20:0  
906.8534 [M+NH4]+ TAG 18:0/18:0/18:1  
906.8534 [M+NH4]+  344023487 
908.8641 [M+NH4]+  TAG 54:0 140684022 
920.7164 [M+NH4]+ TAG 16:0/18:2/22:6 
TAG 56:8 
 
920.7164 [M+NH4]+ TAG 16:0/18:3/22:5  
920.7164 [M+NH4]+ TAG 16:0/20:4/20:4  
920.7164 [M+NH4]+ TAG 18:1/18:2/20:5  
920.7164 [M+NH4]+ TAG 18:1/18:3/20:4  
920.7164 [M+NH4]+ TAG 18:2/18:2/20:4  
920.7164 [M+NH4]+  164657162 
922.7840 [M+NH4]+ TAG 16:0/18:1/22:6 
TAG 56:7 
133460906 
922.7840 [M+NH4]+ TAG 16:0/18:2/22:5  
922.7840 [M+NH4]+ TAG 16:0/20:3/20:4  
922.7840 [M+NH4]+ TAG 18:1/18:1/20:5  
922.7840 [M+NH4]+  343796330 
924.8015 [M+NH4]+ TAG 16:0/18:1/22:5 
TAG 56:6 
 
924.8015 [M+NH4]+ TAG 16:0/20:2/20:4  
924.8015 [M+NH4]+  511904034 
926.7880 [M+NH4]+ TAG 16:0/18:0/22:5 
TAG 56:5 
 
926.7880 [M+NH4]+ TAG 18:0/18:1/20:4 97606884 
926.7880 [M+NH4]+ TAG 18:1/18:1/20:3  
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926.7880 [M+NH4]+  523769967 
928.8328 [M+NH4]+  TAG 56:4 532758186 
930.8484 [M+NH4]+ TAG 18:0/18:1/20:2 
TAG 56:3 
 
930.8484 [M+NH4]+ TAG 18:0/18:2/20:1  
930.8484 [M+NH4]+ TAG 18:1/18:1/20:1  
930.8484 [M+NH4]+ TAG 18:1/18:2/20:0  
930.8484 [M+NH4]+  701215457 
932.8641 [M+NH4]+  TAG 56:2 566747136 
934.8797 [M+NH4]+  TAG 56:1 210937697 
936.8954 [M+NH4]+  TAG 56:0 67035881 
940.7389 [M+NH4]+  TAG 58:12 2375764 
942.7545 [M+NH4]+  TAG 58:11 11774262 
944.7702 [M+NH4]+  TAG 58:10 39590063 
946.7858 [M+NH4]+  TAG 58:9 11508803 
948.8015 [M+NH4]+  TAG 58:8 179183287 
950.8171 [M+NH4]+  TAG 58:7 199447504 
952.8328 [M+NH4]+  TAG 58:6 190990099 
954.8484 [M+NH4]+  TAG 58:5 199355344 
956.8641 [M+NH4]+  TAG 58:4 325814221 
958.8797 [M+NH4]+  TAG 58:3 495400242 
960.8954 [M+NH4]+  TAG 58:2 371319258 
962.9110 [M+NH4]+  TAG 58:1 121311166 
964.9267 [M+NH4]+  TAG 58:0 25088472 
966.7545 [M+NH4]+  TAG 60:13 1165179 
968.7702 [M+NH4]+  TAG 60:12 7540026 
970.7858 [M+NH4]+  TAG 60:11 15166455 
972.8015 [M+NH4]+  TAG 60:10 22921778 
974.8171 [M+NH4]+  TAG 60:9 33170155 
976.8328 [M+NH4]+  TAG 60:8 55402051 
978.8484 [M+NH4]+  TAG 60:7 78243871 
980.8641 [M+NH4]+  TAG 60:6 96924672 
982.8797 [M+NH4]+  TAG 60:5 143914935 
984.8954 [M+NH4]+  TAG 60:4 178872795 
986.9110 [M+NH4]+  TAG 60:3 2252155662 
988.9267 [M+NH4]+  TAG 60:2 52650137 
990.9423 [M+NH4]+  TAG 60:1 27269602 
992.9580 [M+NH4]+  TAG 60:0 12942781 
996.8021 [M+NH4]+  TAG 62:12 2594211 
998.8177 [M+NH4]+  TAG 62:11 2171482 
1000.8333 [M+NH4]+  TAG 62:10 4770559 
1002.8489 [M+NH4]+  TAG 62:9 10449710 
1004.8645 [M+NH4]+  TAG 62:8 29642858 
1006.8801 [M+NH4]+  TAG 62:7 46555212 
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1008.8957 [M+NH4]+  TAG 62:6 45556733 
1010.9113 [M+NH4]+  TAG 62:5 9159493 
1012.9269 [M+NH4]+  TAG 62:4 12950277 
1014.9425 [M+NH4]+  TAG 62:3 6561222 
1016.9581 [M+NH4]+  TAG 62:2 7670887 
1018.9737 [M+NH4]+  TAG 62:1 7194299 
1020.9893 [M+NH4]+  TAG 62:0 5586068 
1024.8334 [M+NH4]+  TAG 64:12 <LOD 
1026.8490 [M+NH4]+  TAG 64:11 <LOD 
1028.8646 [M+NH4]+  TAG 64:10 2365080 
1030.8802 [M+NH4]+  TAG 64:9 6043299 
1032.8958 [M+NH4]+  TAG 64:8 11664077 
1034.9114 [M+NH4]+  TAG 64:7 7898949 
1036.9270 [M+NH4]+  TAG 64:6 2302619 
1038.9426 [M+NH4]+  TAG 64:5 <LOD 
1040.9582 [M+NH4]+  TAG 64:4 <LOD 
1042.9738 [M+NH4]+  TAG 64:3 1410872 
1044.9894 [M+NH4]+  TAG 64:2 3068418 
1047.0050 [M+NH4]+  TAG 64:1 1759337 
1049.0206 [M+NH4]+  TAG 64:0 857072 
1054.8803 [M+NH4]+  TAG 66:11 1321467 
1056.8959 [M+NH4]+  TAG 66:10 10553978 
1058.9115 [M+NH4]+  TAG 66:9 3662434 
1060.9271 [M+NH4]+  TAG 66:8 <LOD 
1062.9427 [M+NH4]+  TAG 66:7 <LOD 
1064.9583 [M+NH4]+  TAG 66:6 <LOD 
1068.9895 [M+NH4]+  TAG 66:4 <LOD 
1071.0051 [M+NH4]+  TAG 66:3 <LOD 
1073.0207 [M+NH4]+  TAG 66:2 <LOD 
1075.0363 [M+NH4]+  TAG 66:1 <LOD 
1077.0519 [M+NH4]+  TAG 66:0 <LOD 
Mass-to-charge ratio (m/z); Triacylglycerol (TAG); Limit of detection (LOD). 	
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Table C.1.  Fatty Acid Composition of Whole Blood – Relative Percent 
Whole Blood Total Lipids 
(% weight fatty acid in total fatty acids) 
Name P1 P2 P3 Average SD 
C 12:0 0.07 0.05 0.04 0.05 0.01 
C 14:0 0.68 0.83 0.68 0.73 0.09 
C 16:0 20.75 20.15 21.12 20.67 0.49 
C 17:0 0.31 0.29 0.28 0.29 0.02 
C 18:0 11.52 12.42 12.90 12.28 0.70 
C 20:0 0.30 0.36 0.36 0.34 0.04 
C 22:0 0.70 0.84 0.83 0.79 0.08 
C 23:0 0.18 0.20 0.18 0.19 0.01 
C 24:0 1.19 1.63 1.58 1.47 0.24 
SFAs 35.68 36.78 37.97 36.81 1.15 
C 12:1 0.01 0.01 0.01 0.01 <0.01 
C 14:1 0.03 0.03 0.01 0.02 0.01 
C 16:1 0.77 0.78 0.65 0.73 0.07 
C 18:1n-7 1.54 1.52 1.80 1.62 0.16 
C 18:1n-9 15.02 16.11 15.89 15.68 0.58 
C 20:1n-9 0.22 0.26 0.25 0.24 0.02 
C 22:1n-9 0.04 0.07 0.08 0.06 0.02 
C 24:1n-9 1.67 1.92 1.73 1.77 0.13 
MUFAs 19.29 20.71 20.42 20.14 0.75 
C 18:2n-6 24.24 18.44 19.83 20.83 3.03 
C 18:3n-6 0.06 0.32 0.11 0.16 0.14 
C 20:2n-6 0.25 0.20 0.22 0.22 0.02 
C 20:3n-6 0.98 1.22 1.12 1.10 0.12 
C 20:4n-6 7.77 10.11 10.13 9.33 1.35 
C 22:2n-6 0.08 0.09 0.09 0.09 0.01 
C 22:4n-6 0.66 1.00 1.46 1.04 0.40 
C 22:5n-6 0.24 0.35 0.43 0.34 0.10 
N-6 34.26 31.72 33.40 33.13 1.30 
C 18:3n-3 0.70 0.47 0.38 0.52 0.16 
C 20:3n-3 0.05 0.04 0.04 0.04 0.01 
C 20:5n-3 0.96 0.84 0.25 0.68 0.38 
C 22:5n-3 1.00 1.23 1.12 1.12 0.11 
C 22:6n-3 2.98 2.69 1.63 2.43 0.71 
N-3 5.69 5.27 3.42 4.79 1.21 
C 20:3n-9 0.07 0.12 0.08 0.09 0.03 
PUFAs 40.02 37.11 36.90 38.01 1.75 
HUFAs 14.70 17.60 16.25 16.18 1.45 
EPA+DHA 3.94 3.53 1.88 3.12 1.09 
Total 94.99 94.59 95.29 94.96 0.35 
Saturated fatty acids (SFAs); Mono-unsaturated fatty acids (MUFAs); Omega-6 fatty acids (N-6); Omega-3 fatty 
acids (N-3); Polyunsaturated fatty acids (PUFAs); Highly unsaturated fatty acids (HUFAs); Eicosapentaenoic acid 
(EPA); Docosahexaenoic acid (DHA).  
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Table D.1.  Fatty Acid Composition of Blood Cholesteryl Esters (n = 3) 
Concentration (µg fatty acid/100 µL whole blood) 
Fatty Acid Baseline Week 4 Week 8 Week 12 
C 14:0 0.21 ± 0.13 0.21 ± 0.08 0.29 ± 0.08 0.51 ± 0.21 
C 16:0 3.91 ± 0.73 4.65 ± 1.53 4.33 ± 0.96 5.70 ± 2.18 
C 18:0 2.73 ± 0.56 4.02 ± 1.81 2.81 ± 0.49 4.37 ± 2.01 
C 20:0 0.07 ± 0.01 0.13 ± 0.08 0.06 ± 0.01 0.25 ± 0.26 
C 22:0 0.03 ± <0.01a 0.04 ± 0.01ab 0.05 ± <0.01ab 0.07 ± 0.02b 
C 24:0 0.03 ± 0.01a 0.03 ± 0.01a 0.03 ± 0.01a 0.06 ± <0.01b 
SFAs 7.11 ± 1.02 9.25 ± 3.37 7.77 ± 1.38 11.29 ± 4.78 
C 12:1 <0.01 ± <0.01 0.01 ± <0.01 0.07 ± 0.07 0.08 ± 0.01 
C 14:1 0.01 ± 0.01 0.01 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 
C 16:1 0.60 ± 0.58 0.38 ± 0.30 0.53 ± 0.41 0.43 ± 0.19 
C 18:1n-7 0.24 ± 0.07 0.24 ± 0.04 0.27 ± 0.07 0.33 ± 0.08 
C 18:1n-9 4.89 ± 3.17 4.45 ± 0.45 5.32 ± 2.99 6.80 ± 2.63 
C 20:1n-9 0.03 ± 0.01a 0.05 ± 0.03ab 0.04 ± 0.02a 0.13 ± 0.05b 
C 22:1n-9 0.28 ± 0.02 0.25 ± 0.03 0.25 ± 0.05 0.23 ± 0.03 
C 24:1n-9 <0.01 ± <0.01a 0.01 ± 0.01a 0.01 ± <0.01a 0.03 ± 0.01b 
MUFAs 6.06 ± 3.87 5.41 ± 0.48 6.51 ± 3.45 8.05 ± 2.89 
C 18:2n-6 7.36 ± 1.80 7.39 ± 2.40 8.86 ± 3.52 9.96 ± 2.64 
C 18:3n-6 0.15 ± 0.15 0.18 ± 0.08 0.23 ± 0.11 0.20 ± 0.10 
C 20:2n-6 <0.01 ± <0.01 <0.01 ± <0.01 <0.01 ± <0.01 0.01 ± 0.01 
C 20:3n-6 0.14 ± 0.04 0.13 ± 0.06 0.15 ± 0.04 0.15 ± 0.04 
C 20:4n-6 1.06 ± 0.34 0.94 ± 0.46 1.12 ± 0.34 1.20 ± 0.32 
C 22:2n-6 0.02 ± <0.01a 0.03 ± 0.01ab 0.02 ± 0.01a 0.05 ± 0.02b 
C 22:4n-6 0.01 ± 0.01 <0.01 ± <0.01 <0.01 ± <0.01 0.01 ± 0.01 
C 22:5n-6 0.01 ± <0.01 0.01 ± 0.01 0.01 ± <0.01 0.01 ± <0.01 
N-6 8.75 ± 2.19 8.69 ± 3.00 10.40 ± 3.99 11.59 ± 3.07 
C 18:3n-3 0.08 ± 0.03 0.09 ± 0.03 0.11 ± 0.04 0.12 ± 0.02 
C 20:3n-3 <0.01 ± <0.01 <0.01 ± <0.01 0.01 ± 0.01 0.01 ± <0.01 
C 20:5n-3 0.08 ± 0.06a 0.14 ± 0.11a 0.29 ± 0.15ab 0.50 ± 0.14b 
C 22:5n-3 0.03 ± 0.03a 0.04 ± 0.04ab 0.05 ± 0.03ab 0.26 ± 0.16b 
C 22:6n-3 0.05 ± 0.01a 0.06 ± 0.04ab 0.09 ± 0.03ab 0.14 ± 0.03b 
N-3 0.24 ± 0.12a 0.33 ± 0.19a 0.55 ± 0.24a 1.03 ± 0.12b 
C 20:3n-9 0.01 ± <0.01 <0.01 ± <0.01 <0.01 ± <0.01 0.01 ± <0.01 
PUFAs 8.99 ± 2.27 9.02 ± 3.19 10.95 ± 4.23 12.62 ± 3.14 
HUFAs 1.39 ± 0.43 1.34 ± 0.68 1.74 ± 0.58 2.28 ± 0.40 
EPA+DHA 0.13 ± 0.07a 0.21 ± 0.14a 0.38 ± 0.18ab 0.64 ± 0.17b 
N6/N3 39.63 ± 11.16a 31.16 ± 13.64ab 19.33 ± 1.25ab 11.20 ± 2.58b 
%n-3 HUFA in 
total HUFA 11.69 ± 4.64
a 16.98 ± 4.99ab 24.59 ± 3.59b 40.30 ± 5.76c 
Total 22.17 ± 6.13 23.69 ± 4.95 25.23 ± 7.99 31.97 ± 10.70 
Saturated fatty acids (SFAs); Mono-unsaturated fatty acids (MUFAs); Omega-6 fatty acids (N-6); Omega-3 fatty 
acids (N-3); Polyunsaturated fatty acids (PUFAs); Highly unsaturated fatty acids (HUFAs); Eicosapentaenoic acid 
(EPA); Docosahexaenoic acid (DHA). Omega-6:Omega-3 ratio (N-6/N-3). Superscript differences represent 
significantly different values after one-way ANOVA + Tukey HSD (p < 0.05). 
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Table D.2.  Fatty Acid Composition of Blood Free Fatty Acids (n = 3) 
Concentration (µg fatty acid/100 µL whole blood) 
Fatty Acid Baseline Week 4 Week 8 Week 12 
C 14:0 0.69 ± 0.32 0.49 ± 0.30 0.30 ± 0.02 0.29 ± 0.14 
C 16:0 3.93 ± 0.68 4.48 ± 0.76 4.03 ± 0.36 3.93 ± 0.94 
C 18:0 3.67 ± 0.46 4.06 ± 0.36 3.89 ± 0.49 3.45 ± 0.45 
C 20:0 0.12 ± 0.03 0.14 ± 0.04 0.14 ± 0.05 0.10 ± 0.01 
C 22:0 0.03 ± 0.01 0.03 ± 0.02 0.03 ± 0.01 0.01 ± 0.01 
C 24:0 0.03 ± 0.02 0.03 ± 0.02 0.03 ± 0.01 0.01 ± 0.01 
SFAs 9.28 ± 1.84 9.56 ± 1.55 8.72 ± 0.84 8.00 ± 1.57 
C 12:1 <0.01 ± <0.01 0.01 ± 0.01 <0.01 ± <0.01 <0.01 ± <0.01 
C 14:1 0.01 ± <0.01 0.01 ± <0.01 0.02 ± 0.01 0.02 ± 0.01 
C 16:1 0.35 ± 0.43 0.17 ± 0.17 0.13 ± 0.06 0.15 ± 0.07 
C 18:1n-7 0.13 ± 0.07 0.15 ± 0.04 0.11 ± 0.01 0.17 ± 0.09 
C 18:1n-9 4.27 ± 2.87 3.51 ± 0.63 3.27 ± 0.28 3.22 ± 2.05 
C 20:1n-9 0.03 ± 0.01 0.04 ± <0.01 0.02 ± 0.01 0.02 ± 0.01 
C 22:1n-9 0.18 ± 0.03 0.19 ± 0.01 0.18 ± <0.01 0.22 ± 0.03 
C 24:1n-9 0.01 ± <0.01 0.01 ± 0.01 <0.01 ± <0.01 <0.01 ± <0.01 
MUFAs 4.98 ± 3.23 4.09 ± 0.85 3.73 ± 0.30 3.80 ± 2.23 
C 18:2n-6 0.75 ± 0.35 0.95 ± 0.22 1.03 ± 0.01 1.10 ± 0.50 
C 18:3n-6 0.16 ± 0.02 0.19 ± 0.05 0.16 ± <0.01 0.15 ± 0.01 
C 20:2n-6 0.01 ± <0.01 <0.01 ± <0.01 0.01 ± <0.01 0.01 ± <0.01 
C 20:3n-6 0.04 ± 0.02 0.03 ± 0.01 0.03 ± 0.02 0.02 ± 0.01 
C 20:4n-6 0.02 ± 0.01 0.01 ± 0.01 0.02 ± <0.01 0.03 ± 0.01 
C 22:2n-6 0.04 ± 0.01a 0.03 ± <0.01ab 0.02 ± <0.01b 0.02 ± <0.01b 
C 22:4n-6 0.01 ± <0.01 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 
C 22:5n-6 0.01 ± <0.01 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 
N-6 1.03 ± 0.35 1.24 ± 0.23 1.30 ± 0.01 1.35 ± 0.50 
C 18:3n-3 0.03 ± 0.01 0.05 ± 0.01 0.03 ± 0.01 0.04 ± 0.02 
C 20:3n-3 0.01 ± <0.01 <0.01 ± <0.01 0.01 ± 0.01 0.01 ± <0.01 
C 20:5n-3 0.02 ± <0.01a 0.01 ± 0.01ab <0.01 ± <0.01b <0.01 ± <0.01b 
C 22:5n-3 <0.01 ± <0.01ab <0.01 ± <0.01ab <0.01 ± <0.01ab 0.01 ± <0.01b 
C 22:6n-3 0.01 ± 0.01 0.01 ± 0.01 0.01 ± <0.01 <0.01 ± <0.01 
N-3 0.07 ± <0.01 0.08 ± <0.01 0.05 ± 0.01 0.06 ± 0.02 
C 20:3n-9 <0.01 ± <0.01 0.01 ± <0.01 <0.01 ± <0.01 0.01 ± 0.01 
PUFAs 1.10 ± 0.35 1.32 ± 0.24 1.35 ± 0.02 1.41 ± 0.50 
HUFAs 0.12 ± 0.02 0.09 ± 0.03 0.10 ± 0.02 0.10 ± 0.02 
EPA+DHA 0.03 ± 0.01a 0.02 ± 0.01ab 0.01 ± <0.01ab 0.01 ± 0.01b 
N6/N3 15.51 ± 4.85 15.94 ± 2.59 27.51 ± 7.63 24.42 ± 11.18 
%n-3 HUFA in 
total HUFA 33.47 ± 13.85 24.77 ± 9.93 17.53 ± 5.99 22.21 ± 4.56 
Total 15.37 ± 5.21 14.97 ± 2.23 13.81 ± 0.95 13.21 ± 4.22 
Saturated fatty acids (SFAs); Mono-unsaturated fatty acids (MUFAs); Omega-6 fatty acids (N-6); Omega-3 fatty 
acids (N-3); Polyunsaturated fatty acids (PUFAs); Highly unsaturated fatty acids (HUFAs); Eicosapentaenoic acid 
(EPA); Docosahexaenoic acid (DHA). Omega-6:Omega-3 ratio (N-6/N-3). Superscript differences represent 
significantly different values after one-way ANOVA + Tukey HSD (p < 0.05). 
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Table D.3.  Fatty Acid Composition of Blood Phosphatidylcholines (n = 3) 
Concentration (µg fatty acid/100 µL whole blood) 
Fatty Acid Baseline Week 4 Week 8 Week 12 
C 14:0 0.39 ± 0.12 0.17 ± 0.07 0.24 ± 0.04 0.32 ± 0.08 
C 16:0 18.75 ± 6.74 16.83 ± 6.51 20.28 ± 4.84 20.59 ± 3.27 
C 18:0 9.71 ± 3.35 10.16 ± 3.39 12.04 ± 4.38 11.28 ± 2.05 
C 20:0 0.16 ± 0.03 0.15 ± 0.03 0.18 ± 0.09 0.15 ± 0.01 
C 22:0 0.06 ± 0.02 0.05 ± 0.03 0.05 ± 0.01 0.06 ± 0.02 
C 24:0 0.11 ± 0.04 0.08 ± 0.05 0.07 ± 0.02 0.10 ± 0.04 
SFAs 29.62 ± 10.27 27.71 ± 10.08 33.17 ± 9.06 32.84 ± 5.39 
C 12:1 <0.01 ± <0.01 <0.01 ± <0.01 <0.01 ± <0.01 <0.01 ± <0.01 
C 14:1 0.01 ± <0.01 <0.01 ± <0.01 <0.01 ± <0.01 <0.01 ± <0.01 
C 16:1 0.39 ± 0.28 0.22 ± 0.13 0.37 ± 0.27 0.28 ± 0.07 
C 18:1n-7 1.01 ± 0.48 0.96 ± 0.25 1.05 ± 0.14 1.17 ± 0.10 
C 18:1n-9 9.66 ± 4.58 7.12 ± 2.94 7.73 ± 1.97 7.59 ± 1.40 
C 20:1n-9 0.12 ± 0.07 0.10 ± 0.04 0.10 ± 0.01 0.11 ± 0.01 
C 22:1n-9 0.27 ± 0.03 0.26 ± 0.01 0.26 ± 0.01 0.26 ± 0.01 
C 24:1n-9 0.07 ± 0.03 0.06 ± 0.02 0.05 ± 0.01 0.06 ± 0.02 
MUFAs 11.53 ± 5.30 8.73 ± 3.36 9.56 ± 2.34 9.48 ± 1.47 
C 18:2n-6 10.85 ± 5.53 9.99 ± 5.10 11.28 ± 3.40 12.57 ± 1.89 
C 18:3n-6 0.05 ± 0.03 0.04 ± 0.02 0.09 ± 0.10 0.03 ± 0.01 
C 20:2n-6 0.19 ± 0.10 0.15 ± 0.07 0.17 ± 0.04 0.17 ± 0.03 
C 20:3n-6 1.45 ± 0.93 1.14 ± 0.72 1.24 ± 0.56 1.10 ± 0.42 
C 20:4n-6 4.54 ± 2.60 3.98 ± 2.28 4.29 ± 1.00 4.41 ± 0.73 
C 22:2n-6 0.04 ± <0.01 0.03 ± 0.02 0.03 ± <0.01 0.03 ± 0.01 
C 22:4n-6 0.15 ± 0.07 0.12 ± 0.06 0.11 ± 0.03 0.09 ± 0.02 
C 22:5n-6 0.10 ± 0.06 0.07 ± 0.05 0.07 ± 0.03 0.06 ± 0.03 
N-6 17.38 ± 9.23 15.53 ± 8.29 17.29 ± 5.03 18.47 ± 3.05 
C 18:3n-3 0.13 ± 0.06 0.11 ± 0.04 0.11 ± 0.03 0.14 ± 0.04 
C 20:3n-3 0.01 ± <0.01 0.01 ± <0.01 0.01 ± <0.01 0.02 ± 0.01 
C 20:5n-3 0.23 ± 0.14a 0.39 ± 0.24a 0.70 ± 0.25ab 1.05 ± 0.20b 
C 22:5n-3 0.27 ± 0.13 0.32 ± 0.18 0.39 ± 0.13 0.43 ± 0.08 
C 22:6n-3 0.76 ± 0.45 0.97 ± 0.59 1.18 ± 0.36 1.58 ± 0.38 
N-3 1.40 ± 0.74 1.80 ± 1.05 2.39 ± 0.76 3.22 ± 0.65 
C 20:3n-9 0.07 ± 0.06 0.06 ± 0.05 0.07 ± 0.04 0.05 ± 0.02 
PUFAs 18.85 ± 10.01 17.39 ± 9.39 19.74 ± 5.81 21.74 ± 3.71 
HUFAs 7.58 ± 4.30 7.06 ± 4.16 8.07 ± 2.33 8.80 ± 1.75 
EPA+DHA 0.99 ± 0.56 1.36 ± 0.83 1.88 ± 0.60 2.63 ± 0.54 
N6/N3 12.65 ± 1.61a 8.89 ± 1.02b 7.30 ± 0.45bc 5.76 ± 0.25c 
%n-3 HUFA in 
total HUFA 16.88 ± 1.62
a 23.79 ± 0.66b 28.08 ± 1.15c 35.03 ± 0.43d 
Total <0.01 ± 25.37 53.82 ± 22.72 62.48 ± 16.35 64.06 ± 10.17 
Saturated fatty acids (SFAs); Mono-unsaturated fatty acids (MUFAs); Omega-6 fatty acids (N-6); Omega-3 fatty 
acids (N-3); Polyunsaturated fatty acids (PUFAs); Highly unsaturated fatty acids (HUFAs); Eicosapentaenoic acid 
(EPA); Docosahexaenoic acid (DHA). Omega-6:Omega-3 ratio (N-6/N-3). Superscript differences represent 
significantly different values after one-way ANOVA + Tukey HSD (p < 0.05). 
Appendix D. Fish Oil Supplementation-Fatty Acid Composition of Lipid Pools (Chapter 8) 	
 142 
Table D.4.  Fatty Acid Composition of Blood Phosphatidylserines (n = 3) 
Concentration (µg fatty acid/100 µL whole blood) 
Fatty Acid Baseline Week 4 Week 8 Week 12 
C 14:0 0.14 ± 0.02 0.14 ± 0.07 0.21 ± 0.12 0.05 ± 0.01 
C 16:0 2.55 ± 0.61 2.33 ± 0.57 2.50 ± 0.45 1.38 ± 0.04 
C 18:0 4.65 ± 0.89a 4.35 ± 0.59a 3.24 ± 0.60ab 2.42 ± 0.21b 
C 20:0 0.10 ± 0.02a 0.09 ± 0.01ab 0.10 ± <0.01ab 0.08 ± 0.01b 
C 22:0 0.03 ± 0.01ab 0.03 ± 0.01a 0.05 ± 0.01b 0.04 ± 0.01ab 
C 24:0 0.05 ± 0.01 0.05 ± 0.02 0.05 ± <0.01 0.05 ± 0.01 
SFAs 7.64 ± 1.46a 7.07 ± 1.30a 6.29 ± 0.56ab 4.09 ± 0.21b 
C 12:1 0.01 ± <0.01 <0.01 ± <0.01 <0.01 ± <0.01 <0.01 ± <0.01 
C 14:1 0.01 ± 0.01 0.01 ± <0.01 <0.01 ± <0.01 <0.01 ± <0.01 
C 16:1 0.05 ± 0.03 0.07 ± 0.08 0.08 ± 0.08 0.01 ± 0.01 
C 18:1n-7 0.11 ± 0.02 0.10 ± 0.07 0.11 ± 0.07 0.06 ± 0.05 
C 18:1n-9 2.15 ± 0.75 1.38 ± 0.98 2.71 ± 1.61 0.59 ± 0.29 
C 20:1n-9 0.03 ± 0.01 0.03 ± 0.03 0.03 ± 0.01 0.02 ± <0.01 
C 22:1n-9 0.23 ± 0.01 0.25 ± 0.03 0.22 ± <0.01 0.24 ± 0.01 
C 24:1n-9 0.03 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.04 ± 0.01 
MUFAs 2.62 ± 0.74 1.88 ± 1.20 3.19 ± 1.72 0.96 ± 0.35 
C 18:2n-6 0.36 ± 0.11 0.35 ± 0.27 0.46 ± 0.35 0.12 ± 0.04 
C 18:3n-6 0.01 ± <0.01 0.01 ± <0.01 0.01 ± <0.01 0.01 ± <0.01 
C 20:2n-6 0.02 ± <0.01 0.02 ± 0.01 0.02 ± 0.01 0.01 ± <0.01 
C 20:3n-6 0.07 ± 0.03a 0.07 ± 0.03ab 0.04 ± 0.01ab 0.02 ± <0.01b 
C 20:4n-6 0.70 ± 0.10 0.79 ± 0.44 0.38 ± 0.08 0.26 ± 0.02 
C 22:2n-6 0.03 ± 0.01 0.02 ± 0.01 0.02 ± <0.01 0.02 ± <0.01 
C 22:4n-6 0.15 ± 0.07 0.14 ± 0.05 0.08 ± 0.01 0.05 ± 0.01 
C 22:5n-6 0.04 ± 0.01 0.04 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 
N-6 1.37 ± 0.20 1.45 ± 0.77 1.02 ± 0.40 0.50 ± 0.06 
C 18:3n-3 0.04 ± 0.02 0.04 ± 0.02 0.04 ± 0.04 0.02 ± <0.01 
C 20:3n-3 0.01 ± <0.01 <0.01 ± <0.01 <0.01 ± <0.01 <0.01 ± <0.01 
C 20:5n-3 0.02 ± <0.01 0.03 ± 0.02 0.02 ± <0.01 0.03 ± <0.01 
C 22:5n-3 0.11 ± 0.02 0.12 ± 0.05 0.07 ± 0.01 0.06 ± 0.01 
C 22:6n-3 0.13 ± 0.01 0.19 ± 0.11 0.09 ± 0.02 0.09 ± 0.02 
N-3 0.29 ± 0.03 0.38 ± 0.19 0.22 ± 0.06 0.20 ± 0.02 
C 20:3n-9 0.01 ± 0.01 0.01 ± <0.01 0.01 ± 0.01 <0.01 ± <0.01 
PUFAs 1.80 ± 0.20 1.83 ± 0.97 1.25 ± 0.46 1.08 ± 0.73 
HUFAs 1.28 ± 0.20 1.39 ± 0.69 0.71 ± 0.12 0.80 ± 0.51 
EPA+DHA 0.15 ± 0.02 0.21 ± 0.13 0.11 ± 0.02 0.12 ± 0.02 
N6/N3 4.64 ± 0.64a 3.82 ± 0.11ab 4.68 ± 1.02a 2.53 ± 0.16b 
%n-3 HUFA in 
total HUFA 20.66 ± 3.69 24.31 ± 0.83 25.69 ± 1.31 26.94 ± 11.24 
Total 11.61 ± 0.43 10.78 ± 3.41 10.73 ± 2.18 7.54 ± 3.31 
Saturated fatty acids (SFAs); Mono-unsaturated fatty acids (MUFAs); Omega-6 fatty acids (N-6); Omega-3 fatty 
acids (N-3); Polyunsaturated fatty acids (PUFAs); Highly unsaturated fatty acids (HUFAs); Eicosapentaenoic acid 
(EPA); Docosahexaenoic acid (DHA). Omega-6:Omega-3 ratio (N-6/N-3). Superscript differences represent 
significantly different values after one-way ANOVA + Tukey HSD (p < 0.05). 
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Table D.5.  Fatty Acid Composition of Blood Phosphatidylinositols (n = 3) 
Concentration (µg fatty acid/100 µL whole blood) 
Fatty Acid Baseline Week 4 Week 8 Week 12 
C 14:0 0.25 ± 0.18 0.30 ± 0.31 0.10 ± 0.03 0.20 ± 0.11 
C 16:0 3.35 ± 0.56 5.65 ± 2.72 2.61 ± 0.44 3.45 ± 0.49 
C 18:0 4.31 ± 1.22 7.17 ± 4.47 5.15 ± 0.35 6.36 ± 0.30 
C 20:0 0.12 ± 0.03 0.18 ± 0.09 0.10 ± <0.01 0.13 ± 0.03 
C 22:0 0.04 ± 0.02 0.05 ± 0.03 0.03 ± 0.01 0.05 ± 0.01 
C 24:0 0.05 ± 0.02 0.05 ± 0.03 0.03 ± 0.01 0.05 ± 0.03 
SFAs 8.33 ± 1.40 13.68 ± 7.08 8.18 ± 0.78 10.49 ± 0.70 
C 12:1 <0.01 ± <0.01 <0.01 ± <0.01 <0.01 ± <0.01 0.01 ± <0.01 
C 14:1 0.01 ± 0.02 0.02 ± 0.04 <0.01 ± <0.01 0.01 ± 0.01 
C 16:1 0.13 ± 0.06 0.11 ± 0.09 0.05 ± 0.01 0.08 ± 0.02 
C 18:1n-7 0.13 ± 0.02a 0.23 ± 0.06b 0.12 ± 0.02a 0.18 ± <0.01ab 
C 18:1n-9 2.89 ± 1.60 4.18 ± 3.28 1.42 ± 0.33 3.08 ± 1.53 
C 20:1n-9 0.03 ± 0.01 0.05 ± 0.02 0.02 ± <0.01 0.04 ± <0.01 
C 22:1n-9 0.22 ± 0.01 0.24 ± 0.04 0.22 ± <0.01 0.22 ± 0.01 
C 24:1n-9 0.03 ± 0.01 0.03 ± 0.02 0.04 ± 0.02 0.05 ± 0.02 
MUFAs 3.45 ± 1.66 4.87 ± 3.51 1.87 ± 0.35 3.67 ± 1.56 
C 18:2n-6 0.69 ± 0.14 0.95 ± 0.34 0.46 ± 0.11 0.75 ± 0.19 
C 18:3n-6 0.01 ± <0.01 0.02 ± 0.02 0.01 ± <0.01 0.01 ± <0.01 
C 20:2n-6 0.02 ± <0.01 0.02 ± 0.02 0.02 ± <0.01 0.03 ± 0.02 
C 20:3n-6 0.10 ± 0.04 0.14 ± 0.04 0.13 ± 0.03 0.19 ± 0.07 
C 20:4n-6 1.08 ± 0.55 1.90 ± 0.53 1.33 ± 0.09 2.05 ± 0.26 
C 22:2n-6 0.01 ± <0.01 0.03 ± 0.01 0.02 ± <0.01 0.02 ± <0.01 
C 22:4n-6 0.17 ± 0.07a 0.38 ± 0.07b 0.22 ± 0.07ab 0.30 ± 0.08ab 
C 22:5n-6 0.05 ± 0.03 0.04 ± 0.01 0.05 ± 0.01 0.07 ± 0.02 
N-6 2.12 ± 0.63 3.47 ± 0.81 2.24 ± 0.10 3.42 ± 0.31 
C 18:3n-3 0.04 ± 0.01 0.05 ± 0.03 0.02 ± 0.01 0.04 ± 0.02 
C 20:3n-3 <0.01 ± <0.01 <0.01 ± <0.01 0.01 ± 0.01 0.01 ± <0.01 
C 20:5n-3 0.02 ± 0.01a 0.07 ± 0.02bc 0.03 ± <0.01ab 0.10 ± 0.02c 
C 22:5n-3 0.11 ± 0.04a 0.25 ± 0.03bc 0.20 ± 0.05ab 0.36 ± 0.08c 
C 22:6n-3 0.16 ± 0.08a 0.31 ± 0.09ab 0.26 ± 0.01a 0.53 ± 0.13b 
N-3 0.33 ± 0.12a 0.69 ± 0.16bc 0.52 ± 0.05ab 1.04 ± 0.18c 
C 20:3n-9 0.01 ± <0.01 0.01 ± 0.01 0.01 ± <0.01 0.01 ± 0.01 
PUFAs 2.47 ± 0.75 3.71 ± 1.76 2.77 ± 0.06 3.66 ± 1.74 
HUFAs 1.69 ± 0.79 2.62 ± 1.49 2.24 ± 0.07 2.80 ± 1.66 
EPA+DHA 0.18 ± 0.08a 0.38 ± 0.11ab 0.30 ± 0.02a 0.63 ± 0.16b 
N6/N3 6.51 ± 0.54a 5.04 ± 0.03b 4.36 ± 0.61bc 3.35 ± 0.48c 
%n-3 HUFA in 
total HUFA 17.39 ± 1.78 30.29 ± 16.43 22.20 ± 1.96 51.67 ± 42.97 
Total 14.25 ± 2.79 22.37 ± 9.64 12.82 ± 1.06 17.01 ± 5.01 
Saturated fatty acids (SFAs); Mono-unsaturated fatty acids (MUFAs); Omega-6 fatty acids (N-6); Omega-3 fatty 
acids (N-3); Polyunsaturated fatty acids (PUFAs); Highly unsaturated fatty acids (HUFAs); Eicosapentaenoic acid 
(EPA); Docosahexaenoic acid (DHA). Omega-6:Omega-3 ratio (N-6/N-3). Superscript differences represent 
significantly different values after one-way ANOVA + Tukey HSD (p < 0.05). 
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Table D.6.  Fatty Acid Composition of Blood Sphingomyelins (n = 3) 
Concentration (µg fatty acid/100 µL whole blood) 
Fatty Acid Baseline Week 4 Week 8 Week 12 
C 14:0 0.51 ± 0.40 0.50 ± 0.57 0.12 ± 0.01 0.14 ± 0.08 
C 16:0 6.34 ± 2.37 5.73 ± 1.04 5.09 ± 1.07 5.23 ± 0.70 
C 18:0 5.05 ± 0.33 4.51 ± 0.87 3.52 ± 0.68 4.06 ± 1.50 
C 20:0 0.32 ± 0.10 0.32 ± 0.03 0.34 ± 0.15 0.31 ± 0.02 
C 22:0 0.74 ± 0.29 0.69 ± 0.18 0.98 ± 0.32 0.84 ± 0.12 
C 24:0 1.14 ± 0.58 1.06 ± 0.38 1.31 ± 0.13 1.26 ± 0.26 
SFAs 14.56 ± 4.29 13.18 ± 1.46 11.67 ± 2.03 12.13 ± 1.76 
C 12:1 <0.01 ± <0.01 <0.01 ± <0.01 <0.01 ± <0.01 <0.01 ± <0.01 
C 14:1 0.02 ± 0.02 0.02 ± 0.02 <0.01 ± <0.01 0.01 ± <0.01 
C 16:1 0.07 ± 0.02 0.09 ± 0.10 0.04 ± 0.01 0.05 ± 0.03 
C 18:1n-7 0.11 ± 0.03 0.15 ± 0.03 0.07 ± 0.01 0.14 ± 0.09 
C 18:1n-9 3.33 ± 2.11 5.20 ± 5.58 1.24 ± 0.50 1.78 ± 0.96 
C 20:1n-9 0.02 ± 0.01 0.04 ± 0.02 0.03 ± 0.01 0.03 ± 0.01 
C 22:1n-9 0.27 ± 0.02 0.29 ± 0.02 0.26 ± 0.02 0.26 ± <0.01 
C 24:1n-9 1.33 ± 0.45 1.26 ± 0.19 1.58 ± 0.13 1.63 ± 0.32 
MUFAs 5.15 ± 2.51 7.05 ± 5.71 3.22 ± 0.42 3.90 ± 1.04 
C 18:2n-6 0.46 ± 0.20 0.63 ± 0.38 0.40 ± 0.11 0.49 ± 0.14 
C 18:3n-6 <0.01 ± <0.01 0.01 ± <0.01 <0.01 ± <0.01 <0.01 ± <0.01 
C 20:2n-6 0.02 ± <0.01 0.02 ± 0.01 0.02 ± <0.01 0.02 ± 0.01 
C 20:3n-6 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 
C 20:4n-6 0.09 ± 0.05 0.10 ± 0.05 0.12 ± 0.02 0.12 ± <0.01 
C 22:2n-6 0.02 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 
C 22:4n-6 0.01 ± <0.01 0.01 ± <0.01 0.01 ± <0.01 0.01 ± <0.01 
C 22:5n-6 0.01 ± <0.01 0.02 ± 0.02 0.01 ± <0.01 0.01 ± <0.01 
N-6 0.64 ± 0.28 0.83 ± 0.42 0.60 ± 0.12 0.70 ± 0.15 
C 18:3n-3 0.03 ± 0.02 0.03 ± 0.01 0.02 ± 0.01 0.02 ± <0.01 
C 20:3n-3 <0.01 ± <0.01 <0.01 ± <0.01 0.01 ± <0.01 <0.01 ± <0.01 
C 20:5n-3 0.01 ± <0.01a 0.02 ± <0.01b 0.02 ± <0.01b 0.03 ± <0.01c 
C 22:5n-3 0.01 ± <0.01 0.01 ± <0.01 0.01 ± <0.01 0.01 ± <0.01 
C 22:6n-3 0.02 ± 0.01 0.04 ± 0.02 0.04 ± <0.01 0.04 ± 0.01 
N-3 0.07 ± 0.03 0.10 ± 0.03 0.10 ± 0.01 0.11 ± 0.01 
C 20:3n-9 0.01 ± <0.01 0.01 ± <0.01 <0.01 ± <0.01 0.01 ± 0.01 
PUFAs 0.71 ± 0.28 0.93 ± 0.45 0.70 ± 0.12 0.82 ± 0.15 
HUFAs 0.18 ± 0.08 0.22 ± 0.07 0.23 ± 0.04 0.26 ± 0.01 
EPA+DHA 0.03 ± 0.02a 0.06 ± 0.02ab 0.06 ± <0.01ab 0.07 ± 0.01b 
N6/N3 10.03 ± 4.98 7.76 ± 1.94 6.07 ± 1.51 6.70 ± 1.81 
%n-3 HUFA in 
total HUFA 24.89 ± 6.22 34.04 ± 7.11 34.42 ± 6.48 34.12 ± 2.39 
Total 20.43 ± 7.06 21.16 ± 7.57 15.59 ± 2.00 16.84 ± 1.31 
Saturated fatty acids (SFAs); Mono-unsaturated fatty acids (MUFAs); Omega-6 fatty acids (N-6); Omega-3 fatty 
acids (N-3); Polyunsaturated fatty acids (PUFAs); Highly unsaturated fatty acids (HUFAs); Eicosapentaenoic acid 
(EPA); Docosahexaenoic acid (DHA). Omega-6:Omega-3 ratio (N-6/N-3). Superscript differences represent 
significantly different values after one-way ANOVA + Tukey HSD (p < 0.05). 
Appendix D. Fish Oil Supplementation-Fatty Acid Composition of Lipid Pools (Chapter 8) 	
 145 
Table D.7.  Fatty Acid Composition of Blood Triacylglycerols (n = 3) 
Concentration (µg fatty acid/100 µL whole blood) 
Fatty Acid Baseline Week 4 Week 8 Week 12 
C 14:0 0.47 ± 0.47 0.29 ± 0.10 0.36 ± 0.06 0.29 ± 0.03 
C 16:0 5.50 ± 2.64 4.58 ± 1.72 5.73 ± 1.56 4.23 ± 0.84 
C 18:0 3.14 ± 1.25 2.98 ± 1.01 3.37 ± 0.40 2.76 ± 0.44 
C 20:0 0.07 ± 0.03 0.07 ± 0.01 0.07 ± 0.01 0.06 ± 0.02 
C 22:0 0.03 ± 0.01 0.03 ± 0.02 0.03 ± 0.01 0.03 ± <0.01 
C 24:0 0.02 ± <0.01 0.03 ± 0.01 0.03 ± <0.01 0.02 ± 0.01 
SFAs 9.39 ± 2.78 8.18 ± 2.85 9.83 ± 1.53 7.53 ± 1.32 
C 12:1 <0.01 ± <0.01 <0.01 ± <0.01 0.01 ± <0.01 0.01 ± <0.01 
C 14:1 0.03 ± 0.02 0.03 ± 0.02 0.03 ± 0.02 0.02 ± <0.01 
C 16:1 0.64 ± 0.72 0.39 ± 0.28 0.50 ± 0.37 0.35 ± 0.15 
C 18:1n-7 0.36 ± 0.31 0.30 ± 0.08 0.37 ± 0.15 0.28 ± 0.04 
C 18:1n-9 5.00 ± 2.81 7.46 ± 4.24 6.41 ± 1.51 4.69 ± 1.94 
C 20:1n-9 0.06 ± 0.02 0.07 ± 0.04 0.08 ± 0.01 0.05 ± 0.02 
C 22:1n-9 0.27 ± 0.02a 0.23 ± 0.01ab 0.24 ± <0.01ab 0.22 ± 0.02b 
C 24:1n-9 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 
MUFAs 6.37 ± 3.87 8.50 ± 4.19 7.64 ± 1.95 5.63 ± 1.99 
C 18:2n-6 1.37 ± 0.46 1.88 ± 0.68 2.17 ± 0.58 1.81 ± 0.57 
C 18:3n-6 0.07 ± 0.02 0.05 ± 0.03 0.09 ± 0.03 0.07 ± 0.02 
C 20:2n-6 0.01 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.01 ± <0.01 
C 20:3n-6 0.07 ± 0.02 0.05 ± 0.01 0.08 ± 0.02 0.06 ± 0.01 
C 20:4n-6 0.10 ± 0.05 0.10 ± 0.02 0.14 ± 0.02 0.10 ± 0.02 
C 22:2n-6 0.02 ± <0.01 0.03 ± 0.02 0.03 ± 0.01 0.02 ± 0.01 
C 22:4n-6 0.02 ± 0.01 0.02 ± <0.01 0.02 ± 0.01 0.01 ± <0.01 
C 22:5n-6 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.02 0.01 ± <0.01 
N-6 1.68 ± 0.59 2.17 ± 0.68 2.57 ± 0.62 2.09 ± 0.63 
C 18:3n-3 0.10 ± 0.05 0.11 ± 0.04 0.13 ± 0.02 0.14 ± 0.03 
C 20:3n-3 0.01 ± <0.01 0.01 ± 0.01 0.01 ± <0.01 0.01 ± <0.01 
C 20:5n-3 0.02 ± 0.01a 0.06 ± 0.01ab 0.10 ± 0.02b 0.07 ± 0.02b 
C 22:5n-3 0.03 ± 0.02 0.13 ± 0.17 0.14 ± 0.07 0.10 ± 0.08 
C 22:6n-3 0.03 ± 0.02a 0.04 ± 0.01ab 0.07 ± 0.02ab 0.08 ± 0.02b 
N-3 0.18 ± 0.10 0.34 ± 0.21 0.46 ± 0.03 0.40 ± 0.10 
C 20:3n-9 0.02 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 <0.01 ± <0.01 
PUFAs 1.86 ± 0.69 2.51 ± 0.86 3.03 ± 0.63 2.49 ± 0.73 
HUFAs 0.30 ± 0.15a 0.43 ± 0.16a 0.60 ± 0.03b 0.45 ± 0.12ab 
EPA+DHA 0.04 ± 0.04a 0.10 ± 0.02ab 0.17 ± 0.03c 0.16 ± 0.02bc 
N6/N3 9.92 ± 2.50 7.15 ± 2.52 5.57 ± 1.19 5.19 ± 0.28 
%n-3 HUFA in 
total HUFA 24.84 ± 4.57
a 49.06 ± 21.60ab 54.89 ± 9.53ab 57.43 ± 5.69b 
Total 17.63 ± 7.04 24.22 ± 13.13 20.50 ± 3.50 15.65 ± 3.68 
Saturated fatty acids (SFAs); Mono-unsaturated fatty acids (MUFAs); Omega-6 fatty acids (N-6); Omega-3 fatty 
acids (N-3); Polyunsaturated fatty acids (PUFAs); Highly unsaturated fatty acids (HUFAs); Eicosapentaenoic acid 
(EPA); Docosahexaenoic acid (DHA). Omega-6:Omega-3 ratio (N-6/N-3). Superscript differences represent 
significantly different values after one-way ANOVA + Tukey HSD (p < 0.05). 
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Table D.8.  Fatty Acid Composition of Whole Blood (n = 20)* 
Concentration 
(µg fatty acid per 100 µL whole blood) 
Fatty Acid Baseline Week 4 Week 8 
C 12:0 0.14 ± 0.07a 0.20 ± 0.09ab 0.21 ± 0.08b 
C 14:0 1.20 ± 0.50 1.65 ± 0.70 1.61 ± 0.55 
C 16:0 33.02 ± 7.90a 43.43 ± 10.84b 43.60 ± 8.79b 
C 18:0 18.61 ± 3.36a 23.12 ± 5.02b 23.72 ± 4.87b 
C 20:0 0.44 ± 0.09a 0.59 ± 0.12ab 0.75 ± 0.48b 
C 22:0 1.21 ± 0.29a 1.67 ± 0.34b 1.82 ± 0.22b 
C 24:0 2.36 ± 0.56a 3.25 ± 0.712b 3.65 ± 0.53b 
SFAs 61.12 ± 12.53a 79.06 ± 17.23b 82.12 ± 15.31b 
C 12:1 <0.01 ± <0.01a <0.01 ± <0.01a 0.01 ± <0.01b 
C 14:1 0.05 ± 0.05 0.08 ± 0.06 0.08 ± 0.06 
C 16:1 1.53 ± 0.98 2.05 ± 0.98 2.12 ± 1.03 
C 18:1n-7 2.36 ± 0.56a 2.99 ± 0.59b 3.06 ± 0.48b 
C 18:1n-9 22.68 ± 5.85a 31.27 ± 7.14b 31.31 ± 5.57b 
C 20:1n-9 0.37 ± 0.08a 0.44 ± 0.09b 0.45 ± 0.06b 
C 22:1n-9 0.47 ± 0.03a 0.32 ± 0.05b 0.49 ± 0.08a 
C 24:1n-9 2.67 ± 0.61a 3.63 ± 0.62b 4.16 ± 0.46c 
MUFAs 30.83 ± 8.531 41.36 ± 8.95b 42.37 ± 7.07b 
C 18:2n-6 28.41 ± 5.33a 41.22 ± 7.40b 40.16 ± 7.11b 
C 18:3n-6 0.29 ± 0.14a 0.49 ± 0.29b 0.49 ± 0.23b 
C 20:2n-6 0.40 ± 0.12a 0.59 ± 0.18b 0.59 ± 0.12b 
C 20:3n-6 2.76 ± 1.13 3.28 ± 1.38 3.35 ± 1.02 
C 20:4n-6 17.16 ± 4.14a 20.51 ± 4.81b 20.92 ± 3.09b 
C 22:2n-6 0.09 ± 0.02 0.10 ± 0.03 0.11 ± 0.04 
C 22:4n-6 2.53 ± 0.80 2.91 ± 0.84 2.86 ± 0.35 
C 22:5n-6 0.58 ± 0.16 0.68 ± 0.15 0.68 ± 0.13 
N-6 52.22 ± 10.16a 69.78 ± 13.06b 69.16 ± 10.31b 
C 18:3n-3 0.67 ± 0.28a 0.94 ± 0.35b 0.97 ± 0.29b 
C 20:3n-3 0.05 ± 0.02 0.07 ± 0.03 0.06 ± 0.03 
C 20:5n-3 0.80 ± 0.36a 1.64 ± 0.43b 2.68 ± 0.58c 
C 22:5n-3 2.17 ± 0.59a 2.82 ± 0.90b 3.26 ± 0.51b 
C 22:6n-3 3.95 ± 0.75a 5.39 ± 1.05b 6.88 ± 1.26c 
N-3 7.65 ± 1.50a 10.85 ± 2.28b 13.85 ± 2.04c 
PUFAs 59.87 ± 11.36a 80.63 ± 15.08b 83.01 ± 12.04b 
HUFAs 30.02 ± 6.73a 37.28 ± 8.22b 40.70 ± 4.99b 
EPA+DHA 4.76 ± 0.97a 7.03 ± 1.34b 9.57 ± 1.67c 
N-6/N-3 6.89 ± 0.84a 6.51 ± 0.73a 5.01 ± 0.43b 
%n-3 HUFA in 
total HUFA 23.48 ± 2.51
a 26.73 ± 2.10b 31.65 ± 2.52c 
Total 151.82 ± 31.14a 201.04 ± 39.79b 207.51 ± 31.37b 
Saturated fatty acids (SFAs); Mono-unsaturated fatty acids (MUFAs); Omega-6 fatty acids (N-6); Omega-3 fatty 
acids (N-3); Polyunsaturated fatty acids (PUFAs); Highly unsaturated fatty acids (HUFAs); Eicosapentaenoic acid 
(EPA); Docosahexaenoic acid (DHA). Omega-6:Omega-3 ratio (N-6/N-3). Superscript differences represent 
significantly different values after one-way ANOVA + Tukey HSD (p < 0.05). 
 
* supporting data from Dr. Ashley Patterson’s Doctoral Thesis (Reference: Patterson, 2012) 
 
 
  
Appendix D. Fish Oil Supplementation-Fatty Acid Composition of Lipid Pools (Chapter 8) 	
 147 
Table D.9. Fatty Acid Composition of Whole Blood (n = 5)* 
Concentration 
(µg fatty acid per 100 µL whole blood) 
Fatty Acid Baseline Week 4 Week 8 Week 12 
C 12:0 0.14 ± 0.06ab 0.22 ± 0.14b 0.19 ± 0.08ab 0.07 ± 0.02a 
C 14:0 1.42 ± 0.74 1.70 ± 0.90 1.63 ± 0.54 1.11 ± 0.26 
C 16:0 37.60 ± 9.34 44.77 ± 8.42 45.07 ± 14.16 41.84 ± 7.05 
C 18:0 20.92 ± 4.91 24.02 ± 3.62 25.39 ± 9.20 22.97 ± 3.82 
C 20:0 0.50 ± 0.13 0.58 ± 0.08 0.98 ± 0.97 0.56 ± 0.12 
C 22:0 1.42 ± 0.40 1.55 ± 0.35 1.83 ± 0.28 1.60 ± 0.24 
C 24:0 2.58 ± 0.45 2.90 ± 0.69 3.46 ± 0.83 2.86 ± 0.51 
SFAs 69.20 ± 14.94 81.53 ± 14.47 86.11 ± 27.06 76.21 ± 11.77 
C 12:1 <0.01 ± <0.01a <0.01 ± <0.01a 0.01 ± <0.01ab 0.01 ± <0.01b 
C 14:1 0.07 ± 0.09 0.10 ± 0.10 0.08 ± 0.05 0.06 ± 0.02 
C 16:1 1.89 ± 1.72 2.21 ± 0.98 2.20 ± 1.63 1.89 ± 0.50 
C 18:1n-7 2.74 ± 0.57 3.19 ± 0.25 2.99 ± 0.63 3.33 ± 0.26 
C 18:1n-9 26.01 ± 6.68 33.62 ± 5.75 30.65 ± 8.30 34.90 ± 9.55 
C 20:1n-9 0.39 ± 0.09 0.44 ± 0.07 0.40 ± 0.03 0.42 ± 0.07 
C 22:1n-9 0.47 ± 0.04a 0.30 ± 0.04b 0.51 ± 0.05a 0.53 ± 0.04a 
C 24:1n-9 3.11 ± 0.64a 3.33 ± 0.40ab 4.06 ± 0.48b 3.30 ± 0.37ab 
MUFAs 36.23 ± 11.46 43.85 ± 7.06 41.66 ± 10.68 44.81 ± 9.84 
C 18:2n-6 29.90 ± 5.38a 42.38 ± 7.69ab 38.94 ± 9.94ab 51.42 ± 15.21b 
C 18:3n-6 0.37 ± 0.21 0.71 ± 0.47 0.65 ± 0.28 0.53 ± 0.18 
C 20:2n-6 0.42 ± 0.12 0.46 ± 0.07 0.57 ± 0.11 0.45 ± 0.05 
C 20:3n-6 2.99 ± 1.30 3.21 ± 0.93 3.20 ± 1.07 2.67 ± 0.57 
C 20:4n-6 21.83 ± 3.32 23.43 ± 3.38 21.88 ± 3.90 22.76 ± 4.31 
C 22:2n-6 0.08 ± 0.02 0.12 ± 0.04 0.12 ± 0.07 0.11 ± 0.02 
C 22:4n-6 3.31 ± 1.03 3.46 ± 1.00 3.07 ± 0.29 2.56 ± 0.58 
C 22:5n-6 0.68 ± 0.14 0.71 ± 0.09 0.68 ± 0.18 0.51 ± 0.08 
N-6 59.59 ± 10.46 74.47 ± 12.49 69.11 ± 15.07 81.02 ± 19.33 
C 18:3n-3 0.64 ± 0.14a 0.85 ± 0.21ab 0.85 ± 0.18ab 1.04 ± 0.14b 
C 20:3n-3 0.06 ± 0.03 0.06 ± 0.01 0.04 ± 0.02 0.06 ± 0.01 
C 20:5n-3 0.89 ± 0.31a 1.74 ± 0.48ab 2.71 ± 0.87bc 4.11 ± 1.21c 
C 22:5n-3 2.52 ± 0.51a 3.04 ± 0.44ab 3.21 ± 0.30ab 3.40 ± 0.34b 
C 22:6n-3 4.25 ± 0.90a 5.37 ± 0.73ab 6.16 ± 1.52ab 7.33 ± 1.11b 
N-3 8.36 ± 1.67a 11.05 ± 1.53ab 12.98 ± 2.68bc 15.93 ± 2.41c 
PUFAs 67.95 ± 11.86 85.52 ± 13.82 82.09 ± 17.67 96.95 ± 21.24 
HUFAs 36.53 ± 6.24 41.01 ± 5.85 40.96 ± 7.46 43.41 ± 6.91 
EPA+DHA 5.14 ± 1.18a 7.10 ± 1.20ab 8.87 ± 2.30bc 11.44 ± 2.24c 
N-6/N-3 7.18 ± 0.72a 6.74 ± 0.63a 5.32 ± 0.29b 5.07 ± 0.84b 
%n-3 HUFA in 
total HUFA 21.11 ± 1.79
a 24.91 ± 1.55b 29.47 ± 1.19c 34.35 ± 1.63d 
Total 173.38 ± 35.96 210.90 ± 32.91 209.85 ± 52.47 217.96 ± 42.15 
Saturated fatty acids (SFAs); Mono-unsaturated fatty acids (MUFAs); Omega-6 fatty acids (N-6); Omega-3 fatty 
acids (N-3); Polyunsaturated fatty acids (PUFAs); Highly unsaturated fatty acids (HUFAs); Eicosapentaenoic acid 
(EPA); Docosahexaenoic acid (DHA). Omega-6:Omega-3 ratio (N-6/N-3). Superscript differences represent 
significantly different values after one-way ANOVA + Tukey HSD (p < 0.05). 
 
* supporting data from Dr. Ashley Patterson’s Doctoral Thesis (Reference: Patterson, 2012) 
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Table D.10.  Fatty Acid Composition of Erythrocytes (n = 20)* 
Concentration 
(µg fatty acid per 200 mg erythrocytes) 
Fatty Acid Baseline Week 4 Week 8 
C 12:0 0.37 ± 0.05a 0.17 ± 0.13b 0.23 ± 0.13b 
C 14:0 2.38 ± 0.61ab 2.84 ± 0.79a 1.98 ± 0.48b 
C 16:0 86.60 ± 7.29 79.99 ± 11.19 80.54 ± 15.37 
C 18:0 52.56 ± 4.89 50.45 ± 7.44 52.82 ± 8.19 
C 20:0 1.19 ± 0.19 1.16 ± 0.25 1.31 ± 0.35 
C 22:0 4.54 ± 0.53 4.40 ± 0.76 4.40 ± 0.96 
C 24:0 12.56 ± 1.72 12.24 ± 2.09 12.35 ± 2.45 
SFAs 179.77 ± 11.88 164.89 ± 21.05 170.60 ± 28.48 
C 12:1 0.01 ± 0.01 0.01 ± <0.01 0.04 ± 0.08 
C 14:1 0.02 ± 0.01 0.02 ± 0.02 0.08 ± 0.13 
C 16:1 1.11 ± 0.48 0.97 ± 0.29 1.01 ± 0.31 
C 18:1n-7 5.06 ± 0.52a 4.49 ± 0.60b 4.52 ± 0.70b 
C 18:1n-9 49.83 ± 4.91a 45.52 ± 6.48ab 44.93 ± 7.50b 
C 20:1n-9 1.06 ± 0.23 0.97 ± 0.25 0.96 ± 0.26 
C 22:1n-9 0.57 ± 0.07a 0.42 ± 0.06b 0.59 ± 0.18a 
C 24:1n-9 13.06 ± 1.69 12.67 ± 1.37 12.59 ± 1.98 
MUFAs 73.35 ± 6.29a 66.77 ± 8.28b 66.99 ± 10.18b 
C 18:2n-6 40.82 ± 5.38 37.39 ± 6.57 36.49 ± 6.58 
C 18:3n-6 0.19 ± 0.06 0.14 ± 0.06 0.18 ± 0.10 
C 20:2n-6 0.98 ± 0.16 0.89 ± 0.20 0.98 ± 0.17 
C 20:3n-6 6.20 ± 1.69 5.49 ± 1.51 5.22 ± 1.32 
C 20:4n-6 54.40 ± 6.02a 49.12 ± 5.97b 48.29 ± 7.35b 
C 22:2n-6 0.27 ± 0.08 0.25 ± 0.08 0.27 ± 0.13 
C 22:4n-6 12.90 ± 2.04a 11.39 ± 2.11b 10.44 ± 1.80b 
C 22:5n-6 2.28 ± 0.37a 1.98 ± 0.31b 1.76 ± 0.28b 
N-6 118.03 ± 9.42a 106.67 ± 13.48b 103.63 ± 14.12b 
C 18:3n-3 0.60 ± 0.18a 0.59 ± 0.13b 0.82 ± 0.23b 
C 20:3n-3 0.07 ± 0.03 0.08 ± 0.03 0.11 ± 0.10 
C 20:5n-3 1.89 ± 0.65a 2.46 ± 0.59a 3.98 ± 1.00b 
C 22:5n-3 8.44 ± 1.39 8.33 ± 1.48 9.31 ± 1.84 
C 22:6n-3 13.61 ± 2.76 13.58 ± 3.35 15.08 ± 2.73 
N-3 24.62 ± 3.37a 25.04 ± 4.78a 29.29 ± 4.97b 
PUFAs 142.65 ± 12.15 131.70 ± 17.89 132.92 ± 18.55 
HUFAs 99.79 ± 9.08 92.43 ± 12.04 94.17 ± 12.55 
EPA+DHA 15.50 ± 2.92a 16.04 ± 3.73a 19.05 ± 3.52b 
N-6/N-3 4.84 ± 0.46a 4.32 ± 0.40b 3.57 ± 0.30c 
%n-3 HUFA in 
total HUFA 24.03 ± 2.05
a 26.30 ± 2.15b 30.15 ± 2.10c 
Total 395.77 ± 26.49 363.36 ± 45.50 370.52 ± 55.65 
Saturated fatty acids (SFAs); Mono-unsaturated fatty acids (MUFAs); Omega-6 fatty acids (N-6); Omega-3 fatty 
acids (N-3); Polyunsaturated fatty acids (PUFAs); Highly unsaturated fatty acids (HUFAs); Eicosapentaenoic acid 
(EPA); Docosahexaenoic acid (DHA). Omega-6:Omega-3 ratio (N-6/N-3). Superscript differences represent 
significantly different values after one-way ANOVA + Tukey HSD (p < 0.05). 
 
* supporting data from Dr. Ashley Patterson’s Doctoral Thesis (Reference: Patterson, 2012) 
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Table D.11.  Fatty Acid Composition of Erythrocytes (n = 5)* 
Concentration 
(µg fatty acid per 200 mg erythrocytes) 
Fatty Acid Baseline Week 4 Week 8 Week 12 
C 12:0 0.34 ± 0.04a 0.09 ± 0.01b 0.15 ± 0.02c 0.03 ± 0.01d 
C 14:0 2.07 ± 0.29a 2.75 ± 0.41b 1.89 ± 0.44a 1.46 ± 0.19a 
C 16:0 81.90 ± 3.96 74.43 ± 5.68 68.19 ± 15.09 68.63 ± 4.79 
C 18:0 54.44 ± 4.59a 47.86 ± 2.07ab 47.28 ± 5.83b 49.10 ± 1.61ab 
C 20:0 1.19 ± 0.19a 1.11 ± 0.09ab 1.15 ± 0.14ab 0.93 ± 0.10b 
C 22:0 4.69 ± 0.56a 4.42 ± 0.47ab 4.38 ± 0.87ab 3.34 ± 0.50b 
C 24:0 11.83 ± 2.47 11.17 ± 2.12 11.49 ± 2.39 8.30 ± 1.23 
SFAs 177.94 ± 10.94a 155.49 ± 9.93ab 150.30 ± 27.27ab 144.06 ± 7.67b 
C 12:1 0.01 ± <0.01 0.01 ± <0.01 0.01 ± 0.01 0.01 ± <0.01 
C 14:1 0.03 ± 0.01 0.03 ± 0.02 0.03 ± 0.02 0.04 ± 0.02 
C 16:1 1.06 ± 0.68 0.85 ± 0.29 0.83 ± 0.44 0.71 ± 0.18 
C 18:1n-7 5.03 ± 0.39a 4.33 ± 0.43ab 4.09 ± 0.52b 4.40 ± 0.55ab 
C 18:1n-9 47.63 ± 5.06 41.99 ± 4.45 39.95 ± 8.47 41.78 ± 3.24 
C 20:1n-9 0.95 ± 0.06 0.82 ± 0.06 0.82 ± 0.13 0.82 ± 0.12 
C 22:1n-9 0.54 ± 0.06ab 0.47 ± 0.08a 0.65 ± 0.12b 0.40 ± 0.09a 
C 24:1n-9 12.58 ± 1.86a 11.85 ± 0.87a 12.14 ± 1.09a 8.63 ± 0.86b 
MUFAs 70.72 ± 5.89a 62.03 ± 4.83ab 60.55 ± 10.34ab 57.76 ± 3.34b 
C 18:2n-6 36.45 ± 3.38 32.66 ± 1.55 31.07 ± 6.16 32.51 ± 3.20 
C 18:3n-6 0.19 ± 0.08 0.14 ± 0.08 0.17 ± 0.08 0.12 ± 0.03 
C 20:2n-6 0.86 ± 0.07ab 0.75 ± 0.03a 0.96 ± 0.19b 0.78 ± 0.09ab 
C 20:3n-6 5.42 ± 1.39 4.61 ± 1.12 4.45 ± 1.31 4.28 ± 0.96 
C 20:4n-6 56.08 ± 3.47a 47.70 ± 3.51b 45.96 ± 5.84b 46.96 ± 2.33b 
C 22:2n-6 0.23 ± 0.06 0.22 ± 0.03 0.21 ± 0.04 0.23 ± 0.04 
C 22:4n-6 13.58 ± 2.02a 11.57 ± 1.72ab 11.08 ± 1.92ab 9.82 ± 1.74b 
C 22:5n-6 2.25 ± 0.37a 1.85 ± 0.32ab 1.78 ± 0.41ab 1.53 ± 0.28b 
N-6 115.05 ± 3.60a 99.51 ± 3.78b 95.67 ± 13.25b 96.23 ± 4.87b 
C 18:3n-3 0.48 ± 0.08 0.47 ± 0.04 0.64 ± 0.14 0.47 ± 0.11 
C 20:3n-3 0.06 ± 0.01 0.07 ± 0.02 0.07 ± 0.01 0.07 ± 0.01 
C 20:5n-3 1.72 ± 0.40a 2.21 ± 0.32ab 3.35 ± 0.87b 5.21 ± 0.84c 
C 22:5n-3 8.39 ± 0.35ab 7.76 ± 0.34a 8.75 ± 1.06ab 9.53 ± 0.87b 
C 22:6n-3 11.86 ± 2.34ab 11.20 ± 1.82a 13.12 ± 2.29ab 15.29 ± 1.44b 
N-3 22.51 ± 2.89a 21.70 ± 2.15a 25.93 ± 3.81ab 30.57 ± 2.36b 
PUFAs 137.56 ± 5.42 121.21 ± 5.28 121.60 ± 16.61 126.80 ± 6.73 
HUFAs 99.36 ± 5.17a 86.96 ± 4.71b 88.55 ± 10.93ab 92.70 ± 3.99ab 
EPA+DHA 13.58 ± 2.73a 13.41 ± 2.09a 16.46 ± 3.02ab 20.50 ± 2.04b 
N-6/N-3 5.17 ± 0.59a 4.61 ± 0.35a 3.70 ± 0.26b 3.16 ± 0.17b 
%n-3 HUFA in 
total HUFA 22.11 ± 1.79
a 24.38 ± 1.50b 28.51 ± 1.11b 32.44 ± 1.20c 
Total 386.23 ± 21.35a 338.73 ± 19.31ab 332.45 ± 53.88ab 328.63 ± 16.86b 
Saturated fatty acids (SFAs); Mono-unsaturated fatty acids (MUFAs); Omega-6 fatty acids (N-6); Omega-3 fatty 
acids (N-3); Polyunsaturated fatty acids (PUFAs); Highly unsaturated fatty acids (HUFAs); Eicosapentaenoic acid 
(EPA); Docosahexaenoic acid (DHA). Omega-6:Omega-3 ratio (N-6/N-3). Superscript differences represent 
significantly different values after one-way ANOVA + Tukey HSD (p < 0.05). 
 
* supporting data from Dr. Ashley Patterson’s Doctoral Thesis (Reference: Patterson, 2012) 
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Table D.12.  Fatty Acid Composition of Plasma Phospholipids (n = 20)* 
Concentration 
(µg fatty acid per 100 µL plasma) 
Fatty Acid Baseline Week 4 Week 8 
C 12:0 0.05 ± 0.02a 0.18 ± 0.20ab 0.19 ± 0.22b 
C 14:0 0.53 ± 0.16a 0.66 ± 0.23ab 0.75 ± 0.21b 
C 16:0 26.93 ± 5.93a 30.31 ± 5.30ab 32.84 ± 7.82b 
C 18:0 15.52 ± 3.15a 18.58 ± 4.34b 19.02 ± 5.01b 
C 20:0 0.55 ± 0.10 0.57 ± 0.09 0.54 ± 0.08 
C 22:0 1.45 ± 0.33a 1.35 ± 0.37ab 1.18 ± 0.31b 
C 24:0 1.31 ± 0.31 1.23 ± 0.37 1.09 ± 0.31 
SFAs 47.92 ± 9.54a 54.65 ± 10.09ab 57.32 ± 12.78b 
C 12:1 0.01 ± 0.01a 0.01 ± 0.01a 0.06 ± 0.05b 
C 14:1 0.01 ± 0.01 0.02 ± 0.02 0.02 ± 0.01 
C 16:1 0.44 ± 0.30 0.56 ± 0.19 0.55 ± 0.29 
C 18:1n-7 1.72 ± 0.35 1.97 ± 0.54 2.08 ± 0.54 
C 18:1n-9 9.55 ± 2.91a 13.76 ± 8.66ab 16.47 ± 7.42b 
C 20:1n-9 0.21 ± 0.05 0.26 ± 0.16 0.29 ± 0.11 
C 22:1n-9 0.32 ± 0.11a 0.40 ± 0.28a 0.49 ± 0.19b 
C 24:1n-9 2.29 ± 0.40a 1.97 ± 0.64a 1.66 ± 0.45b 
MUFAs 14.68 ± 3.66a 19.08 ± 9.45ab 21.78 ± 8.36b 
C 18:2n-6 20.44 ± 3.74 23.36 ± 6.15 23.74 ± 5.17 
C 18:3n-6 0.11 ± 0.08 0.10 ± 0.07 0.12 ± 0.07 
C 20:2n-6 0.37 ± 0.12 0.35 ± 0.10 0.34 ± 0.09 
C 20:3n-6 3.37 ± 1.27 3.12 ± 1.17 3.20 ± 1.17 
C 20:4n-6 11.83 ± 3.05 10.66 ± 2.40 10.67 ± 3.14 
C 22:2n-6 0.05 ± 0.02 0.06 ± 0.05 0.06 ± 0.05 
C 22:4n-6 0.46 ± 0.12a 0.38 ± 0.10ab 0.31 ± 0.09b 
C 22:5n-6 0.35 ± 0.10a 0.26 ± 0.07b 0.21 ± 0.07b 
N-6 36.99 ± 6.84 38.29 ± 8.01 38.64 ± 8.85 
C 18:3n-3 0.30 ± 0.17a 0.76 ± 1.19ab 1.04 ± 0.96b 
C 20:3n-3 0.05 ± 0.02 0.04 ± 0.02 0.04 ± 0.01 
C 20:5n-3 0.72 ± 0.41a 1.22 ± 0.27b 2.09 ± 0.68c 
C 22:5n-3 1.04 ± 0.34a 1.13 ± 0.34ab 1.37 ± 0.49b 
C 22:6n-3 3.37 ± 0.70a 3.75 ± 0.75ab 4.28 ± 0.86b 
N-3 5.48 ± 1.21a 6.91 ± 1.52b 8.82 ± 2.25c 
PUFAs 42.47 ± 7.60 45.20 ± 9.26 47.46 ± 10.89 
HUFAs 21.20 ± 4.82 20.57 ± 3.87 22.18 ± 5.58 
EPA+DHA 4.09 ± 0.98a 4.98 ± 0.88b 6.38 ± 1.43c 
N-6/N-3 6.89 ± 1.06a 5.59 ± 0.74b 4.43 ± 0.50c 
%n-3 HUFA in 
total HUFA 24.62 ± 3.64
a 30.04 ± 2.58b 35.47 ± 3.65c 
Total 105.07 ± 20.17a 118.93 ± 23.55ab 126.57 ± 28.18b 
Saturated fatty acids (SFAs); Mono-unsaturated fatty acids (MUFAs); Omega-6 fatty acids (N-6); Omega-3 fatty 
acids (N-3); Polyunsaturated fatty acids (PUFAs); Highly unsaturated fatty acids (HUFAs); Eicosapentaenoic acid 
(EPA); Docosahexaenoic acid (DHA). Omega-6:Omega-3 ratio (N-6/N-3). Superscript differences represent 
significantly different values after one-way ANOVA + Tukey HSD (p < 0.05). 
 
* supporting data from Dr. Ashley Patterson’s Doctoral Thesis (Reference: Patterson, 2012) 
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Table D.13.  Fatty Acid Composition of Plasma Phospholipids (n = 5)* 
Concentration 
(µg fatty acid per 100 µL plasma) 
Fatty Acid Baseline Week 4 Week 8 Week 12 
C 12:0 0.07 ± 0.02 0.20 ± 0.31 0.13 ± 0.03 0.11 ± 0.06 
C 14:0 0.62 ± 0.24 0.61 ± 0.33 0.77 ± 0.23 0.88 ± 0.27 
C 16:0 29.66 ± 9.72 27.17 ± 8.92 36.28 ± 13.28 34.05 ± 9.27 
C 18:0 17.28 ± 5.02 16.45 ± 4.70 23.82 ± 7.97 24.02 ± 8.93 
C 20:0 0.59 ± 0.10 0.53 ± 0.11 0.57 ± 0.11 0.64 ± 0.18 
C 22:0 1.48 ± 0.39 1.30 ± 0.31 1.15 ± 0.46 1.26 ± 0.27 
C 24:0 1.33 ± 0.41 1.21 ± 0.28 1.06 ± 0.44 1.23 ± 0.28 
SFAs 52.89 ± 15.71 48.97 ± 15.29 65.78 ± 21.83 64.76 ± 19.61 
C 12:1 0.01 ± <0.01a 0.01 ± 0.01a 0.07 ± 0.04b 0.01 ± <0.01a 
C 14:1 0.01 ± 0.01 0.02 ± 0.01 0.01 ± <0.01 0.02 ± 0.02 
C 16:1 0.58 ± 0.57 0.53 ± 0.25 0.62 ± 0.51 0.42 ± 0.13 
C 18:1n-7 1.95 ± 0.60 2.06 ± 0.81 2.27 ± 0.70 2.01 ± 0.35 
C 18:1n-9 10.91 ± 5.29 15.40 ± 13.09 19.75 ± 8.06 9.55 ± 3.35 
C 20:1n-9 0.20 ± 0.07 0.28 ± 0.21 0.33 ± 0.12 0.19 ± 0.05 
C 22:1n-9 0.33 ± 0.15 0.29 ± 0.13 0.56 ± 0.18 0.47 ± 0.15 
C 24:1n-9 2.51 ± 0.32 2.02 ± 0.42 1.69 ± 0.64 1.96 ± 0.45 
MUFAs 16.63 ± 6.54 20.70 ± 14.29 25.49 ± 9.66 14.89 ± 4.17 
C 18:2n-6 20.09 ± 5.93 20.95 ± 9.24 25.25 ± 8.20 23.22 ± 6.69 
C 18:3n-6 0.16 ± 0.12 0.12 ± 0.09 0.14 ± 0.08 0.18 ± 0.04 
C 20:2n-6 0.36 ± 0.16 0.30 ± 0.10 0.33 ± 0.14 0.32 ± 0.10 
C 20:3n-6 3.54 ± 1.96 2.94 ± 1.17 3.24 ± 1.41 2.68 ± 1.04 
C 20:4n-6 14.58 ± 3.31 11.93 ± 3.11 12.16 ± 3.99 12.51 ± 2.82 
C 22:2n-6 0.05 ± 0.02 0.04 ± 0.05 0.04 ± 0.03 0.05 ± 0.02 
C 22:4n-6 0.53 ± 0.16a 0.38 ± 0.11ab 0.33 ± 0.12ab 0.26 ± 0.04b 
C 22:5n-6 0.43 ± 0.14a 0.26 ± 0.09ab 0.22 ± 0.12b 0.21 ± 0.10b 
N-6 39.75 ± 10.85 36.93 ± 13.29 41.72 ± 13.74 39.43 ± 10.15 
C 18:3n-3 0.35 ± 0.21 0.87 ± 1.61 1.65 ± 1.04 0.23 ± 0.11 
C 20:3n-3 0.05 ± 0.01 0.04 ± 0.01 0.04 ± 0.02 0.05 ± 0.01 
C 20:5n-3 0.77 ± 0.42a 1.19 ± 0.40ab 2.51 ± 1.17bc 2.81 ± 1.03c 
C 22:5n-3 1.18 ± 0.34 1.19 ± 0.27 1.69 ± 0.73 1.36 ± 0.31 
C 22:6n-3# 3.21 ± 1.07 3.83 ± 1.02 4.28 ± 1.59 5.37 ± 1.39 
N-3 5.56 ± 1.64 7.11 ± 2.95 10.16 ± 3.66 9.82 ± 2.73 
PUFAs 45.31 ± 12.40 44.04 ± 16.22 51.88 ± 17.25 49.24 ± 12.81 
HUFAs 24.30 ± 6.88 21.76 ± 5.95 24.47 ± 8.95 25.24 ± 6.43 
EPA+DHA 3.98 ± 1.38a 5.01 ± 1.39ab 6.79 ± 2.74ab 8.18 ± 2.35b 
N-6/N-3 7.21 ± 0.68a 5.30 ± 0.44b 4.19 ± 0.58c 4.06 ± 0.41c 
%n-3 HUFA in 
total HUFA 21.28 ± 1.37
a 28.79 ± 1.17b 34.42 ± 1.63c 37.83 ± 1.92d 
Total 114.82 ± 34.41 113.72 ± 45.28 143.15 ± 43.42 128.90 ± 35.30 
Saturated fatty acids (SFAs); Mono-unsaturated fatty acids (MUFAs); Omega-6 fatty acids (N-6); Omega-3 fatty 
acids (N-3); Polyunsaturated fatty acids (PUFAs); Highly unsaturated fatty acids (HUFAs); Eicosapentaenoic acid 
(EPA); Docosahexaenoic acid (DHA). Omega-6:Omega-3 ratio (N-6/N-3). Superscript differences represent 
significantly different values after one-way ANOVA + Tukey HSD (p < 0.05). 
 
* supporting data from Dr. Ashley Patterson’s Doctoral Thesis (Reference: Patterson, 2012) 
# baseline DHA and week 12 DHA trend towards significance; p = 0.07. 
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Table E.1.  Characterization of Omega-3 HUFA-Containing Complex Lipids in Whole Blood, 
Plasma and Erythrocytes (n = 9) 
   
Lipid Abundance, n = 9 
(Arbitrary Units, Average ± SD) 
Observed m/z Lipid Adduct Whole Blood Plasma Erythrocytes 
780.5536 PC 16:0/20:5 [M+H]+ 64.19 ± 36.70 57.74 ± 32.66 16.68 ± 8.41 
806.5693 PC 16:0/22:6 [M+H]+ 95.54 ± 39.75 130.36 ± 56.51 28.91 ± 7.27 
812.6159 PC 18:0/20:3 [M+H]+ 35.44 ± 13.97 42.54 ± 12.97 7.91 ± 1.83 
810.6002 PC 18:0/20:4 [M+H]+ 126.79 ± 32.62 178.91 ± 59.73 40.29 ± 8.12 
808.5851 PC 18:0/20:5 [M+H]+ 17.38 ± 12.81 23.51 ± 21.15 6.12 ± 4.62 
838.6322 PC 18:0/22:4 [M+H]+ 2.73 ± 0.49 3.14 ± 0.67 0.82 ± 0.10 
834.6009 PC 18:0/22:6 [M+H]+ 28.71 ± 11.97 39.29 ± 17.54 7.47 ± 1.80 
832.5853 PC 18:1/22:6 [M+H]+ 4.36 ± 1.86 5.54 ± 2.87 1.16 ± 0.24 
740.5227 PE 16:0/20:4 [M+H]+ 13.26 ± 1.88 0.77 ± 0.30 18.60 ± 2.33 
738.5069 PE 16:0/20:5 [M+H]+ 1.13 ± 0.71 0.06 ± 0.06 1.48 ± 0.75 
764.5225 PE 16:0/22:6 [M+H]+ 8.43 ± 2.93 1.96 ± 1.00 17.99 ± 4.75 
722.5114 Plasmenyl-PE P-16:0/20:5 [M+H]+ 1.44 ± 0.81 0.41 ± 0.28 1.67 ± 0.87 
748.5273 Plasmenyl-PE P-16:0/22:6 [M+H]+ 2.97 ± 0.77 1.36 ± 0.54 3.89 ± 0.90 
812.5437 PS 18:0/20:4 [M+H]+ 10.92 ± 1.93 0.10 ± 0.07 26.52 ± 5.13 
836.5434 PS 18:0/22:6 [M+H]+ 7.11 ± 1.51 0.09 ± 0.04 19.11 ± 2.45 
922.7861 TAG 16:0/18:1/22:6 [M+NH4]+ 5.24 ± 4.02 9.12 ± 5.19 <0.01 ± <0.01 
922.7861 TAG 18:1/18:1/20:5 [M+NH4]+ 1.36 ± 0.86 2.43 ± 1.42 <0.01 ± <0.01 
690.6186 CE 20:4 [M+NH4]+ 5.90 ± 2.68 10.48 ± 2.86 <0.01 ± <0.01 
688.6029 CE 20:5 [M+NH4]+ 0.80 ± 1.04 2.53 ± 2.94 <0.01 ± <0.01 
714.6175 CE 22:6 [M+NH4]+ 0.43 ± 0.24 2.07 ± 1.31 <0.01 ± <0.01 
Mass-to-charge ratio (m/z); Phosphatidylcholine (PC); Phosphatidylethanolamine (PE); Phosphatidylserine (PS); 
Triacylglycerol (TAG); Cholesteryl ester (CE). 
 
